Progress in PET Radiopharmaceuticals (Quality Control and Theranostics)

Sushil K. Sharma, PhD
Academic Dean, American International School of Medicine (AISM), Georgetown, Guyana, South America, US Corporate Headquarters, Stone Mountain, Georgia, USA

Series: New Developments in Medical Research
BISAC: MED080000

Clear

$310.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Browse Wishlist
Browse Wishlist

Details

This book describes classical and potential PET radiopharmaceuticals (PET-RPs) which can provide high-resolution 5D images in-vivo to simultaneously diagnose and treat the patient. This novel (theranostic) approach avoids futile therapies, unnecessary radiation exposure, and saves a lot of time, money, and energy.

The most significant challenge is to properly build Cyclotron & PET RPs labs. Existing books offer insufficient knowledge to accomplish the full potential of these highly specialized, expansive, and sophisticated labs, demanding in-depth knowledge, confidence, cooperation, a mutual understanding, adjustment, time management, team effort, patience, resilience, and dedication.

A systematic approach is provided to integrate Cyclotron and PET-RPS labs, run the cyclotron properly, resolve technical problems efficiently, and maintain quality control (QC) without being exposed to an unnecessary radiation hazard due to repetitive run failure, innocence, ignorance, negligence, misconception, misunderstanding, and/or overconfidence. Described QC experiments can be globally reproduced in other labs.

The contents provided are thought-provoking and motivate cyclotron engineers, basic scientists, radiopharmaceutical scientists, radiopharmacists, and physicians to develop novel PET-RPs in this challenging the era of Nanotheranostics.

The most recent knowledge of potential PET-RPs in the early theranostics of cancer, cardiovascular diseases, neurodegenerative diseases, drug addiction, obesity, neurobehavioral disorders, rheumatoid arthritis, and chronic inflammatory illnesses is provided with currently limited treatment options.

This unique, informative, and timely released book will act as a helpful guide; it is an applied textbook for basic biomedical students, scientists, researchers, teachers, doctors, administrators, and affiliated staff involved in current and future development of novel PET-RPs to accomplish personalized theranostics. (Imprint: Nova Biomedical)

Acknowledgement

About this Book

About the Author

Ten Commandments

Abbreviations

Commonly Used PET Radionuclides in Nuclear Medicine

Commonly Used PET Radiopharmaceuticals for Diagnostic & Theranostic Applications

Preface

Part 1: Recent Trends in Cyclotron & PET Radiopharmaceutical Labs

Chapter 1. Basic Requirements of Quality Control in Cyclotron & PET RPs Lab

Chapter 2. Cleaning Cyclotron and PET-Radiopharmaceutical Labs

Chapter 3. Cyclotron and PET Imaging (Basic Principles)

Chapter 4. Radiation Safety and Qaulity Control in Cyclotron Lab

Chapter 5. Purification and Quality Control of PET radiochemicals

Chapter 6. Quality Control of PET Radiopharmaceuticals with Chromatographic Analyses

Chapter 7. Spectroscopic Analyses of PET Radiopharmaceuticals

Chapter 8. Quality Control and System Performance in Cyclotron & PET Radiopharmaceutical Lab

Chapter 9. Quality Control of PET Radiopharmaceuticals with Special Reference to 18FdG

Part 2: Recent PET Biomarkers in Personalized Diagnosis and Theranostics

Chapter 10. Recent Developments in PET Radiopharmaceuticals for Evidence-Based Personalzed Medicine (EBPM)

Chapter 11. 18FdG-PET Neuroimaging

Chapter 12. 18FdG-PET Neuroimaging in Alzheimer’s disease

Chapter 13. Biomarkers in Alzheimer’s disease

Chapter 14. 18FdG-PET Neuroimaging in Drug Addiction

Chapter 15. PET Imaging with 18F-DOPA and 18FdG in Parkinson’s disease

Chapter 16. PET Radiopharmaceuticals in Evidence-Based Personalized Theranostics

Chapter 17. Recent Trends in PET Biomarkers for Personalized Theranostics

Chapter 18. Translational Multimodality Neuroimaging for Personalized Theranostics

Part 3: Translational Fusion Imaging Research (Personalized Theranostics)

Chapter 19. Quality Control and System Performance for Siemens R-4 Micro-Positron Emission Tomography (microPET) Imaging System

Chapter 20. SPECT Imaging in CNS Disorders

Chapter 21. PET Imaging in Translational Medicine

Chapter 22. Recent Trends in PET Radiopharmaceuticals Research for Diagnostics and Theranostics

Index

“This book is a thoroughly compiled addition to the existing literature in the field of radiopharmaceuticals, their quality control and personalized theranostics in various disease conditions. It will serve as a reference book for both basic scientists and clinicians as well as for the new comers in this field undergoing training. PET imaging is a very specialized and technologically advanced area that provides spatiotemporal information and significantly contributes to decision making in complex disease conditions like cancer, brain disorders and cardiovascular problems. Author of this book, Professor Sushil K. Sharma, an expert in the field of neurosciences and medical radiopharmaceutical technology has shared his own personal experience, elaborated findings of others and given a lucid account of fundamentals of PET radiopharmaceuticals and their applications to both basic and clinical research.” - Vijay L. Kumar, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India

Chapter 1

Sharma, S., Krause, G. & Ebadi, M., (2006). Radiation Safety & Quality Control in the Cyclotron Laboratory Radiation Protection Dosimetry, 118, 431-439, 2006.

Chapter 9

Alagona, P. Jr., Hart, D. T. & Eikman, E. A. (1994). Regional distribution of 2-deoxy-2[18F]-Fluoro-D-Glucose for metabolic imaging using positron emission tomography. Int. J. Card. Imaging., 10, 137-143.
Antoch, G., Freudenberg, L. S., Beyer, T., Bockisch, A. & Debatin, J. F. (2004). To enhance or not to enhance ? 18F-FDG and CT contranst agents in dual modality 18F-FDG PET/CT. J. Nucl. Med., 45, 56-65.
Barnes, A., Dai, D., Montaldi, D., Patterson, J. & Wyper, D. (1997). Image quality verses statistical power. Nucl. Med. Commun., 18, 1155-1160.
Bar-Shalom, R., Yefremov, N., Guralnik, L., Gaitini, D., Frenkel, A., Kutten, A., Altman, H., Keidar, Z. & Israel, O. (2003). Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patients management. J. Nucl. Med., 44, 1200-1209.
Beaulieu, S., Kinahan, P., Tseng, J., Dunnwald, L. K., Schubert, E. K., Pham, P., Lewellen, B. & Mankoff, D. A. (2003). SUV varies with time after injection in [18]F-FDG PET of breast cancer: characterization and method to adjust for time differences. J. Nucl. Med., 44, 1044-1050.
Bobek-Billewicz, B., Jurkowski, M. K. & Romanowicz, G. (2005). Usefulness of FDG-PET for the diagnosis of brain tumors. Przegl Lek., 62, 54-60.
Brunner, M., Langer, O., Dobrozemsky, G., Muller, U., Zeitlinger, M., Mitterhauser, M., Wadasak, W., Dudezak, R., Kletter, K. & Muller, M. (2004). [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacain in humans. Antimicrob. Agent Chemother., 48, 3850-3857.
Chun, H., Kim, C. K., Krynckyi, B. R. & Machac, J. (2003). The usefulness of a repeat study for differentiation between bowel activity and local tumor recurrence on FDG PET scans. Clin. Nucl. Med., 28, 672-673.
Costa, D. C., Visvikis, D., Crosdale, I., Pigden, I., Townsend, C., Bomanji, J., Prvulovich, E., Lonn, A. & Ell, P. J. (2003). Positron emmision and computed X-ray tomography: a coming together. Nucl. Med. Commun., 24, 351-358.
Cronin, V., Galantowicz, P. & Nabil, H. A. (1997). Development of oncology protocol using fluorine-18-FDG: one center’s experience. J. Nucl. Med. Technol., 25, 66-69.
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hubner, K., Stabin, M. G., Zubal, G., Kachelriess, M., Cronin, Y. & Holbrook, S. (2006). Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J. Nucl. Med., 47, 85-95.
Ebadi M., Sharma, S., Ghafourifar, P., Brown-Borg, H. & Refaey H. El. (2005). Peroxynitrite in the Pathogenesis of Parkinson’s Disease and the Neuroprotective Role of Metallothioneins. Methods in Enzymol., 396, 276-298.
Ebadi, M. & Sharma S. (2006). Metallothioneins 1 and 2 Attenuate Peroxynitrite-Induced Oxidative Stress in Parkinson’s Disease. Exp. Biol. & Med., 231, 1576-1583.
Everaert, H., Vanhove, C., Lahoutte, T., Muylle, K., Caveliers, V., Bossuyt, A. & Franken, P. R. (2003). Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera. Eur. J. Nucl. Med. Mol. Imaging., 30, 1615-1619.
Gorenberg, M., Hallett, W. A. & O’Doherty, M. J. (2002). Does diabetes affect [18]F-FDG standarised uptake values in lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 29, 1324-1327.
Gutman, F., Gardin, I., Delahaye, N., Rakotoninina, H., Hitzel, A., Manrtique, A., Le Guludec, D. & Vera, P. (2003). Optimization of the OS-EM algorithm and comparison with FBP for imaging reconstruction on a dual head camera: a phantom and a clinical 18F-FDG study. Eur. J. Nucl. Med. Imaging., 30, 1510-1519.
Hess, B., Tagil, K., Cuocolo, A., Anagnostapoulos, C., Bardies, M., Bax, J., Bengel, F., Buseman Sakole, E., Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O’Connor, M., Prvulovich, E., Underwood, R., van Eck-Smit, B. & EANM/ESE, Group. (2005). EANM/ESE procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur. J. Nucl. Med. Mol. Imaaging, 32, 855-897.
Hung, J. C. (2002). Comparison of various requirements of the quality assurance procedures for (18}F-FDG injection. J. Nucl. Med., 43, 1495-1496.
Hung, J. C. (2006). In-Process 20-Minute Endotoxin “Limit Test” for Positron Emission Tomography RPs. Am. J. Pharmacol. Assoc, 46, 89-92.
Jain, M. & Batra, S. K. (2003). Genetically engineered antibody fragments and PET imaging: a new era of radioimmunodaignosis. J. Nucl. Med., 44, 1970-1972.
Knuuti, J., Schelbert, H. R. & Bax, J. J. (2002). The need for standardization of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur. J. Nucl. Med. Mol. Imaging, Eur. J. Nulc. Med. Mo. Imaging, 29, 1257-1266.
Le Bars, D., Lemaire, C., Ginovart, N., Plenevaux, A., Aerts, J., Brihayae, C., Hassoun, W., Leviel, V., Mekhsian, P., Weissmann, D., Pujol, J. F., Luxen, A. & Comar, D. (1998). High-Yield radiosynthesis and preliminary in vivo evaluation of [-[18F]MPPF, a fluoro analogue of WAY-100635. Nucl. Med. Biol., 25, 343-350.
Levivier, M., Massager, N., Wikler, D. & Goldman, S. (2004). Modern multimodal neuroimaging for radiosurgery: the example of PET scan integration. Acta Neurochir Suppl., 91, 1-7.
Macasek, F., Bruder, P., Patakyova, A. & Buriova, E. (2003). Atmospheric pressure electrospray ionization mass spectra of glucose and 2-FdG for quantitative analysis of 2-FdG by high-performance liquid chromatography. Eur. J. Mss Scpectrom., 9, 129-137.
Machac, J. (2005). Cardiac positron emission tomography imaging. Semin. Nucl. Med., 35, 17-36.
Mattarrese, M., Soloviev, D., Todde, S., Neutro, F., Petta, P., Carpinelli, A., Brussermann, M., Galli Kienle, M. & Fazio, F. (2003). Preparation of [11C] radioligands with high specific radioactivity on a commercial PET tracer synthesizer. Nucl. Med. Biol., 30, 79-83.
Mikecz, P., Toth, G., Horvath, G., Lehel, S., Kovacs, Z., Pribozczki, E., Boros, I., Miklovicz, T. & Marian, T. (2002). Synthesis of RPs for PET investigations. Orv. Hetil., 143, 1240-1242.
Mishani, E., Ben-David, I. & Rozen, Y. (2002). Improved method of the quality assurance of [C-11]Choline. Nucl. Med. Biol., 29, 359-362.
Moerlein, S. M., Gaehle, G. C. & Welch, M. J. (2002). Robotic preparation of sodium acetate C-11 injection for use in clinical PET. Nucl. Med. Biol., 29, 613-621.
Nakao, R., Furutka, K., Yamaguchi, M. & Suzuki, K. (2006). Quality control of PET- RPs using HPLC with electrochemical detection. Nucl. Med. Biol., 33, 441-447.
Nakao, R., Ito, T., Yamaguchi, M. & Suzuki, K., (2005). Improved quality control of [18F]FDG by HPLC with UV detection. Nucl. Med. Biol., 32, 907-912.
Nakazawa, N., Wakita, K., Mineura, K., Nakamura, M., Fujii, R., Nakanishi, H., Uji, Y., Matsuura, S., Itani, K., Kanatsuna, T., Ido, T. & Imahori, Y. (2002). Short time bacterial endotoxins tests for positron emission tomography by means of positively changed filters. Kako Igaku, 39, 543-548.
Paans, A. M., Boerdiijk, S. M., Willemsen, A. T. & Pruim, J. (2004). Source of impaired image quality in 3D whole-body FDG PET scanning. Eur. J. Nucl. Med Mol. Imaging, 31, 1207-1208.
Peneulas, I., Marti-Climent, J. M., Blanco, G., Crespo, A., Garcia-Velloso, J. & Richter, J. A. (1999). PET Radiopharmacy Unit Rev. Esp. Med. Nucl., 18, 379-385.
Penuelas Sanchez, I. (2001). PET- RPs. Rev. Esp. Med. Nucl., 20, 477-498.
Riggin, S. L., Kilroy, K. J. & Smith, R. J. (2000). Clinical PET Imaging with the C-PET camera. J. Nucl. Med. Technol., 28, 23-28.
Rosch, F., Herzog, H., Stolz, B., Brockmann, J., Kohle, M., Muhlensiepen, H., Marbach, P. & Muller-Gartner, H. W. (1999). Uptake kinetics of the Somatostatin receptor ligand [86Y]DOTA-Dphe1-Tyr3-octreotide [86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of 90Y-labelled analogue. Eur. J. Nucl. Med., 26, 358-366.
Sharma, S. K. & Ebadi, M. (2005). Distribution Kinetics of 18F-DOPA in Weaver Mutant Mice. Brain Res. Mol. Brain Res., 139, 23-30.
Sharma, S. K., Refaey, H. El. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull., 70, 22-32.
Sharma, S., Krause, G. & Ebadi, M. (2006). Radiation safety and Quality Control in the Cyclotron Laboratory. Radiation Protection Dosimetry., 118, 431-439.
Somer, E. J., Mardsen, P. K., Benatar, N. A., Goodey, J., O’Doherty, M. J. & Smith, M. A. (2003). PET-MR imaging furion in soft tissue sarcoma: accuracy, reliability, and practicality of interactive point-based and automated mutal information techniques. Eur. J. Nucl. Med. Mol. Imaging, 30, 54-62.
Sothworth, R., Dearling, J. L., Medina, R. A., Flynn, A. A., Pedley, R. B. & Garlick, P. B. (2002). Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart: application of a new autoradiographic technique. Eur. J. Nucl. Med. Mol. Imaging., 29, 1334-1341.
Steel, C. J., Brady, F., Luthra, S. K., Brown, G., Khan, I., Poole, K. G., Sergis, A., Jones, T. & Price, P. M. (1999). An automated radiosynthesis of 2-[11C]thymidine using anhydrous [11C] urea derived from [11C]phosgene. Appl. Radiat. Isot., 51, 377-388.
Sundaresan, G., Yazaki, P. J., Shiverly, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F. Ghambhir, S. S. & Wu, A. M. (2003). 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of zenografts in athymic mice. J. Nucl. Med., 44, 1962-1969.
Takasawa, M., Murase, K., Oku, N., Kawamata, M., Imaizumi, M., Yoshikawa, T., Osaki, Y., Paul, A. K., Kitagawa, K., Matsumoto, M. & Hori, M. (2002). Automatic determination of brain perfusion index for measurement of cerebral blood flow using spectral analysis and 99mTc-HMPAO. Eur. J. Nucl. Med. Mol. Imaging., 29, 1443-1446.
Tatsumi, M., Clarck, P. A., Nakamoto, Y. & Wahl, R. L. (2003). Impact of body habits on quantitative and qualitative image quality in whole-body FDG-PET. Eur J. Nucl. Mol Imaging., 30, 40-45.
Tatsumi, M., Yutani, K. & Nishimura, T. (2000). Evaluation of lung cancer by 99m Tc-tetrafosmin SPECT: comparison with [18F] FDG-PET. J. Comput. Assist. Tomogr., 24, 574-580.
Tochon-Danguy, H. J., Sachinidis, J. I., Egan, G. F., Chan, J. G., Berlangieri, S. U., McKay, W. J. & Scott, A. M. (1999). Positron emission tomography: radioisotope and radiopharmaceutical production. Australas Phys Eng. Sci. Med., 22, 136-144.
Visvikis, D., Costa, D. C., Croasdale, I., Lonn, A. H., Bomanji, J., Gacinovic, S. & Ell, P. J. (2003). CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur. J. Nucl. Med. Mol. Imaging, 30, 344-353.
Warland, S., Jamar, F., Mathieu, I., De Camps, J., Lonneus, M., Sibomana, M., Labor, D., Michel, C. & Pauwel, S. (2003). Quantitation in PET using isotopes emitting prompt single gammas: applicatioin to yttrium-86. Eur. Nucl. Med. Mol. Imaging., 30, 354-361.
Whone, A. L., Bailey, D. L., Remy, P., Pavese, N. & Brooks, J. (2004). A technique for standardized central analysis of 6-18F-Fluoro-L-DOPA PET data from a multicenter study. J. Nucl. Med., 45, 1135-1145.
Yoo, J., Tang, L., Perkins, T. A., Rowland, D. J., Laforest, R., Lewis, J. S. & Wlech, M. J. (2005). Preparation of high specific activity 86Y using a small biomedical cyclotron. Nucl. Med. Biol., 32, 891-897.

Chapter 10

Adam, M. J. & Jivan, S. (1988). Synthesis and purification of L-6-[18F]fluorodopa. Appl. Radiat. Isot., 39, 1203–1210.
Agdeppa, E. D., Kepe, V., Liu. J., Flores-Torres, S., Satyamurthy, N., Petric, A., et al. (2001). Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci., 21, RC189.
Alauddin, M. M. & Conti, P. S. (1998). Synthesis and preliminary evaluation of 9- (4-[18F]-fluoro-3-hydroxymethylbutyl) Guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol., 25, 175–180.
Andersen, M. L., Kessler, E., Murnane, K. S., McClung, J. C., Tufik, S. & Howell, L. L. (2010). Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology (Berl)., 210, 439-448.
Anderson, C. J., Wadas, T. J., Wong, E. H. & Weisman, G. R. (2008). Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging, Q. J. Nucl. Med. Mol. Imaging., 52, 185–192.
Antoni, G. & Langstrom, B. (2008). RPs: molecular imaging using positron emission tomography. Handb Exp Pharmacol., 185, 177-201.
Aznavour, N. & Zimmer, L. (2007). [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacol., 52, 695–707.
Banks, M. L., Czoty, P. W., Gage, H. D., Bounds, M. C., Garg, P. K., Garg, S. & Nader, M. A. (2008). Effects of Cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology, 33, 219-225.
Bauer, A., Holschbach, M. H., Cremer, M., Weber, S., Boy, C., Shah, N. J., et al. (2003). Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. J Nucl Med., 44, 1682–1689.
Beer, A. J., Kessler, H., Wester, H. J. & Schwaiger, M. (2011). PET Imaging of Integrin α-Vβ3 Expression. Theranostics., 1, 48-57.
Boswell, C. A., Regino, C. A., Baidoo, K. E., Wong, K. J., Bumb, A., Xu, H., Milenic, D. E., Kelley, J. A., Lai, C. C. & Brechbiel, M. W. (2008). Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling, Bioconjug. Chem., 19, 1476–1484.
Boswell, C. A., Sun, X., Niu, W., Weisman, G. R., Wong, E. H., Rheingold, A. L. & Anderson, C. J. (2004). Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes, J. Med. Chem., 47, 1465–1474.
Bruus-Jensen, K., Poethko, T., Schottelius, M., Hauser, A., Schwaiger, M. & Wester, H. J. (2006). Chemoselective hydrazone formation between HYNICfunctionalized peptides and 18F-fluorinated aldehydes. Nucl Med Biol., 33, 173–83.
Cai, H., Fissekis, J. & Conti, P. S. (2009). Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and 64Cu radiolabelling, Dalton Trans., 2009, 5395–400.
Cai, H., Li, Z., Huang, C. W., Park, R., Shahinian, A. H. & Conti, P. S. (2010a). An improved synthesis and biological evaluation of a new caged-like bifunctional chelator 4-((8-amino-3, 6, 10, 13, 16, 19- hexaazabicyclo [6.6.6] icosane-1-ylamino) methyl) benzoic acid (AmBaSar) for 64Cu-RPs, Nucl. Med. Biol., 37, 57–65.
Cai, H., Li, Z., Huang, C. W., Park, R., Shahinian, A. H. & Conti, P. S. (2010). An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3, 6, 10, 13, 16, 19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl) benzoic acid, for 64Cu RPs, Nucl. Med. Biol., 37, 57–65.
Cai, H., Li, Z., Huang, C. W., Shahinian, A. H., Wang, H., Park, R. & Conti, P. S. (2010b). Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved MicroPET imaging of integrin αvβ3 expression, Bioconjug. Chem., 21, 1417–1424.
Carson, R. E., Lixin, L., Watabe, H., Der, M. G., Adams, H. R., Jagoda, E., et al. (2000). PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol., 27, 493–497.
Chambers, R. D. & Spink, R. C. H. (1999). Microreactors for elemental fluorine. Chem. Comm., 883-884.
Chen, K. & Conti, P. S. (2010). Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews. Advanced Drug Delivery Reviews, 62, 1005–1022.
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., et al. (2005). Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med., 46, 945.
Christian, B. T., Narayanan, T., Shi, B., Morris, E. D., Mantil, J. & Mukherjee, J. (2004). Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab., 24, 309–322.
Coenen, H. H., Elsinga, P. H., Iwata, R., Kilbourn, M. R., Pillai, M. R. A., Rajan, M. G. R., Wagner, Jr. H. N. & Zaknun, J. J. (2010). Fluorine-18 radiopharmaceutical’s beyond [18F]FDG for use in oncology and neurosciences. Nuc Med and Biol., 37, 727–740.
Cole, W. C., DeNardo, S. J., Meares, C. F., McCall, M. J., DeNardo, G. L., Epstein, A. L., O'Brien, H. A. & Moi, M. K. (1986). Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B., 13, 363–368.
Cole, W. C., DeNardo, S. J., Meares, C. F., McCall, M. J., DeNardo, G. L., Epstein, A. L., O'Brien, H. A. & Moi, M. K. (1987). Comparative serum stability of radiochelates for antibody RPs, J. Nucl. Med., 28, 83–90.
Czoty, P. W., Morgan, D., Shannon, E. E., Gage, H. D. & Nader, M. A. (2004). Characterization of dopamine D1 and D2 receptor function in socially housed cynomolgus monkeys selfadministering Cocaine. Psychopharmacology (Berl), 174, 381-388.
de Bruin, B., Kuhnast, B., Hinnen, F., Yaouancq, L., Amessou, M., Johannes, L., et al. (2005). 1-[3-(2-[18F]fluoropyridin-3-yloxy) propyl]pyrrole- 2,5-dione: design, synthesis, and radiosynthesis of a new [18F] fluoropyridine-based maleimide reagent for the labeling of peptides and proteins. Bioconjugate Chem., 16, 406-420.
de Vries, E. F. J., Luurtsema, G., Brüssermann, M., Elsinga, P. H. & Vaalburg, W. (1999). Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]Fluoro-L-DOPA. Appl Radiat Isot, 51, 389–394.
DeGrado, T. R., Baldwin, S. W., Wang, S., Orr, M. D., Liao, R. P., Friedman, H. S., et al. (2011). Synthesis and evaluation of 18F-labeled Choline analogs as oncologic PET tracers. J Nucl Med., 42, 1805–1817.
DeGrado, T. R., Coleman, R. E., Wang, S., Baldwin, S. W., Orr, M. D., Robertson, C. N., et al. (2001). Synthesis and evaluation of 18F-labeled Choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res, 61, 110–117.
Dekker, B. A., Keen, H. G., Lyons, S., Disley, L., Hastings, H., Reader, A. J., Ottewell, P., Watson, A. & Zweit, J. (2005b). MBP–annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl. Med. Biol., 32, 241–252.
Dekker, B. A., Keen, H. G., Shaw, D., Disley, L., Hastings, D., Hadfield, J., Reader, A. Allan, D., Julyan, P., Watson, A. & Zweit, J. (2005a). Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl. Med. Biol., 32, 403–413.
Deng, H., Cobb, S. L., Gee, A. D., Lockhart, A., Martarello, L., McGlinchey, R. P. et al. (2006). Fluorinase mediated C-18F bond formation, an enzymatic tool for PET labelling. Chem Commun (Camb), 14, 652–654.
Dewey, S. L., Smith, G. S., Logan, J., Brodie, J. D., Yu, D. W., Ferrieri, R. A., King, P. T., MacGregor, R. R., Martin, T. P., Wolf, A. P., et al. (1992). GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-Raclopride and positron emission tomography. J Neurosci, 12, 3773-3780.
Di Bartolo, N., Donlevy, T. M. & Smith, S. V. (2001). Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging, J. Chem. Soc., Dalton Trans., 2303–2309.
Di Bartolo, N., Sargeson, A. M. & Smith, S. V. (2006). New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr, Org. Biomol. Chem., 4, 3350–3357.
Ebadi, M. & Sharma, S. (2006). Metallothioneins 1 and 2 attenuate peroxynitrite induced oxidative stress in Parkinson’s disease. J. Exp. Biol. & Med., 231, 1576-1583.
Ebadi, M., Sharma, S., Ghafourifar, P., Brown-Borg, H. & Refaey, H. El. (2005). Peroxynitrite in the Pathogenesis of Parkinson’s Disease and the Neuroprotective Role of Metallothioneins. Methods in Enzymol., 396, 276-298.
Egerton, A., Demjaha, A., McGuire, P., Mehta, M. A. & Howes, O. D. (2010). The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage., 50, 524-531.
Elsinga, P. H., Franssen, E. J., Hendrikse, N. H., Fluks, L., Weemaes, A. M., Van der Graaf, W. T., De Vries, E. G., Visser, G. M. & Vaalburg, W. (1996). Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J. Nucl. Med., 37, 1571–1575.
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H. & Winger, G. (2002). 3, 4-MethylenedioxymethAmphetamine (MDMA, “ecstasy”) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl), 161, 356-364.
Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M., Sherman, P., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H. & Winger, G. (2004). Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology., 29, 1270-1281.
Ferreira, C. L., Yapp, D. T., Lamsa, E., Gleave, M., Bensimon, C., Jurek, P. & Kiefer, G. E. (2008). Evaluation of novel bifunctional chelates for the development of Cu-64-based RPs, Nucl. Med. Biol., 35, 875–882.
Fletcher, P. D. I., Haswell, S. J., Pombo-Villar, E., Warrington, B. H., Watts, P., Wong, S. Y. F. & Zhang, X. (2002). Micro reactors: principles and applications in organic synthesis. Tetrahedron., 58, 4735–4757.
Floeth, F. W., Sabel, M., Stoffels, G., Pauleit, D., Hamacher, K., Steiger, H. J., et al. (2008). Prognostic value of 18F-fluoroethyl-L-Tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med, 49, 730–737.
Fowler, J. S., Kroll, C., Ferrieri, R., Alexoff, D., Logan, J., Dewey, S. L., Schiffer, W., Schlyer, D., Carter, P., King, P., Shea, C., Xu, Y., Muench, L., Benveniste, H., Vaska, P. & Volkow, N. D. (2007). PET studies of d-methAmphetamine pharmacokinetics in primates: comparison with lmethAmphetamine and (--)-Cocaine. J Nucl Med., 48, 1724-1732.
Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., Macgregor, R. R., Hitzemann, R., Logan, J., Bendriem, B., Gatley, S. J., et al. (1989). Mapping Cocaine binding sites in human and baboon brain in vivo. Synapse., 4, 371-377.
Gillies, J. M., Najima, N. & Zweita, J. (2006). Analysis of metal radioisotope impurities generated in [18O]H2O during the cyclotron production of fluorine-18. Applied Radiation and Isotopes., 64, 431–434.
Gillies, J. M., Prenant, C., Chimon, G. N., Smethurst, G. J., Dekker, B. A. & Zweit, J. (2006b). Microfluidic technology for PET radiochemistry. Appl Radiat Isot., 64, 333-336.
Gillies, J. M., Prenant, C., Chimon, G. N., Smethurst, G. J., Perrie, W., Hamblett, I., Dekker, B. & Zweit, J. (2006a). Microfluidic reactor for the radiosynthesis of PET radiotracers. Appl Radiat Isot., 64, 325-332.
Hadd, A. G., Raymond, D. E., Halliwell, J. W., Jacobson, S. C. & Ramsey, J. M. (1997). Microchip device for performing enzyme assays. Anal. Chem., 69, 3407–3412.
Hara, T., Kosaka, N. & Kishi, H. (2002). Development of 18F-fluoroethylCholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med., 43, 187–199.
Hara, T. & Yuasa, M. (1997). Automated synthesis of fluorine-18 labeled Choline analogue: 2-fluoroetheyl-dimethyl-2-oxyethylammonium. J Nucl Med., 38(Suppl), 44P.
Hashimoto, K., Tsukada, H., Nishiyama, S., Fukumoto, D., Kakiuchi, T. & Iyo, M. (2007). Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methAmphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry., 61, 577-581.
Haug, A., Auernhammer, C. J., Wängler, B., Tiling, R., Schmidt, G., Göke, B., et al. (2009). Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging, 36, 765–770

.
Heiss, W. D. & Hilker, R. (2004). The sensitivity of 18F-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol, 11, 5–12.
Henry, P. K., Murnane, K. S., Votaw, J. R. & Howell, L. L. (2010). Acute brain metabolic effects of Cocaine in rhesus monkeys with a history of Cocaine use. Brain Imaging and Behavior., 4, 212-219.
Hnatowich, D. J., Layne, W. W., Childs, R. L., Lanteigne, D., Davis, M. A., Griffin, T. W. & Doherty, P. W. (1983). Radioactive labeling of antibody: a simple and efficient method. Science., 220, 613–615.
Howell, L. L., Carroll, F. I., Votaw, J. R., Goodman, M. M. & Kimmel, H. L. (2007). Effects of combined dopamine and serotonin transporter inhibitors on Cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther., 320,757-765.
Howell, L. L., Hoffman, J. M., Votaw, J. R., Landrum, A. M. & Jordan, J. F. (2001). An apparatus and behavioral training protocol to conduct positron emission tomography (PET) neuroimaging in conscious rhesus monkeys. J Neurosci Methods, 106,161-169.
Howell, L. L., Hoffman, J. M., Votaw, J. R., Landrum, A. M., Wilcox, K. M. & Lindsey, K. P. (2002). Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. Psychopharmacology (Berl), 159, 154-160.
Howell, L. L. & Murnane, K. S. (2011). Nonhuman primate positron emission tomography neuroimaging in drug abuse research. Pharmacol Exp Ther., 337, 324-334.
Howell, L. L., Votaw, J. R., Goodman, M. M. & Lindsey, K. P. (2010). Cortical activation during Cocaineuse and extinction in rhesus monkeys. Psychopharmacology (Berl), 208, 191-199.
Hwang, D. R., Dence, C. S., Bonasera, T. A. & Welch, M. J. (1998). No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Int J Radiat Appl Instrum [A], 40, 117–126.
Ishikawa, Y., Iwata, R., Furumoto, S. & Takai, Y. (2005). Automated preparation of hypoxic cell marker [18F]FRP-170 by on-column hydrolysis. Appl Radiat Isot., 62, 705–710.
Iwata, R. (2004). Reference Book for PET- RPs. (2004) Cyclotron and Radioisotope Center, Tohoku University. Japan. 4th Edition.
Jacobs, A. H., Thomas, A., Kracht, L. W., Li, H., Dittmar, C., Garlip, G., et al. (2005). 18F-Fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med., 46, 1948–1958.
Jacobson, M. S., Hung, J. C., Mays, T. L. & Mullan, B. P. (2002). The planning and design of a new PET radiochemistry facility. Mol Imaging Biol., 4, 119-127.
Kaneta, T., Takai, Y., Iwata, R., Hakamatsuka, T., Yasuda, H., Nakayama, K., et al. (2007). Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl. Med., 21, 1–7.
Keen, H. G., Dekker, B. A., Disley, L., Hastings, H., Lyons, S., Reader, A. J., Ottewell, P., Watson, A. & Zweit, J. (2005). Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl. Med. Biol., 32, 395–402.
Kilbourn, M. R., Hockley, B., Lee, L., Hou, C., Goswami, R., Ponde, D. E., et al. (2007). Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine (DTBZ) in rat and monkey brain. Nucl Med Biol., 34, 233–237.
Kimmel, H. L., O’Connor, J. A., Carroll, F. I. & Howell, L. L. (2007). Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of Cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav., 86, 45-54.
Klok, R. P., Klein, P. J., Herscheid, J. D. M. & Windhorst, A. D. (2006). Synthesis of N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ([18F]FP-β-CIT). J Labelled Comp Radiopharm., 49, 77–89.
Klongpanichapak, S., Govitrapong, P., Sharma, S. & Ebadi, M. (2006). Attenuation of Cocaine and MethAmphetamine Neurotoxicity by Coenzyme Q10. Neurochem Res, 31, 303–311.
Koehler, L., Gagnon, K., McQuarrie, S. & Wuest, F. (2010). Iodine-124: a promising positron emitter for organic PET chemistry, Molecules., 15, 2686–2718.
Kondo, M., Nakano, A., Saito, D. & Shimono, Y. (1998). Assessment of “microvascular no-reflow phenomenon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J. Am. Coll. Card., 32, 898–903.
Koopmans, K. P., Brouwers, A. H., De Hooge, M. N., Van der Horst-Schrivers, A. N., Kema, I. P. & Wolffenbuttel, B. H. (2005). Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med, 46, 1240–1243.
Kopp, M. U., de Mello, A. J. & Manz, A. (1998). Chemical amplification: continuous flow PCR on a chip. Science., 280, 1046–1047.
Kumar, P., Mercer, J., Doerkson, C., Tonkin, K. & McEwan, A. J. (2007). Clinical production, stability studies and PET imaging with 16-alpha-[18F] fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharmaceut Sci., 10, 256s–265s.
Kumar, R., Dhanpathi, H., Basu, S., Rubello, D., Fanti, S. & Alavi, A. (2008). Oncologic PET tracers beyond [18F]FDG and the novel quantitative approaches in PET imaging, Q. J. Nucl. Med. Mol. Imaging., 52, 50–55.
Kung, H. F., Kung, M. P., Wey, S. P., Lin, K. J. & Yen, T. C. (2007). Clinical acceptance of molecular imaging agent: a long march with [99mTc] TRODAT. Nucl Med Biol., 34, 787–789.
Lary, A., Robinson, M. D., Dianne Preksto, P. A. C., Carlos, M. C. & David, S. H. (1998). Intraoperative Gamma Probe-Directed Biopsy of Asymptomatic Suspected Bone Metastases. Ann Thoracic Surgery., 65,1426–1432.
Lemaire, C., Cantineau, R., Guillaume, M., Plenevaux, A. & Christiaens, L. (1991). Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med., 32, 2266–2272.
Li, X., Jung, Y. W., Snyder, S. E., Blair, J., Sherman, P. S., Desmond, T., et al. (2008). 5-tert-butyl-2-(4′-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABAA receptor radioligands. Nucl Med Biol., 35, 549–559.
Li, Z. B., Chen, K., Wu, Z., Wang, H., Niu, G. & Chen, X., (2009). 64Cu-labeled PEGylated polyethylenimine for cell trafficking and tumor imaging, Mol. Imaging Biol., 11, 415–423.
Li, Z. & Conti, P. S. (2010). Radiopharmaceutical chemistry for positron emission tomography. Advanced Drug Delivery Reviews., 62, 1031–1051.
Li, Z. B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L. & Chen, X. (2007). 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression, J. Nucl. Med., 48, 1162–1171.
Lindsey, K. P., Wilcox, K. M., Votaw, J. R., Goodman, M. M., Plisson, C., Carroll, F. I., Rice, K. C. & Howell, L. L. (2004). Effects of dopamine transporter inhibitors on Cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther., 309, 959-969.
Liu, S. (2008). Bifunctional coupling agents for radiolabeling of biomolecules and targetspecific delivery ofmetallic radionuclides, Adv. Drug Deliv. Rev., 60, 1347–1370.
Lodi, F., Rizzello, A., Carpinelli, A., Di Pierro, D., Cicoria, G., Mesisca, V., Marengo, M. & Boschi, S. (2008). Automated synthesis of [11C]Meta hydroxyephedrine, a PET RP for Studying Sympathetic innervations in the Heart. Computers in Cardiology., 35, 341-343.
Mach, R. H., Nader, M. A., Ehrenkaufer, R. L., Line, S. W., Smith, C. R., Gage, H. D. & Morton, T. E. (1997). Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol Biochem Behav., 57, 477-486.
Manz, A. & Widmer, H. M. (1990). Miniaturized total chemical analysis systems: a novel concept for chemical sensing. Sensors Actuators B., 1, 244–1248.
Marrière, E., Rouden, J., Tadino, V. & Lasne, M. C. (2000). Synthesis of Analogues of (−)-Cytisine for in Vivo Studies of Nicotinic Receptors Using Positron Emission Tomography. Org. Lett., 2, 1121-1124.
Martarello, L., Schaffrath, C., Deng, H., Gee, A. D., Lockhart, A. & O’Hagan, D. (2003). The first enzymatic method for C-18F bond formation: the synthesis of 5′-[18F]-fluoro-5′-deoxyadenosine for imaging with PET. J. of Labelled Compounds and RPs., 46, 1181–1189.
Martina, S. J., Eisenbartha, J. A., Wagner-Utermanna, U., Mierb, W., Henzeb, M., Pritzkowc, H., et al. (2002). A new precursor for the radiosynthesis of [18F] FLT. Nucl Med Biol., 29, 263–273.
Miller, P. W., Long, N. J., Vilar, R. & Gee, A. D. (2008). Synthesis of 11C, 18F, 15O, and 13NRadiolabels for Positron Emission Tomography. Angew. Chem. Int. Ed., 47, 8998–9933.
Minn, H., Kauhanen, S., Seppänen, M. & Nuutila, P. (2009). 18F-FDOPA: a multiple-target molecule. J Nucl Med., 1915–1918.
Morrish, P. K,, Sawle, G. V. & Brooks, D. J. (1996). An [18F]DOPA-PET and clinical study of the rate of the progression in Parkinson’s disease. Brain., 119, 585–591.
Mukherjee, J., Yang, Z. Y., Das, M. K. & Brown, T. (1995). Fluorinated benzamide neuroleptics III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]- 5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol., 22, 283–296.
Mukherjee, J., Yang, Z. Y., Lew, R., Brown, T., Kronmal, S., Cooper, M. D. & Seiden, L. S. (1997). Evaluation of d-Amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse., 27, 1-13.
Nader, M. A. & Czoty, P. W. (2005). PET imaging of dopamine D2 receptors in monkey models of Cocaine abuse: genetic predisposition versus environmental modulation. Am J Psychiatry., 162, 1473-1482.
Namavari, M., Bishop, A., Satyamurthy, N., Bida, G. & Barrio, J. R. (1992). Regioselective radiofluorodestannylation with [18F]F2 and [18F] CH3COOF: a high yield synthesis of 6-[18F]fluoro-L-dopa. Appl Rad Isot, 43, 989–996.
Okarvi, S. M. (2001). Recent progress in fluorine-18 labelled peptide RPs. Eur J. Nucl. Med., 28, 929-938.
Pretze, M., Grobe-Gehling, P. & Mamat, C. (2011). Cross-Coupling Reactions as Versatile Tool for the Preparation of PET Radiotracers. Molecules, 16, 1129-1163.
Reischl, G., Ehrlichmann, W., Bieg, C., Solbach, C., Kumar, P., Wiebe, L. I., et al. (2005). Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot, 62, 897–901.
Rostovtsev, V. V., Green, L. G., Folkin, V. V. & Sharpless, B. K. (2002). A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem Int Ed., 41, 2596–2599.
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O’Keefe, G., et al. (2008). Imaging of amyloid beta in Alzheimer’s disease with 18FBAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol., 7, 129–35.
Ryzhikov, N. N., Seneca, N., Krasikova, R. N., Gomzina, N. A., Shchukin, E., Fedorova, O. S. et al. (2005). Preparation of highly specific radioactivity [18F] flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol., 32, 109–116.
Salvadori, P. A. (2008). RPs, drug development and pharmaceuticals regulations in Europe. Current RPs, 1, 7–11.
Sargeson, A. M., (1996). The potential for the cage complexes in biology, Coord. Chem. Rev., 151, 89–114.
Scheffel, U., Szabo, Z., Mathews, W. B., Finley, P. A., Dannals, R. F., Ravert, H. T., Szabo, K., Yuan, J. & Ricaurte, G. A. (1998). In vivo detection of short- and long-term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain. Synapse, 29, 183-192.
Schirrmacher, R., Wangler, C. & Schirrmacher, E. (2007). Recent developments and trends in 18F-radiochemistry: syntheses and applications. Mini-Reviews in Organic Chemistry., 4, 317–329.
Schmaljohann, J., Gundisch, D., Minnerop, M., Bucerius, J., Joe, A., Reinhardt, M., et al. (2006). In vitro evaluation of nicotinic acetylCholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nucl Med Biol., 33, 305-309.
Seneca, N., Finnema, S. J., Farde, L., Gulyas, B., Wikstrom, H. V., Halldin, C. & Innis, R. B. (2006). Effect of Amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]Raclopride. Synapse, 59, 260-269.
Sharma, S. & Ebadi, M. (2005). Distribution kinetics of 18F-DOPA in Weaver Mutant Mice. Mol Brain Res., 139, 23-30.
Sharma, S. & Ebadi, M. (2008). SPECT neuroimaging in translational research of CNS disorders. Neurochemistry International., 52, 352–62.
Sharma, S. & Ebadi, M. (2008). Therapeutic Potential of Metallothioneins in Parkinson’s Disease. New Research in Parkinson’s Disease. In New Research in Parkinson’s Disease. Eds: Timothy F Hahn and Julian Werner, Nov Science Publishers, Inc. pp. 1-41, USA.


Sharma, S. & Ebadi, M. (2010). In-vivo Molecular Imaging in Parkinson’s Disease. In Parkinson’s Disease (Eds: Manuchair Ebadi & Rnlald Pfiffer). CRC Press.
Sharma, S., Krause, G. & Ebadi, M. (2006). Radiation Safety and Quality Control in the Cyclotron Laboratory. Radiation Protection Dosimetry., 118, 431-439.
Sharma, S., Krause, G. & Ebadi, M., (2007). Basic Requirements of Quality Control of PET- RPs. Proceedings of the International Atomic Energy Agency, Bangkok, Thailand (Extended Synopsis: IAEA-CN-157/171p, Nov 10-14).
Sharma, S., Refaey, H. El. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse models of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res Bull., 70, 22-30.
Shen, B., Ehrlichmann, W., Uebele, M., Machulla, H. J. & Reischl, G. (2009). Automated synthesis of n.c.a. [18F]FDOPA via nucleophilic aromatic substitution with [18F]Fluoride. Appl Radiat Isot., 67, 1650–1653.
Shokeen, M. & Anderson, C. J. (2009). Molecular imaging of cancer with copper-64 RPs and positron emission tomography (PET), Acc. Chem. Res., 42, 832–841.
Slifstein, M., Narendran, R., Hwang, D. R., Sudo, Y., Talbot, P. S., Huang, Y. & Laruelle, M. (2004). Effect of Amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse., 54, 46-63.
Smith, S. V. (2008). Sarar technology for the application of copper-64 in biology and materials science, Q. J. Nucl. Med. Mol. Imaging, 52, 193–202.
Sprague, J. E., Peng, Y., Fiamengo, A. L., Woodin, K. S., Southwick, E. A., Weisman, G. R., Wong, E. H., Golen, J. A., Rheingold, A. L. & Anderson, C. J. (2007). Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycleamide complexes as models of peptide conjugate imaging agents, J. Med. Chem., 50, 2527–235.
Sprague, J. E., Peng, Y., Sun, X., Weisman, G. R., Wong, E. H., Achilefu, S. & Anderson, C. J. (2004). Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator, Clin. Cancer Res., 10, 8674–8682.
Sun, X., Wuest, M., Weisman, G. R., Wong, E. H., Reed, D. P., Boswell, C. A., Motekaitis, R., Martell, A. E., Welch, M. J. & Anderson, C. J. (2002). Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands, J. Med. Chem., 45, 469–477.
Suzuki, M., Yamaguchi, K., Honda, G., Iwata, R., Furumoto, S., Jeong, M., et al. (2005). An experimental study on O-[18F]fluoromethyl-L-Tyrosine for differentiation between tumor and inflammatory tissues. Ann Nucl Med., 19, 589–595.
Tang, G., Wang, M., Tang, X., Gan, M. & Luo, L. (2005). Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nucl Med Biol., 32, 553–558.
Theodore, W. H., Carson, R. E., Andreasen, P., Zametkin, A., Blasberg, R., Leiderman, D. B., et al. (1992). PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy. Epilepsy Res., 13, 129–139.
Timerbaev, A. R., Semenova, O. P., Buchberger, W. & Bonn, G. K. (1996). Speciation studies by capillary electrophoresis-Simultaneous determination of chromium(III) and chromium(VI). Anal Bioanal Chem., 354, 414-419.
Tipre, D. N., Zoghbi, S. S., Liow, J. S, Green, M. V., Seidel, J., Ichise, M., et al. (2006). PET imaging of brain 5-HT1A receptors in rat in vivo with 18FFCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J Nucl Med., 47, 345–353.
Tokunaga, M., Seneca, N., Shin, R. M., Maeda, J., Obayashi, S., Okauchi, T., Nagai, Y., Zhang, M. R., Nakao, R., Ito, H., Innis, R. B., Halldin, C., Suzuki, K., Higuchi, M. & Suhara, T. (2009). Neuroimaging and physiological evidence for involvement of glutamatergic transmission tracer of Cholinergic neurons of the heart. Nucl Med Biol, 21, 189–195.
Van-Berckel, B. N., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D. R., Huang, Y., Narendran, R., Van Heertum, R. & Laruelle, M. (2006). Modulation of Amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology., 31, 967-977.
Vernaleken, I., Buchholz, H. G., Kumakura, Y., Siessmeier, T., Stoeter, P., Bartenstein, P., et al. (2007). “Prefrontal” cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp., 28, 931-939.
Villemagne, V., Yuan, J., Wong, D. F., Dannals, R. F., Hatzidimitriou, G., Mathews, W. B., Ravert, H. T., Musachio, J., McCann, U. D. & Ricaurte, G. A. (1998). Brain dopamine neurotoxicity in baboons treated with doses of methAmphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci., 187, 419-427.
Volkow, N. D., Fowler, J. S., Gatley, S. J., Dewey, S. L., Wang, G. J., Logan, J., Ding, Y. S., Franceschi, D., Gifford, A., Morgan, A., Pappas, N. & King, P. (1999). Comparable changes in synaptic dopamine induced by Methylphenidate and by Cocaine in the baboon brain. Synapse.,

31, 59-66.
Voss, S. D., Smith, S. V., DiBartolo, N., McIntosh, L. J., Cyr, E. M. & Bonab, A. A. (2007). Dearling JL, Carter EA, Fischman AJ, Treves ST, Gillies SD, Sargeson AM, Huston JS, Packard AB, Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates, Proc. Natl Acad. Sci. USA, 104, 17489–174493.
Wadas, T. J., Wong, E. H., Weisman, G. R. & Anderson, C. J. (2007). Copper chelation chemistry and its role in copper RPs, Curr. Pharm. Des., 13, 3–16.
Wagner, Jr. H. N. (2009). Brain Imaging. Springer-Verlag London Limited.
Wei, L., Ye, Y., Wadas, T. J., Lewis, J. S., Welch, M. J., Achilefu, S. & Anderson, C. J. (1996). 64Cu labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity, Nucl. Med. Biol., 36, 277–285.
Wu, X. F., Anbarasan, P., Neumann, H. & Beller, M. (2010). Vom Edelmetall zum Nobelpreis: Palladiumkatalysierte Kupplungen als Schlüsselmethode in der organischen Chemie. Angew. Chem., 122, 9231-9234.
Wuest, F., Carlson, K. E. & Katzenellenbogen, J. A. (2008). Expeditious synthesis of steroids containing a 2-methylsulfanyl-acetyl side chain as potential glucocorticoid receptor imaging agents. Steroids., 73, 69–76.
Wuest, F., Kniess, T., Bergmann, R. & Pietzsch, J. (2008). Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorganic & Medicinal Chem., 16, 7662–7670.

Chapter 11

Anonymous, (1998). Guidelines for neuroimaging evaluation of patients with uncontrolled epilepsy considered for surgery. Commission on neuroimaging of the International League Against Epilepsy. Epilepsia., 39, 1375-1376.
Adams, K. M., Gilman, S., Johnson-Greene, D., Koeppe, R. A., Junck, L., Kluin, K. J., Martorello, S., Johnson, M. J., Heumann, M. & Hill, E. (1998). The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolismstudied with positron emission tomography in older Alcoholic patients. Alcohol. Clin.. Exp.. Res., 22,105-110.
Alger, J. R., Frank, J. A., Bizzi, A., Fulham, M. J., DeSouza, B. X., Duhaney, M. O., Inscoe, S. W., Black, J. L., van Zijl, P. C. & Moonen, C. T. (1990). Glucose metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 FdG FDG-PET NEUROIMAGING. Radiology., 177, 633-641.
Ances, B. M., Vitaliani, R., Taylor, R. A., Liebeskind, D. S., Voloschin, A., Houghton, D. J., Galetta, S. L., Dichter, M., Alavi, A., Rosenfeld, M. R. & Dalmau, J. (2006). Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and FDG-PET NEUROIMAGING correlates. Brain., 128, 1764-1777.
Asano, E., Juhasz, C., Shah, A., Muzik, O., Chugani, D. C., Shah, J., Sood, S. & Chugani, H. T. (2006). Origin and propagation of epileptic spasms delineated on electrocorticography. Epilepsia., 46, 1086-1089.
Baba, H., Uchida, K., Sadato, N., Yonekura, Y., Kamoto, Y., Maezawa, Y., Furusawa, N. & Abe, Y. (1999). Potential usefulness of 18F-2-fluoro-deoxy-D-glucose positron emission tomography in cervical compressive myelopathy. Spine., 24,1449-1454.
Barreto, J. A. & Gonzalez-Lima, F. (1995). A landscape parametric profile approach for rat brain image analysis. Neuroimage., 2, 35-43.
Bokde, A. L., Teipel, S. J., Drzezga, A., Thissen, J., Bartenstein, P., Dong, W., Leinsinger, G., Born, C., Schwaiger, M., Moeller, H. J. & Hampel, H. (2006). Association between cognitive performance and cortical glucose metabolismin patients with mild Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 20, 352-357.
Borbely, K., Nyary, I., Toth, M., Ericson, K. & Gulyas, B. (2006). Optimization of semi-quantification in metabolic FDG-PET NEUROIMAGING studies with (18)F-FdG and (11)C-methionine in the determination of malignancy of gliomas. J. Neurol. Sci., 263(1-2), 232.
Borbely, K. (2006). [Functional neuroimaging in movement disorders]. Orv. Hetil., 142, 2347-2355.
Borbely, K., Fulham, M. J., Brooks, R. A. & Di Chiro, G. (1992). FDG-PET NEUROIMAGING-FdG of cranial and spinal neuromas. J. Nucl. Med., 33(11), 1931-1934..
Broderick, D. F. (2006). neuroimaging in neuropsychiatry. Psychiatr. Clin. North. Am., 28, 549-566.
Brunetti, A., Fulham, M. J., Aloj, L., De Souza, B., Nieman, L., Oldfield, E. H. & Di Chiro, G. (1998). Decreased brain glucose utilization in patients with Cushing's disease. J. Nucl. Med., 39, 786-790.
Brunetti, A., Berg, G., Di Chiro, G., Cohen, R. M., Yarchoan, R., Pizzo, P. A., Broder, S., Eddy, J., Fulham, M. J. & Finn, R. D. (1989). Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a FDG-PET NEUROIMAGING-FDG study. J. Nucl. Med., 30, 581-590.
Bryant, C. A. & Jackson, S. H. (1998). Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs. Aging., 13, 211-222.
Cascino, G. D. (2006). Surgical Treatment for Extratemporal Epilepsy. Curr. Treat. Options. Neurol., 6, 257-262.
Chae, J. H., Nahas, Z., Lomarev, M., Denslow, S., Lorberbaum, J. P., Bohning, D. E. & George, M. S. (2006). A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J. Psychiatr. Res., 37, 443-455.
Chan, S., Chin, S. S., Nordli, D. R., Goodman, R. R., DeLaPaz, R. L. & Pedley, T. A. (1998). Prospective magnetic resonance imaging identification of focal cortical dysplasia, including the non-balloon cell subtype. Ann. Neurol., 44, 749-757.
Cho, Y. W., Motamedi, G. K., Laufenberg, I., Sohn, S. I., Lim, J. G., Lee, H., Yi, S. D., Lee, J. H., Kim, D. K., Reba, R., Gaillard, W. D., Theodore, W. H., Lesser, R. P. & Steinlein, O. K. (2006). A Korean kindred with autosomal dominant nocturnal frontal lobe epilepsy and mental retardation. Arch. Neurol., 60, 1625-1632.
Chugani, H. T., Shewmon, D. A., Shields, W. D., Sankar, R., Comair, Y., Vinters, H. V. & Peacock, W. J. (1993). Surgery for intractable infantile spasms: neuroimaging perspectives. Epilepsia., 34, 764-771.
Clark, C. M., Ammann, W., Martin, W. R., Ty, P. & Hayden, M. R. (1991). The FDG/FDG-PET NEUROIMAGING methodology for early detection of disease onset: a statistical model. J. Cereb. Blood. Flow. Metab., 11, A96-102.
Csaba, J., (2006). Positron emission tomography in presurgical localization of epileptic foci. Ideggyogy. Sz., 56, 249-254.
da Silva, E. A., Chugani, D. C., Muzik, O. & Chugani, H. T. (1997). Identification of frontal lobe epileptic foci in children using positron emission tomography. Epilepsia., 38, 1198-1208.
da Silva, E. A., Chugani, D. C., Muzik, O. & Chugani, H. T. (1997). Landau-Kleffner syndrome: metabolic abnormalities in temporal lobe are a common feature. J. Child. Neurol., 12, 489-495.
De Souza, B., Brunetti, A., Fulham, M. J., Brooks, R. A., DeMichele, D., Cook, P., Nieman, L., Doppman, J. L., Oldfield, E. H. & Di Chiro, G. (1990). Pituitary microadenomas: a FDG-PET NEUROIMAGING study. Radiology., 177, 39-44.
Demetriades, A. K. (2006). Functional neuroimaging in Alzheimer's type dementia. J. Neurol. Sci., 204, 247-251.
Di Chiro, G. & Fulham, M. J. (1993). Virchow’s shackles: can FDG-PET NEUROIMAGING-FDG challenge tumor histology? AJNR. Am. J. Neuroradiol., 14, 524-527.
Di Chiro, G., Oldfield, E., Wright, D. C., De Michele, D., Katz, D. A., Patronas, N. J., Doppman, J. L., Larson, S. M., Ito, M. & Kufta, C. V. (1988). Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: FDG-PET NEUROIMAGING and neuropathologic studies. AJR. Am. J. Roentgenol., 150, 189-197.
Doraiswamy, P. M., Steffens, D. C., Pitchumoni, S. & Tabrizi, S. (1998). Early recognition of Alzheimer’s disease: what is consensual? What is controversial? What is practical? J. Clin. Psychiatry., 59 Suppl 13, 6-18.
Dougherty, D. D., Weiss, A. P., Cosgrove, G. R., Alpert, N. M., Cassem, E. H., Nierenberg, A. A., Price, B. H., Mayberg, H. S, Fischman, A. J. & Rauch, S. L. (2006). Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J. Neurosurg., 99, 1010-1017.
Drevets, W. C., Price, J. L., Bardgett, M. E., Reich, T., Todd, R. D. & Raichle, M. E. (2006). Glucose metabolismin the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol. Biochem. Behav., 71, 431-447.
Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M. & Kurz, A. (2006). Cerebral metabolic changes accompanying conversion of MCI into Alzheimer's disease: a FDG-PET NEUROIMAGING follow-up study. Eur. J. Nucl. Med. Mol. Imaging., 30, 1104-1113.
Duarte, P. S., Zhuang, H., King, D. & Alavi, A. (2006). [Brain glucose hypometabolism in patients with mesial-temporal sclerosis demonstrated by FDG-FDG-PET NEUROIMAGING]. Arq. Neuropsiquiatr., 58, 869-876.
Duncan, J. S. (2006). Brain imaging in idiopathic generalized epilepsies. Epilepsia., 46 Suppl 9, 108-111.
Dupont, S., Bouilleret, V., Hasboun, D., Semah, F. & Baulac, M. (2003). Functional anatomy of the insula: new insights from imaging. Surg. Radiol. Anat., 25, 113-119.
Eidelberg, D., Moeller, J. R. & Dhawan, V. (1994). FdG-PET neuroimagingsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S., and. The metabolic topography of parkinsonism. J. Cereb. Blood. Flow. Metab., 14, 783-801.
Fedi, M., Reutens, D., Okazawa, H., Andermann, F., Boling, W., Dubeau, F., White, C., Nakai, A., Gross, D. W., Andermann, E. & Diksic, M. (2006). Localizing value of alpha-methyl-L-tryptophan FDG-PET NEUROIMAGING in intractable epilepsy of neocortical origin. Neurology., 57, 1629-1636.
Fogarasi, A., Hegyi, M., Neuwirth, M., Halasz, P., Barsi, P., Farkas, V. & Bognar, L. (2006). Comparative evaluation of concomitant structural and functional neuroimages in Rasmussen's encephalitis. J. neuroimaging., 13, 339-345.
Fontaine, A., Azouvi, P., Remy, P., Bussel, B. & Samson, Y. (1999). Functional anatomy of neuropsychological deficits after severe traumatic brain injury. Neurology., 53, 1963-1968.
Francavilla, T. L., Miletich, R. S., DeMichele, D., Patronas, N. J., Oldfield, E. H., Weintraub, B. D. & Di Chiro, G. (1991). Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery., 28, 826-833.
Francavilla, T. L., Miletich, R. S., Di Chiro, G., Patronas, N. J., Rizzoli, H. V. & Wright, D. C. (1989). Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery., 24, 1-5.
Frasson, E., Moretto, G., Beltramello, A., Smania, N., Pampanin, M., Stegagno, C., Tanel, R. & Rizzuto, N. (1998). Neuropsychological and neuroimaging correlates in corticobasal degeneration. Ital. J. Neurol. Sci., 19, 321-328.
Fulham, M. J., Brunetti, A., Aloj, L., Raman, R., Dwyer, A. J. & Di Chiro, G. (1995). Decreased cerebral glucose metabolismin patients with brain tumors: an effect of corticosteroids. J. Neurosurg., 83, 657-664.
Fulham, M. J., Dietz, M. J., Duyn, J. H., Shih, H. H., Alger, J. R. & Di Chiro, G. (1994). Transsynaptic reduction in N-acetyl-aspartate in cerebellar diaschisis: a proton MR spectroscopic imaging study. J. Comput. Assist. Tomogr., 18, 697-704.
Fulham, M. J., Melisi, J. W., Nishimiya, J., Dwyer, A. J. & Di Chiro, G. (1993). Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology., 189, 221-225.
Fulham, M. J., Bizzi, A., Dietz, M. J., Shih, H. H., Raman, R., Sobering, G. S., Frank, J. A., Dwyer, A. J., Alger, J. R. & Di Chiro, G. (1992). Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology., 185, 675-686.
Fulham, M. J., Dubinsky, R. M., Polinsky, R. J., Brooks, R. A., Brown, R. T., Curras, M. T., Baser, S., Hallett, M. & Di Chiro, G. (1991). Computed tomography, magnetic resonance imaging and positron emission tomography with [18F]FdG in multiple system atrophy and pure autonomic failure. Clin. Auton. Res., 1, 27-36.
Ferner, R. E. & O’Doherty, M. J. (2002). Neurofibroma and schwannoma. Current Opin Neurol., 15(6), 679-684.
Glantz, M. J., Hoffman, J. M., Coleman, R. E., Friedman, A. H., Hanson, M. W., Burger, P. C., Herndon, J. E., 2nd, Meisler, W. J. & Schold, S. C. Jr. (1991). Identification of early recurrence of primary central nervous system tumors by [18F]FdG positron emission tomography. Ann. Neurol., 29, 347-355.
Glenn, L. W. (2006). Innovations in neuroimaging of skull base pathology. Otolaryngol. Clin. North. Am., 38, 613-629.
Goldstein, R. Z. & Volkow, N. D. (2006). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry., 159, 1642-1652.
Gordon, C. T., Frazier, J. A., McKenna, K., Giedd, J., Zametkin, A., Zahn, T., Hommer, D., Hong, W., Kaysen, D. & Albus, K. E. (1994). Childhood-onset schizophrenia: an NIMH study in progress. Schizophr. Bull., 20, 697-712.
Gulyás, B. & Halldin, C. (2012). New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging., 56(2), 173-190.
Gur, R. E., Mozley, P. D., Resnick, S. M., Mozley, L. H., Shtasel, D. L., Gallacher, F., Arnold, S. E., Karp, J. S., Alavi, A. & Reivich, M. (1995). Resting cerebral glucose metabolismin first-episode and previously treated patients with schizophrenia relates to clinical features. Arch. Gen. Psychiatry., 52, 657-667.
Gzesh, D., Goldstein, S., Sperling, M. R. & Alavi, A. (1990). Complex partial epilepsy: the role of neuroimaging in localizing a seizure focus for surgical intervention. J. Nucl. Med., 31, 1839-1843.
Haemers, I., Kono, S., Goldman, S., Gitlin, J. D. & Pandolfo, M. (2006). Clinical, molecular, and FDG-PET NEUROIMAGING study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia. J. Neurol. Neurosurg. Psychiatry., 75, 334-337.
Hamaguchi, T., Kitamoto, T., Sato, T., Mizusawa, H., Nakamura, Y., Noguchi, M., Furukawa, Y., Ishida, C., Kuji, I., Mitani, K., Murayama, S., Kohriyama, T., Katayama, S., Yamashita, M., Yamamoto, T., Udaka, F., Kawakami, A., Ihara, Y., Nishinaka, T., Kuroda, S., Suzuki, N., Shiga, Y., Arai, H., Maruyama, M. & Yamada, M. (2006). Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology., 64, 643-648.
Hampel, H., Teipel, S. J., Alexander, G. E., Pogarell, O., Rapoport, S. I. & Moller, H. J. (2006). In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and FDG-PET NEUROIMAGING. J. Neural. Transm., 109, 837-855.
Hansen, E. S., Hasselbalch, S., Law, I. & Bolwig, T. G. (2006). The caudate nucleus in obsessive-compulsive disorder. Reduced glucose metabolism following treatment with paroxetine: a FDG-PET NEUROIMAGING study. Int. J. Neuropsychopharmacol., 5, 1-10.
Henry, T. R., Ross, D. A., Schuh, L. A. & Drury, I. (1999). Indications and outcome of ictal recording with intracerebral and subdural electrodes in refractory complex partial seizures. J lin. Neurophysiol., 16, 426-438.
Henry, T. R. & Pennell, P. B. (1998). Neuropharmacological imaging in epilepsy with FDG-PET NEUROIMAGING and SPECT. Q. J. Nucl. Med., 42, 199-210.
Henry, T. R. (1996). Functional neuroimaging with positron emission tomography. Epilepsia., 37, 1141-1154.
Henry, T. R., Mazziotta, J. C., Engel, J., Jr. Christenson, P. D., Zhang, J. X., Phelps, M. E. & Kuhl, D. E. (1990). Quantifying interictal metabolic activity in human temporal lobe epilepsy. J. Cereb. Blood. Flow. Metab., 10, 748-57.
Hoffman, J. M. (2006). New advances in brain tumor imaging. Curr. Opin. Oncol., 13, 148-153.
Hojo, K., Imamura, T., Takanashi, M., Ishii, K., Sasaki, M., Imura, S., Ozono, R., Takatsuki, Y., Takauchi, S. & Mori, E. (1999). Hereditary sensory neuropathy with deafness and dementia: a clinical and neuroimaging study. Eur. J. Neurol., 6, 357-361.
Hsu, J. L., Wang, H. C. & Hsu, W. C. (2006). Hyperglycemia-induced unilateral basal ganglion lesions with and without hemichorea. A FDG-PET NEUROIMAGING study. J. Neurol., 251, 1486-1490.
Irwin, M. (2001). Neuroimmunology of disordered sleep in depression and Alcoholism. Neuropsychopharmacology, 25(5 Suppl), S45-49.
Ishii, K., Ikerjiri, Y., Sasaki, M., Kitagaki, H. & Mori, E. (1999). Regional cerebral glucose metabolismand blood flow in a patient with Marchiafava-Bignami disease. AJNR. Am. J. Neuroradiol., 20, 1249-1251.
Ishii, K., Sakamoto, S., Sasaki, M., Kitagaki, H., Yamaji, S., Hashimoto, M., Imamura, T., Shimomura, T., Hirono, N. & Mori, E. (1998). Cerebral glucose metabolismin patients with frontotemporal dementia. J. Nucl. Med., 39, 1875-1878.
Ishii, K., Imamura, T., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., Hashimoto, M., Hirono, N., Shimomura, T. & Mori, E. Regional cerebral glucose metabolismin dementia with Lewy bodies and Alzheimer's disease. Neurology., 51, 125-130. 1998.
Ishii, K., Sasaki, M., Kitagaki, H., Yamaji, S., Sakamoto, S., Matsuda, K. & Mori, E. (1997). Reduction of cerebellar glucose metabolismin advanced Alzheimer's disease. J. Nucl. Med., 38, 925-928.
Kareken, D. A., Unverzagt, F., Caldemeyer, K., Farlow, M. R. & Hutchins, G. D. (1998). Functional brain imaging in apraxia. Arch. Neurol., 55, 107-113.
Kawachi, T., Ishii, K., Sakamoto, S., Sasaki, M., Mori, T., Yamashita, F., Matsuda, H. & Mori, E. (2006). Comparison of the diagnostic performance of FDG-FDG-PET NEUROIMAGING and VBM-MRI in very mild Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging., 33(7), 801-809.
Kennedy, A. M., Newman, S. K., Frackowiak, R. S., Cunningham, V. J., Roques, P., Stevens, J., Neary, D., Bruton, C. J., Warrington, E. K. & Rossor, M. N. (1995). Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain., 118, 185-205.
Kerrison, J. B., Lancaster, J. L., Zamarripa, F. E., Richardson, L. A., Morrison, J. C., Holck, D. E., Andreason, K. W., Blaydon, S. M. & Fox, P. T. (2006). Positron emission tomography scanning in essential blepharospasm. Am. J. Ophthalmol., 136, 846-852.
Kerwin, R. (1994). Functional neuroimaging in Alzheimer’s disease: how far should we go? Eur. J. Nucl. Med., 21, 1041-1043.
Kimbrell, T. A., Little, J. T., Dunn, R. T., Frye, M. A., Greenberg, B. D., Wassermann, E. M., Repella, J. D., Danielson, A. L., Willis, M. W., Benson, B. E., Speer, A. M., Osuch, E., George, M. S. & Post, R. M. (1999). Frequency dependence of antidepressant response to left prefrontal reFdG-PET neuroimagingitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. Biol. Psychiatry., 46, 1603-1613.
Knowlton, R. C., Laxer, K. D., Ende, G., Hawkins, R. A., Wong, S. T., Matson, G. B., Rowley, H. A., Fein, G. & Weiner, M. W. (1997). Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy. Ann. Neurol., 42, 829-837.
Kotagal, P. & Arunkumar, G. S. (1998). Lateral frontal lobe seizures. Epilepsia., 39 Suppl 4, S62-8, S62-68.
Kuzniecky, R. (1998). Symptomatic occipital lobe epilepsy. Epilepsia., 39 Suppl 4, S24-31, S24-31.
Kuzniecky, R. I. (1996). Neuroimaging in pediatric epilepsy. Epilepsia. 37 Suppl 1, S10-21, S10-21.
Kwon, J. S., Kim, J. J., Lee, D. W., Lee, J. S., Lee, D. S., Kim, M. S., Lyoo, I. K., Cho, M. J. & Lee, M. C. (2006). Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. Psychiatry. Res., 122, 37-47.
Laakso, A., Wallius, E., Kajander, J., Bergman, J., Eskola, O., Solin, O., Ilonen, T., Salokangas, R. K., Syvalahti, E. & Hietala, J. (2006). Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am. J. Psychiatry., 160, 904-910.
Langguth, B., Eichhammer, P., Zowe, M., Marienhagen, J., Kleinjung, T., Jacob, P., Sand, P. & Hajak, G. (2006). [Low frequency FdG-PET neuroimagingitive transcranial magnetic stimulation (rTMS) for the treatment of chronic tinnitus--are there long-term effects?]. Psychiatr. Prax., 31 Suppl 1, S52-24. 2006.
Lee, A. G. & Martin, C. O. Neuro-ophthalmic findings in the visual variant of Alzheimer's disease. Ophthalmology., 111, 376-380, 2006.
Lee, D. S., Lee, S. K. & Lee, M. C. (2006). Functional neuroimaging in epilepsy: FDG FDG-PET NEUROIMAGING and ictal SPECT. J. Korean. Med. Sci., 16, 689-696.
Lee, S. K., Choe, G., Hong, K. S., Nam, H. W., Kim, J. Y., Chung, C. K., Lee, D. S. & Chang, K. H. (2006). neuroimaging findings of cortical dyslamination with cytomegaly. Epilepsia., 42, 850-866.
Levivier, M., Massager, N., Wikler, D. & Goldman, S. (2006). Modern multimodal neuroimaging for radiosurgery: the example of FDG-PET NEUROIMAGING scan integration. Acta. Neurochir. Suppl., 91, 1-7.
Little, J. T., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Benson, B. E., Willis, M. W., Luckenbaugh, D. A. & Post, R. M. (2006). Bupropion and venlafaxine responders differ in pretreatment regional cerebral glucose metabolism in unipolar depression. Biol. Psychiatry., 57, 220-228.
Madakasira, P. V., Simkins, R., Narayanan, T., Dunigan, K., Poelstra, R. J. & Mantil, J. (2006). Cortical dysplasia localized by [11C]methionine positron emission tomography: case report. AJNR. Am. J. Neuroradiol., 23, 844-846.
Maeda, Y., Oguni, H., Saitou, Y., Mutoh, A., Imai, K., Osawa, M., Fukuyama, Y., Hori, T., Yamane, F., Kubo, O., Ishii, K. & Ishiwata, K. Rasmussen syndrome: multifocal spread of inflammation suggested from MRI and FDG-PET NEUROIMAGING findings. Epilepsia., 44, 1118-1121.
Markowitsch, H. J., Kessler, J., Weber-Luxenburger, G., Van der Ven, C., Albers, M. & Heiss, W. D. (2006). neuroimaging and behavioral correlates of recovery from mnestic block syndrome and other cognitive deteriorations. Neuropsychiatry. Neuropsychol. Behav. Neurol., 13, 60-66.
Martin, W. R., Hoskinson, M., Kremer, B., Maguire, C. & McEwan, A. (1995). Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography. J. Neuroimaging., 5, 227-232.
Massager, N., David, P., Goldman, S., Pirotte, B., Wikler, D., Salmon, I., Nagy, N., Brotchi, J. & Levivier, M. (2006). Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J. Neurosurg., 93, 951-957.
Matsuda, H. (2006). Neuroimaging for surgical treatment of epilepsy. Rinsho. Shinkeigaku., 45, 920-922.
Matsushita, S., Arai, H., Okamura, N., Ohmori, T., Takasugi, K., Matsui, T., Maruyama, M., Iwatsubo, T. & Higuchi, S. (2006). Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the MCI stage of Alzheimer's disease. Biol. Psychiatry., 52, 907-910.
Matthews, B., Siemers, E. R. & Mozley, P. D. (2006). Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry., 11, 146-519.
McIntosh, A. R. Gonzalez-Lima, F. (1994). Network interactions among limbic cortices, basal forebrain, and cerebellum differentiate a tone conditioned as a Pavlovian excitor or inhibitor: FdG mapping and covariance structural modeling. J. Neurophysiol., 72, 1717-1733.
Mizoguchi, S., Suzuki, Y., Kiyosawa, M., Mochizuki, M. & Ishii, K. (2006). Neuroimaging analysis of a case with left homonymous hemianopia and left hemispatial neglect. Jpn. J. Ophthalmol., 47, 59-63.
Mohamed, A., Eberl, S., Fulham, M. J., Kassiou, M., Zaman, A., Henderson, D., Beveridge, S., Constable, C. & Lo, S. K. (2006). Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG FDG-PET NEUROIMAGING imaging). Eur. J. Nucl. Med. Mol. Imaging., 32, 180-185.
Mountz, J. M., Liu, H. G. & Deutsch, G. (2006). Neuroimaging in cerebrovascular disorders: measurement of cerebral physiology after stroke and assessment of stroke recovery. Semin. Nucl. Med., 33, 56-76.
Munoz-Yunta, J. A., Freixas, A., Valls-Santasusana, A. & Maldonado, A. (1999). [Stereotypes, developmental disorders and neuroimaging studies]. Rev. Neurol., 28, S124-130.
Naidu, S., Kaufmann, W. E., Abrams, M. T., Pearlson, G. D., Lanham, D. C., Fredericksen, K. A., Barker, P. B., Horska, A., Golay, X., Mori, S., Wong, D. F., Yablonski, M., Moser, H. W. & Johnston, M. V. (2006). Neuroimaging studies in Rett syndrome. Brain. Dev., 23 Suppl 1, 62-71.
Nestor, P. J., Graham, N. L., Fryer, T. D., Williams, G. B., Patterson, K. & Hodges, J. R. (2006). Progressive non-fluent aphasia is associated with glucose hypometabolism centred on the left anterior insula. Brain., 126, 2406-2418.
Newberg, A. B. & Alavi, A. (2006). Neuroimaging in patients with head injury. Semin. Nucl. Med., 33, 136-147.
Nofzinger, E. A., Buysse, D. J., Germain, A., Price, J. C., Miewald, J. M. & Kupfer, D. J. (2006). Functional neuroimaging evidence for hyperarousal in insomnia. Am. J. Psychiatry., 161, 2126-2128.
Nofzinger, E. A. (2006). What can neuroimaging findings tell us about sleep disorders? Sleep. Med., 5 Suppl 1, S16-22.S16-22.
Obrocki, J., Schmoldt, A., Buchert, R. & Andresen, B. (2006). FdG-PET neuroimagingersen, K., and Thomasius, R. Specific neurotoxicity of chronic use of ecstasy. Toxicol. Lett.,127, 285-297.
Okamura, N., Arai, H., Higuchi, M., Tashiro, M., Matsui, T., Hu, X. S., Takeda, A., Itoh, M. & Sasaki, H. (206). [18F]FDG-FDG-PET NEUROIMAGING study in dementia with Lewy bodies and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry., 25, 447-456.
Okumura, A., Yasokawa, Y., Nakayama, N., Miwa, K., Shinoda, J. & Iwama, T. [The clinical utility of MR diffusion tensor imaging and spatially normalized FDG-PET NEUROIMAGING to evaluate traumatic brain injury patients with memory and cognitive impairments]. No. To. Shinkei., 57, 115-122. 2006.
Oquendo, M. A., Krunic, A., Parsey, R. V., Milak, M., Malone, K. M., Anderson, A., van Heertum, R. L. & John Mann, J. (2006). Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology., 30, 1163-1172.
Otsuki, T. (2006). neuroimaging and presurgical evaluation of symptomatic epilepsies. Psychiatry. Clin. Neurosci., 58, S13-15.
Pain, F., Besret, L., Vaufrey, F., Gregoire, M. C., Pinot, L., Gervais, P., Ploux, L., Bloch, G., Mastrippolito, R., Laniece, P. & Hantraye, P. (2006). In vivo quantification of localized neuronal activation and inhibition in the rat brain using a dedicated high temporal-resolution beta +-sensitive microprobe. Proc. Natl. Acad. Sci. U.S.A., 99, 10807-10812.
Parker, A. P., Ferrie, C. D., Keevil, S., Newbold, M., Cox, T., Maisey, M. & Robinson, R. O. (1998). Neuroimaging and spectroscopy in children with epileptic encephalopathies. Arch. Dis. Child., 79, 39-43.
Paulesu, E., Perani, D., Fazio, F., Comi, G., Pozzilli, C., Martinelli, V., Filippi, M., Bettinardi, V., Sirabian, G., Passafiume, D., Anzini, A., Lenzi, G. L., Canal, N. & Fieschi, C. (1996). Functional basis of memory impairment in multiple sclerosis: a[18F]FDG FDG-PET NEUROIMAGING study. Neuroimage., 4, 87-96.
Philippart, M., da Silva, E. & Chugani, H. T. (1997). The value of positron emission tomography in the diagnosis and monitoring of late infantile and juvenile lipopigment storage disorders (so-called Batten or neuronal ceroid lipofuscinoses). Neuropediatrics., 28, 74-76.
Phillips, R. L., Chen, C. Y., Wong, D. F. & London, E. D. (1995). An improved method to calculate cerebral metabolic rates of glucose using FDG-PET NEUROIMAGING. J. Nucl. Med., 36, 1668-1679.
Prvulovic, D., Van de Ven, V., Sack, A. T., Maurer, K. & Linden, D. E. (2006). Functional activation imaging in aging and dementia. Psychiatry. Res., 140, 97-113.
Reed, L. J., Marsden, P., Lasserson, D., Sheldon, N., Lewis, P., Stanhope, N., Guinan, E. & Kopelman, M. D. (1999). FDG-FDG-PET NEUROIMAGING analysis and findings in amnesia resulting from hypoxia. Memory., 7, 599-612.
Ryvlin, P. & Mauguiere, F. (2006). Functional neuroimaging in adults. Rev. Neurol. (Paris)., 160, S117-130.
Ryvlin, P., Philippon, B., Cinotti, L., Froment, J. C., Le Bars, D. & Mauguiere, F. (1992). Functional neuroimaging strategy in temporal lobe epilepsy: a comparative study of 18FDG-FDG-PET NEUROIMAGING and 99mTc-HMPAO-SPECT. Ann. Neurol., 31, 650-666.
Sadzot, B. (1996). Neuroimaging in epilepsy: is there a future for positron emission tomography. Epilepsia., 37, 511-514.
Sakai, Y., Kumano, H., Nishikawa, M., Sakano, Y., Kaiya, H., Imabayashi, E., Ohnishi, T., Matsuda, H., Yasuda, A., Sato, A., Diksic, M. & Kuboki, T. (2006). Cerebral glucose metabolismassociated with a fear network in panic disorder. Neuroreport., 16, 927-931.
Sarangi, S., San Pedro, E. C. & Mountz, J. M. (2006). Anterior choroidal artery infarction presenting as a progressive cognitive deficit. Clin. Nucl. Med., 25, 187-190.
Schifter, T., Hoffman, J. M., Hatten, H. P., Jr. Hanson, M. W., Coleman, R. E. & DeLong, G. R. (1994). Neuroimaging in infantile autism. J. Child. Neurol., 9, 155-161.
Silverman, D. H. & Alavi, A. (2005). FDG-PET NEUROIMAGING imaging in the assessment of normal and impaired cognitive function. Radiol. Clin. North. Am., 43(1), 67-77.
Silverman, D. H., Small, G. W. & Phelps, M. E. (1999). Clinical Value of neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. Clin. Positron. Imaging., 2, 119-130.
Snead, O. C., 3rd, Chen, L. S., Mitchell, W. G., Kongelbeck, S. R., Raffel, C., Gilles, F. H. & Nelson, M. D. Jr. (1996). Usefulness of [18F]FdG positron emission tomography in pediatric epilepsy surgery. Pediatr. Neurol., 14, 98-107.
Soloff, P. H., Meltzer, C. C., Becker, C., Greer, P. J. & Constantine, D. (2006). Gender differences in a fenfluramine-activated FDG FDG-PET NEUROIMAGING study of borderline personality disorder. Psychiatry. Res., 138, 183-195.
Soloff, P. H., Meltzer, C. C., Greer, P. J., Constantine, D. & Kelly, T. M. (2006). A fenfluramine-activated FDG-FDG-PET NEUROIMAGING study of borderline personality disorder. Biol. Psychiatry., 47, 540-547.
Soong, B., Liu, R., Wu, L., Lu, Y. & Lee, H. (2006). Metabolic characterization of spinocerebellar ataxia type 6. Arch. Neurol., 58, 300-304.
Swartz, B.E., Simpkins, F., Halgren, E., Mandelkern, M., Brown, C., Krisdakumtorn, T. & Gee, M. (1996). Visual working memory in primary generalized epilepsy: an 18FDG-FDG-PET NEUROIMAGING study. Neurology., 47, 1203-1212.
Swartz, B. E., Tomiyasu, U., Delgado-Escueta, A. V., Mandelkern, M. & Khonsari, A. (1992). Neuroimaging in temporal lobe epilepsy: test sensitivity and relationships to pathology and postoperative outcome. Epilepsia., 33, 624-634.
Swartz, B. E., Halgren, E., Delgado-Escueta, A. V., Mandelkern, M., Gee, M., Quinones, N., Blahd, W. H. & Repchan, J. (1989). neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia., 30, 547-558.
Tabert, M. H., Chokron, S., Tang, C. Y., Wei, T., Brickman, A. M. & Buchsbaum, M. S. (2006). Visual target detection paradigm for the study of selective attention. Brain. Res. Protoc., 6, 80-85.
Tamminga, C. A. & Conley, R. R. (1997). The application of neuroimaging techniques to drug development. J. Clin. Psychiatry., 58 Suppl 10, 3-6.
Tamminga, C. A. (1995). Images in neuroscience. neuroimaging, I. FDG-PET NEUROIMAGING with [18F]FdG. Am. J. Psychiatry., 152, 1415.
Tanaka, F., Yonekura, Y., Ikeda, A., Terada, K., Mikuni, N., Nishizawa, S., Ishizu, K., Okazawa, H., Hattori, N., Shibasaki, H., Konishi, J. & Onishi, Y. (1997). Presurgical identification of epileptic foci with iodine-123 iomazenil SFDG-PET NEUROIMAGING: comparison with brain perfusion SFDG-PET NEUROIMAGING and FDG FDG-PET NEUROIMAGING. Eur. J. Nucl. Med., 24, 27-34.
Tashiro, M., Kubota, K., Itoh, M., Nakagawa, Y., Kamada, M., Takahashi, Y., Yoshioka, T., Masud, M. & Sasaki, H. (2006). Regional cerebral glucose metabolismof patients with malignant diseases in different clinical phases. Med. Sci. Monit., 7, 226-232.
Tashiro, M., Juengling, F.D., Moser, E., Reinhardt, M.J., Kubota, K., Yanai, K., Sasaki, H., Nitzsche, E.U., Kumano, H. & Itoh, M. (2006). High social desirability and prefrontal cortical activity in cancer patients: a preliminary study. Med. Sci. Monit., 9, CR119-124.
Tedeschi, G., Lundbom, N., Raman, R., Bonavita, S., Duyn, J. H., Alger, J. R. & Di Chiro, G. (1997). Increased Choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J. Neurosurg., 87, 516-524.
Thase, M. E. (2006). Neuroimaging profiles and the differential therapies of depression. Arch. Gen. Psychiatry., 58, 651-653.
Theodore, W. H. Gaillard, W. D. (2006). Neuroimaging and the progression of epilepsy. Prog. Brain. Res., 135, 305-313.2006.
Tirelli, U., Chierichetti, F., Tavio, M., Simonelli, C., Bianchin, G., Zanco, P. & Ferlin, G. (1998). Brain positron emission tomography (FDG-PET NEUROIMAGING) in chronic fatigue syndrome: preliminary data. Am. J. Med., 105, 54S-58S.
Uchida, K., Kobayashi, S., Yayama, T., Kokubo, Y., Nakajima, H., Kakuyama, M., Sadato, N., Tsuchida, T., Yonekura, Y. & Baba, H. (2006). Metabolic neuroimaging of the cervical spinal cord in patients with compressive myelopathy: a high-resolution positron emission tomography study. J. Neurosurg. Spine., 1, 72-9.
Uemura, K. (1990). Functional brain study by radionuclide neuroimaging. No. To. Shinkei., 42, 425-434.
Villemagne, V. L., Phillips, R. L., Liu, X., Gilson, S. F., Dannals, R. F., Wong, D. F., Harris, P. J., Ruff, M., Pert, C., Bridge, P. & London, E. D. (1996). Peptide T and glucose metabolismin AIDS dementia complex. J. Nucl. Med., 37, 1177-1180.
Wang, A. G., Liu, R. S., Liu, J. H., Teng, M. M. & Yen, M. Y. (1999). Positron emission tomography scan in cortical visual loss in patients with organophosphate intoxication. Ophthalmology., 106, 1287-1291.
Weckesser, M., Matheja, P., Rickert, C. H., Strater, R., Palkovic, S., Lottgen, J., Kurlemann, G., Paulus, W., Wassmann, H. & Schober, O. (2006). High uptake of L-3-[123I]iodo-alpha-methyl Tyrosine in pilocytic astrocytomas. Eur. J. Nucl. Med., 28, 273-281.
White, N. S. & Alkire, M. T. (2006). Impaired thalamocortical connectivity in humans during general-anesthetic-induced unconsciousness. Neuroimage., 19, 402-411.
Whiteside, S. P., Port, J. D. & Abramowitz, J. S. (2006). A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry. Res., 132, 69-79.
Wilkinson, M. D., Fulham, M. J. & Besser, M. (2006). Neuroimaging findings in a suprasellar granular cell tumor. J. Comput. Assist. Tomogr., 27, 26-29.
Yamasaki, T., Taniwaki, T., Tobimatsu, S., Arakawa, K., Kuba, H., Maeda, Y., Kuwabara, Y., Shida, K., Ohyagi, Y., Yamada, T. & Kira, J. (2006). Electrophysiological correlates of associative visual agnosia lesioned in the ventral pathway. J. Neurol. Sci., 221, 53-60.
Zahn, R., Buechert, M., Overmans, J., Talazko, J., Specht, K., Ko, C.W., Thiel, T., Kaufmann, R., Dykierek, P., Juengling, F. & Hull, M. (2006). Mapping of temporal and parietal cortex in progressive nonfluent aphasia and Alzheimer’s disease using chemical shift imaging, voxel-based morphometry and positron emission tomography. Psychiatry. Res., 140, 115-1131.

Chapter 12

Anchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E. & Beuthien-Beumann, B. (2005). Heterogeneity of brain glucose metabolism in MCI and clinical progression to Alzheimer disease. Arch. Neurol., 62(11), 1728–1733.


Bokde, A. L., Teipel, S. J., Drzezga, A., Thissen, J., Bartenstein, P., Dong, W., Leinsinger, G., Born, C., Schwaiger, M., Moeller, H. J. & Hampel, H. (2006). Association between cognitive performance and cortical glucose metabolismin patients with mild Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 20, 352-357.
Bryant, C. A. & Jackson, S. H. (1998). Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs. Aging., 13, 211-222.
Buchert, R., Obrocki, J., Thomasius, R., et al. (2006). Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET. Nucl Med Commun, 22, 889-897.
Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., et al. (2005). Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med., 46, 945.
Chen, W. P., Matsunari, I., Noda, A., Yanase, D., Yajima, K., Takeda, N., Yamada, M., Minoshima, S. & Nishimura, S. (2005). Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med., 46(10), 1633-1641.
Chételat, G., Eustache, F., Viader, F., De La Sayette, V., Pélerin, A., Mézenge, F., Hannequin, D., Dupuy, B., Baron, J. C. & Desgranges, B. (2005). FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with MCI. Neurocase., 11(1), 14-25.
Claus J. J., van Harskamp F., Breteler, M. M. B., Krenning, E. P., de Koning, I., vander Cammen T. J. M., Hofman, A. & Hasan, D. (1994). The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer’s disease. A population‐based study. Neurology, vol. 44 no. 3 Part 1 454.
Coleman, R. E. (2005). Positron emission tomography diagnosis of Alzheimer’s disease. Neuroimaging Clin N Am., 15(4), 837-846.
Demetriades, A. K. (2006). Functional neuroimaging in Alzheimer’s type dementia. J. Neurol. Sci., 204, 247-251.
Döbert, N., Pantel, J., Frölich, L., Hamscho, N., Menzel, C. & Grünwald, F. (2005). Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and MCI: metabolic index and perfusion index. Dement Geriatr Cogn Disord., 20(2-3), 63-70.
Doraiswamy, P. M., Steffens, D. C., Pitchumoni, S. & Tabrizi, S. (1998). Early recognition of Alzheimer’s disease: what is consensual? What is controversial? What is practical? J. Clin. Psychiatry., 59 Suppl 13, 6-18.
Drzezga, A., Riemenschneider, M., Strassner, B., Grimmer, T., Peller, M., et al. (2005). Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology., 64, 102–107.
Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M. & Kurz, A. (2006). Cerebral metabolic changes accompanying conversion of MCI into Alzheimer’s disease: a FDG-PET NEUROIMAGING follow-up study. Eur. J. Nucl. Med. Mol. Imaging., 30, 1104-1113.
Ercoli, L. (2006). Perceived Loss of Memory Ability and Cerebral Metabolic Decline in Persons With the Apolipoprotein E-IV Genetic Risk for Alzheimer Disease.  Archives Of General Psychiatry, 63(4), 442-448.
Hamaguchi, T., Kitamoto, T., Sato, T., Mizusawa, H., Nakamura, Y., Noguchi, M., Furukawa, Y., Ishida, C., Kuji, I., Mitani, K., Murayama, S., Kohriyama, T., Katayama, S., Yamashita, M., Yamamoto, T., Udaka, F., Kawakami, A., Ihara, Y., Nishinaka, T., Kuroda, S., Suzuki, N., Shiga, Y., Arai, H., Maruyama, M. & Yamada, M. (2006). Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology., 64, 643-648.
Hampel, H., Teipel, S. J., Alexander, G. E., Pogarell, O., Rapoport, S. I. & Moller, H. J. (2002). In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer’s disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J. Neural. Transm., 109, 837–855.
Harwood, D. G., Sultzer, D. L., Feil, D. M. P. H., Monserratt, L., Freedman, E. & Mandelkern, M. A. (2005). Frontal Lobe Hypometabolism and Impaired Insight in Alzheimer Disease. J Geriatr Psychiatry, 13, 934–941.
Holthoff, V. A., Beuthien-Baumann, B., Kalbe, E., Lüdecke, S., Lenz, O., Zündorf, G., Spirling, S., Schierz, K., Winiecki, P., Sorbi, S. & Herholz, K. (2005). Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry., 57(4), 412-421.
Ishii, K., Soma, T., Kono, A. K., Sasaki, H., Miyamoto, N., Fukuda, T. & Murase, K. (2006). Automatic volumetric measurement of segmented brain structures on magnetic resonance imaging. Radiat Med., 24(6), 422-430.
Ishii K, Ikerjiri, Y., Sasaki, M., et al. (1999). Regional cerebral glucose metabolismand blood flow in a patient with Marchiafava-Bignami disease. Am J. Neuroradiol, 20, 1249-1251.
Ishii, K. & Minoshima, S. (2005). PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease [Electronic version]. European Journal of Nuclear Medicine and Molecular Imaging, 32(12), 1463-1465.
Ishii, K., Imamura, T., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., Hashimoto, M., Hirono, N., Shimomura, T. & Mori, E. (1998). Regional cerebral glucose metabolismin dementia with Lewy bodies and Alzheimer's disease. Neurology., 51, 125-130.
Ishii, K., Sakamoto, S., Sasaki, M., Kitagaki, H., Yamaji, S., Hashimoto, M., Imamura, T., Shimomura, T., Hirono, N. & Mori, E. (1998). Cerebral glucose metabolismin patients with frontotemporal dementia. J. Nucl. Med., 39, 1875-1878.
Ishii, K., Sasaki, M., Kitagaki, H., Yamaji, S., Sakamoto, S., Matsuda, K. & Mori, E. (1997). Reduction of cerebellar glucose metabolismin advanced Alzheimer's disease. J. Nucl. Med., 38, 925-928.
Ishii, K., Kawachi, T., Sasaki, H., Kono, A. K., Fukuda, T., Kojima, Y. & Mori, E. (2005b). Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol., 26(2), 333-340.
Ishii, K., Sasaki, H., Kono, A. K., Miyamoto, N., Fukuda, T. & Mori, E. (2005a). Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging., 32(8), 959-963.
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D. & Haan, M. (2006). Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol, 59, 673–681.
Jeong, S. K., Nam, H. S., Son, M. H., Son, E. J. & Cho, K. H. (2005). Interactive effect of obesity indexes on cognition. Dement Geriatr Cogn Disord, 19, 91–96.
Johnson, S. C., Schmitz, T. W., Moritz, C. H., Meyerand, M. E., Rowley, H. A., Alexander, A. L., Hansen, K. W., Gleason, C. E., Carlsson, C. M., Ries, M. L., Asthana, S., Chen, K., Reiman, E. M. & Alexander, G. E. (2006). Activation of brain regions vulnerable to Alzheimer’s disease: the effect of MCI. Neurobiol Aging., 27(11), 1604-1612.
Kalpouzos, G., Eustache, F., de la Sayette, V., Viader, F., Chételat, G. & Desgranges, B. (2005). Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. J Neurol., 252(5), 548-558.
Kawachi, T., Ishii, K., Sakamoto, S., Sasaki, M., Mori, T., Yamashita, F., Matsuda, H., Mori, E. & Eng, P. T. (2006). Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild AD. Eur J Nucl Med Mol Imaging (AP)., 33(7), 801-809.
Kawachi, T., Ishii, K., Sakamoto, S., Sasaki, M., Mori, T., Yamashita, F., Matsuda, H. & Mori, E. (2006). Comparison of the diagnostic performance of FDG-FDG-PET NEUROIMAGING and VBM-MRI in very mild Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging., 33(7), 801-809.
Kennedy, A. M., Newman, S. K., Frackowiak, R. S., Cunningham, V. J., Roques, P., Stevens, J., Neary, D., Bruton, C. J., Warrington, E. K. & Rossor, M. N. (1995). Chromosome 14 linked familial Alzheimer’s disease. A clinico-pathological study of a single pedigree. Brain., 118, 185-205.
Kepe, V., Barrio, J. R., Huang, S. C., Ercoli, L., Sidharth, P., Shoghi-Jadid, K., Cole, G. M., Satyamurthy, N., Cummings, J. L., Samll, G. W. & Phelps, M. E. (2006). Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A., 103(3), 702–707.
Koeppe, R. A., Gilman, S., Joshi, A., Liu, S., Little, R., Junck, L., Heumann, M., Frey, K. A. & Albin, R. L. (2005). 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med., 46(6), 936-944.
Lascola, C. (2005). Molecular Imaging in Alzheimer’s Disease. Neuroimaging Clinics of North America., 15, 827-83.
Lee, A. G. & Martin, C. O. (2004). Neuro-ophthalmic findings in the visual variant of Alzheimer's disease. Ophthalmology., 111(2), 376-380.
Matthews, B. Siemers, E. R. & Mozley, P. D. (2006). Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry., 11, 146-519.
Mega, M. S., Dinov, I. D., Mazziotta, J. C., Manese, M., Thompson, P. M., Lindshield, C., Moussai, J., Tran, N., Olsen, K., Zoumalan, C. I., Woods, R. P. & Toga, A. W. (2005). Automated brain tissue assessment in the elderly and demented population: construction and validation of a sub-volume probabilistic brain atlas. Neuroimage., 26(4), 1009-1018.
Mielke, R., Pietrzyk, U., Jacobs, A., et al. (1994). HMPAO SPECT and FDG PET in Alzheimer’s disease and vascular dementia comparison of perfusion and metabolic patterns. Eur. J. Nucl. Med., 21(10), 1052-1060.
Montandon, M. L. & Zaidi, H. (2005). Atlas-guided non-uniform attenuation correction in cerebral 3D PET imaging. Neuroimage., 25(1), 278-286.
Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging., 32(4), 486-510.
Mosconi, L., Tsui, W. H., De Santi, S., Li, J., Rusinek, H., Convit, A., Li, Y., Boppana, M. & de Leon, M. J. (2005). Reduced hippocampal metabolism in MCI and AD. Automated FDG-PET image analysis. Neurology., 64, 1860-1867.
Mosconi, L., Herholz, K., Prohovnik, I., Nacmias, B., De Cristofaro, M. T., Fayyaz, M., Bracco, L., Sorbi, S. & Pupi, A. (2005). Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry., 76(1), 15-23.
Mosconi, L., Tsui, W. H., De Santi, S., Li, J., Rusinek, H., Convit, A., Li, Y., Boppana, M. & de Leon, M. J. (2005). Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology., 64(11), 1860-1867.
Mountz, J. M., Liu, H. G. & Deutsch, G. (2003). Neuroimaging in cerebrovascular disorders: measurement of cerebral physiology after stroke and assessment of stroke recovery. Semin Nucl Med., 33(1), 56-76.
Muller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jaqust, W., Trojanowski, J. Q., Toga, A. W. & Beckett, L. (2005). The ADNI. Neuroimaging Clin N Am., 15, 869-877.
Nestor, P. J., Graham, N. L., Fryer, T. D., Williams, G. B., Patterson, K. & Hodges, J. R. (2006). Progressive non-fluent aphasia is associated with glucose hypometabolism centred on the left anterior insula. Brain., 126, 2406-2418.
Okamura, N., Arai, H., Higuchi, M., Tashiro, M., Matsui, T., Hu, X. S., Takeda, A., Itoh, M. & Sasaki, H. (2006). [18F]FDG-FDG-PET NEUROIMAGING study in dementia with Lewy bodies and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry., 25, 447-456.
Prvulovic, D., Van de Ven, V., Sack, A. T., Maurer, K. & Linden, D. E. (2006). Functional activation imaging in aging and dementia. Psychiatry. Res., 140, 97-113.
Pupi, A. & Nobili, F. (2005). PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease [Electronic version]. European Journal of Nuclear Medicine and Molecular Imaging, 32(12), 1466-1472.
Sakamoto, S., Ishii, K., Hosaka, K., Mori, T., Sasaki, M., Mori, E., (2005). Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose. AJNR Am J Neuroradiol. 26(4), 843-847.
Sarangi, S., San Pedro, E. C. & Mountz, J. M. (2006). Anterior choroidal artery infarction presenting as a progressive cognitive deficit. Clin. Nucl. Med., 25, 187-190.
Scheurich, A., Muller, M. J., Siessmeier, T., Bartenstein, P., Schmidt, L. G. & Fellgiebel, A. (2005). Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early alzheimer disease in patients of a memory clinic.. Dement Geriatr Cogn Disord., 20(5), 271-277.
Sharma, S. K. & Dakshinamurti, K. (1993). Suppression of domoic acid induced seizures by 8-(OH)-DPAT. J Neural Transm Gen Sect., 93(2), 87-98.
Silverman, D. H. & Alavi, A. (2005). FDG-PET NEUROIMAGING imaging in the assessment of normal and impaired cognitive function. Radiol. Clin. North. Am., 43(1), 67-77.
Silverman, D. H., Small, G. W. & Phelps, M. E. (1999). Clinical Value of neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. Clin. Positron. Imaging., 2, 119-130.
Suárez-Calvet, M., Camacho, V., Gómez-Ansón, B., Antón, S., Vives-Gilabert, Y., Dols-Icardo, O., Clarimón, J., Alcolea, D., Blesa, R., Fortea, J. & Lleó, A. (2005). Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion.. Alzheimer Dis Assoc Disord., 29(4), 353-356.
Teipel, S. J., Drzega, A., Bartenstein, P., Moller, H. J., Schwaiger, M. & Hampel, H. (2006). Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in AD: a double-blind cross-over trial. Psychopharmacology (Berl)., 187(1), 86-94.
Teipel, S. J., Willoch, F., Ishii, K., et al. (2006). Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer’s disease. Neurobiol Aging., 27, 681–690.
Tuszynski, M. H., Yang, J. H., Barba, D. U. H. S., Bakay, R. A., Pay, M. M., Masliah, E., Conner, J. M., Kobalka, P., Roy, S. & Nagahara, A. H. (2015). Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. JAMA Neurol., 72(10), 1139-1147.
Yanase, D., Matsunari, I., Yajima, K., Chen, W., Fujikawa, A., Nishimura, S., Matsuda, H. & Yamada, M. (2005). Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging., 32(7), 794-805.
Zahn, R., Buechert, M., Overmans, J., Talazko, J., Specht, K., Ko, C. W., et al. (2005). Mapping of temporal and parietal cortex in progressive nonfluent aphasia and Alzheimer’s disease using chemical shift imaging, voxel-based morphometry and positron emission tomography. Psychiatry Res., 140, 115–131.

Chapter 13

Arain, M., Haque, M., Johal, L., Mathur, P., Nel, W., Rais, A., Sandhu, R. & Sharma, S. (2013). Maturation of the adolescent brain. Neuropsychiatric Disease Treatment., 9, 449-461
Abisambra, J. F., Jinwal, U. K., Blair, L. J., O'Leary, J. C., 3rd, Li, Q., Brady, S., Wang, L., Guidi, C. E., Zhang, B., Nordhues, B. A., Cockman, M., Suntharalingham, A., Li, P., Jin, Y., Atkins, C. A. & Dickey, C. A. (2013). Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci. 33, 9498-94507.
Andreasson, U., Perret-Liaudet, A., van Waalwijk, van Doorn, L.J., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., Kulic, L., Lewczuk, P., Mollenhauer, B., Mroczko, B., Parnetti, L., Vanmechelen, E., Verbeek, M.M., Winblad, B., Zetterberg, H., Koel-Simmelink, M. & Teunissen, C. E. (2015). A Practical Guide to Immunoassay Method Validation. Front Neurol., 6, 179.
Bagdy, G. & Juhasz, G. (2013). Biomarkers for personalised treatment in psychiatric diseases. Expert Opin Med Diagn., 7, 417-422.
Bang, J., Jeon, W. K., Lee, I. S., Han, J. S. & Kim, B. Y. (2013). Biphasic functional regulation in hippocampus of rat with chronic cerebral hypoperfusion induced by permanent occlusion of bilateral common carotid artery. PLoS One. 8, e70093.
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E. & Holtzman, D. M. (2006). “Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.Nature Medicine, 12 (7), 856–861.
Bekris, L. M., Lutz, F., Montine, T. J., Yu, C. E., Tsuang, D., Peskind, E. R. & Leverenz, J. B. (2013). MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers., 18, 455-466.
Blennow, K. & Zetterberg, H. (2013). The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am., 97, 369-376.
Braunewell, K. H. (2012). The Vicinin-line proteins VILIP-1 and VILIP-3 in Alzheimer’s disease. –old wine in new bottles. Frontiers in Molecular Neuroscience., 5, 1-11.
Bruck, A., Virta, J. R., Koivunen, J., Koikkalainen, J., Scheinin, N. M., Helenius, H., Någren, K., Helin, S., Parkkola, R., Viitanen, M. & Rinne, J. O. (2013). [11C]PIB, [18F]FDG and MR imaging in patients with MCI. Eur J Nucl Med Mol Imaging., 40(10), 1567-1572.
Buckley, R., Saling, M. M., Ames, D., Rowe, C. C., Lautenschlager, N. T., Macaulay, S. L., Martins, R. N., Masters, C. L., O'Meara, T., Savage, G., Szoeke, C., Villemagne, V. L. & Ellis, K. A. (2013). Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) Research Group. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr., 25, 1307-1315.
Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C. & Salomone, S. (2013). Clinical Development of new Disease-Modifying Drug Treatments For Alzheimer’s Disease. Curr Top Med, 13(15), 1853-1863.
Carboni, L., Lattanzio, F., Candeletti, S., Porcellini, E., Raschi, E., Licastro, F. & Romualdi, P. (2015). Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer’s disease patients. Neurosci Lett., 11, 605, 44-48.
Chapman, R. M., Porsteinsson, A. P., Gardner, M. N., Mapstone, M., McCrary, J. W., Sandoval, T. C., Guillily, M. D., Reilly, L. A. & Degrush, E. (2012). The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion. Curr Alzheimer Res., 10, 732-741.
Chen, Z. & Zhong, C. (2013). Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol., 108, 21-43.
Cheng, L., Quek, C. Y., Sun, X., Bellingham, S. A. & Hill, A. F. (2013). The detection of microRNA associated with Alzheimer’s disease in biological fluids using next-generation sequencing technologies. Front Genet., 4, 150.
Choi, Y. S., Hou, S., Choe, L. H. & Lee, K. H. (2013). Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. J Chromatogr B Analyt Technol Biomed Life Sci., 930, 129-135.
Clelland, C. L., Read, L. L., Panek, L. J., Nadrich, R. H., Bancroft, C. & Clelland, J. D. (2013). Utilization of Never-Medicated Bipolar Disorder Patients towards Development and Validation of a Peripheral Biomarker Profile. PLoS One., 8, e69082. Dakshinamurti, K., Sharma, S. K. & Sundaram, M. (1991). Domoic acid induced seizures activity in rats. Neurosci. Lett., 127, 193-197.
Dakshinamurti, K., Sharma, S. K. & Geiger, J. D. (2003). Neuroprotective actions of pyridoxine. Biochim Biophys Acta., 1647, 225-229.
Dakshinamurti, K., Sharma, S. K., Sundaram, M. & Watanabe, T. (1993). Hippocampal changes in developing postnatal mice following intrauterine exposure to domoic acid. J Neurosci., 13, 4486-4495.
Dani, M., Edison, P. & Brooks, D. J. (2016). Imaging biomarkers in tauopathies. Parkinsonism Relat Disord., Suppl 1, S26-28.
Darreh-Shori, T., Vijayaraghavan, S., Aeinehband, S., Piehl, F., Lindblom, R. P., Nilsson, B., Ekdahl, K. N., Långström, B., Almkvist, O. & Nordberg, A. (2013). Functional variability in butyrylCholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiol Aging., 34, 2465-2481.
DeMarshall, C., Sarkar, A., Nagele, E. P., Goldwaser, E., Godsey, G., Acharya, N. K. & Nagele, R. G. (2015). Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases. Int Rev Neurobiol., 122, 1-51.
Desikan, R. S., Rafii, M. S., Brewer, J. B. & Hess, C. P. (2013). An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment. Am J Neuroradiol., 34, 2075-82
Di Ieva, A., Valli, M. & Cusimano, M. D. (2014). Distinguishing Alzheimer's Disease from Normal Pressure Hydrocephalus: A Search for MRI Biomarkers. J Alzheimers Dis., 38(2), 331-350.
Darreh-Shori T,et al. Show allDonovan, L. E., Dammer, E. B., Duong, D. M., Hanfelt, J. J., Levey, A. I., Seyfried, N. T. & Lah, J. J. (2013). Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alzheimers Res Ther., 5, 32.
Donovan, N. J., Wadsworth, L. P., Lorius, N., Locascio, J. J., Rentz, D. M., Johnson, K. A., Sperling, R. A. & Marshall, G. A. (2014). Alzheimer Disease Neuroimaging Initiative. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry., 22(11), 1168-1179.
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G. & Aisen, P. S. (2013). Alzheimer’s Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med., 369, 341-350.
Doré, V., Villemagne, V. L., Bourgeat, P., Fripp, J., Acosta, O., Chetélat, G., Zhou, L., Martins, R., Ellis, K. A., Masters, C. L., Ames, D., Salvado, O. & Rowe, C. C. (2013). Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol., 70(7), 903-911.
Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., et al. (2001). “Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.” Neurology, 57 (5), 801–805.
Duits, F. H., Martinez-Lage, P., Paquet, C., Engelborghs, S., Lleó, A., Hausner, L., Molinuevo, J. L., Stomrud, E., Farotti, L., Ramakers, I. H., Tsolaki, M., Skarsgård, C., Åstrand, R., Wallin, A., Vyhnalek, M., Holmber-Clausen, M., Forlenza, O. V., Ghezzi, L., Ingelsson, M., Hoff, E. I., Roks, G., de Mendonça, A., Papma, J. M., Izagirre, A., Taga, M., Struyfs, H., Alcolea, D. A., Frölich, L., Balasa, M., Minthon, L., Twisk, J. W., Persson, S., Zetterberg, H., van der Flier, W. M., Teunissen, C. E., Scheltens, P. & Blennow, K. (2015). Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement., S1552-5260(15)02702-8.
Fieremans, E., Benitez, A., Jensen, J. H., Falangola, M. F., Tabesh, A., Deardorff, R. L., Spampinato, M. V., Babb, J. S., Novikov, D. S., Ferris, S. H. & Helpern, J. A. (2013). Novel White Matter Tract Integrity Metrics Sensitive to Alzheimer Disease Progression. AJNR Am J Neuroradiol., 34(11), 2105-2112.
Fiolaki, A., Tsamis, K. I, Milionis, H. J., Kyritsis, A. P., Kosmidou, M. & Giannopoulos, S. (2014). Atherosclerosis, biomarkers of atherosclerosis and Alzheimer’s disease. Int J Neurosci., 124, 1-11.
Fleischman, D. A., Yu, L., Arfanakis, K., Han, S.D., Barnes, L. L., Arvanitakis, Z., Boyle, P. A. & Bennett, D. A. (2013). Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. Frontiers in Neurosci, 5, 21.
Fleischman, D. A., Yu, L., Arfanakis, K., Han, S. D., Barnes, L. L., Arvanitakis, Z., Boyle, P. A. & Bennett, D. A. (2013). Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. Front Aging Neurosci., 5, 21.
Foster, J. K., Albrecht, M. A., Savage, G., Lautenschlager, N. T., Ellis, K. A., Maruff, P., Szoeke, C., Taddei, K., Martins, R., Masters, C. L., Ames, D. & AIBL Research Group. (2013). Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. Brain., 136, 2201-2216.
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R., Jr. Jagust, W. J., Johnson, K. A., Rowe, C. C., Sperling, R. A., Thies, W., Wahlund, L. O., Weiner, M. W., Pasqualetti, P. & Decarli, C. (2013). For ISTAART’s NeuroImaging Professional Interest Area. Neurology., 81, 487-500.
Frost, S. M., Kanagasingam, Y., Sohrabi, H. R., Taddei, K., Bateman, R., Morris, J., Benzinger, T., Goate, A., Masters, C. L. & Martins, R. N. (2013). Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. Curr Alzheimer Res., 10(8), 790-796.
Gandy, S. & Heppner, F. L. (2013). Microglia as dynamic and essential components of the amyloid hypothesis. Neuron., 78, 575-577.
Marutle, A., Gillberg, P. G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L. & Nordberg, A. (2013). 3H-deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. J Neuroinflammation., 10, 90.
Gardner, R. C., Valcour, V. & Yaffe, K. (2013). Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther., 5, 27.
Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N. & Sauer, H. (2013). Alzheimer's Disease Neuroimaging Initiative. PLoS One., 8, e67346.
Gauthier, S., Leuzy, A., Racine, E. & Rosa-Neto, P. (2013). Diagnosis and management of Alzheimer’s disease: Past, present and future ethical issues. Prog Neurobiol., 110, 102-113.
Gauthier, S., Leuzy, A. & Rosa-Neto, P. (2014). How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer’s Disease? Neurodegener Dis., 13(2-3), 197-1999.
Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, O. S., Atasoy, I., Alaylıoğlu, M., Onal, B., Gürvit, H. & Yılmazer, S. (2013). BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer’s Disease or MCI. J Alzheimers Dis., 37(1), 185-195.
Ghani, M., Reitz, C., Cheng, R., Vardarajan, B. N., Jun, G., Sato, C., Naj, A., Rajbhandary, R., Wang, L. S., Valladares, O., Lin, C. F., Larson, E. B., Graff-Radford, N. R., Evans, D., De Jager, P. L., Crane, P. K., Buxbaum, J. D., Murrell, J. R., Raj, T., Ertekin-Taner, N., Logue, M., Baldwin, C. T., Green, R. C., Barnes, L. L., Cantwell, L. B., Fallin, M. D., Go, R. C., Griffith, P. A., Obisesan, T. O., Manly, J. J., Lunetta, K. L., Kamboh, M. I., Lopez, O. L., Bennett, D. A., Hendrie, H., Hall, K. S., Goate, A. M., Byrd, G. S., Kukull, W. A., Foroud, T. M., Haines, J. L., Farrer, L. A., Pericak-Vance, M. A., Lee, J. H., Schellenberg, G. D., St George-Hyslop, P., Mayeux, R. & Rogaeva, E. (2015). Alzheimer’s Disease Genetics Consortium. Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol. Sep 14.
Ghazi, I. E. I., Martin, B. L. & Armitage, I. M. (2011). New Proteins Found Interacting with Brain Metallothionein-3 Are Linked to Secretion. International Journal of Alzheimer’s Disease, 2011, 1-9.
Giannopoulos, P. F., Joshi, Y. B., Chu, J. & Praticò, D. (2013). The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell., 12(6), 1082-1090.
Glodzik, L., Rusinek, H., Pirraglia, E., McHugh, P., Tsui, W., Williams, S., Cummings, M., Li, Y., Rich, K., Randall, C., Mosconi, L., Osorio, R., Murray, J., Zetterberg, H., Blennow, K. & de Leon, M. (2014). Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging., 35(1), 64-71.
Goutagny, R. & Krantic, S. (2013). Hippocampal Oscillatory Activity in Alzheimer’s Disease: Toward the Identification of Early Biomarkers? Aging Dis., 4, 134-140.
Graff-Radford, J. & Kantarci, K. (2013). Magnetic resonance spectroscopy in Alzheimer's disease. Neuropsychiatr Dis Treat., 9, 687-696.
Gubandru, M., Margina, D., Tsitsimpikou, C., Goutzourelas, N., Tsarouhas, K., Ilie, M., Tsatsakis, A. M. & Kouretas, D. (2013). Alzheimer’s disease treated patients showed different patterns for oxidative stress and inflammation markers. Food Chem Toxicol., 61, 209-214.
Guedes, J., Cardoso, A. L. & Pedroso de Lima, M. C. (2013). Involvement of microRNA in microglia-mediated immune response. Clin Dev Immunol., 2013, 11.
Gupta, V. B. (2013). Sundaram R, Martins RN. Multiplex biomarkers in blood. Alzheimers Res Ther., 5, 31.
Gustaw, K. A., Garrett, M. R., Lee, H. G., Castellani, R. J., Zagorski, M. G., Prakasam, A., Siedlak, S. L., Zhu, X., et al. (2008). “Antigen-antibody dissociation in Alzheimer disease: A novel approach to diagnosis.” Journal of Neurochem., 106 (3). 1350–1356.
Haller, S., Garibotto, V., Kövari, E., Bouras, C., Xekardaki, A., Rodriguez, C., Lazarczyk, M.J., Giannakopoulos, P. & Lovblad, K. O. (2013). Neuroimaging of dementia in 2013: what radiologists need to know. Eur Radiol., 23(12),
Harald, H., Yong, S., Dominic, W.M., Paul, A., Les S.M., Henrik, Z., John, T. Q. & Kaj, B. (2010). “Biological markers of amyloid β-related mechanisms in Alzheimer’s disease.” Expl. Neurol., 223 (2), 334–346.


Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., Wallin, A., Minthon, L. & Blennow, K. (2010). “Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with MCI.” Neurobiology of Aging, 31 (3), 357–367.
Hatashita, S. & Yamasaki, H. (2013). Diagnosed MCI due to Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One. 8, e66877.
Hausner, L., Tschäpe, J.A., Schmitt, H.P., Hentschel, F., Hartmann, T. & Frölich, L. (2014). Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer’s disease in the third decade of life. Alzheimers Dement., 10(2), e27-39.
Henderson, V. W. (2014). Alzheimer’s disease: Review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol., 142, 99-106.
Henriksen, K., O’Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss-Coray, T., Soares, H., Bazenet, C., Sjögren, M., Hu, Lovestone, S., Karsdal, M. A. & Weiner, M. W. (2014). Blood-Based Biomarker Interest Group. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement., 10(1), 115-131.
Henriksen, K., Wang, Y., Sørensen, M. G., Barascuk, N., Suhy, J., Pedersen, J. T., Duffin, K. L., Dean, R. A., Pajak, M., Christiansen, C., Zheng, Q. & Karsdal, M. A. (2013). An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS One., 8, e64990.
Hirano, S. & Yamada, M. (2013). [Network analyses in neuroimaging studies]. Brain Nerve, 65, 659-667.
Holland, D., Desikan, R. S., Dale, A. M. & McEvoy, L. K. (2013). Higher Rates of Decline for Women and Apolipoprotein E {varepsilon}4 Carriers. AJNR Am J Neuroradiol., 34(12), 2287-2293.
Howe, E. (2013). Clinical implications of the new diagnostic guidelines for dementia. Innov Clin Neurosci., 10, 32-38.
Hu, K., Harper, D. G., Shea, S. A., Stopa, E. G. & Scheer, F. A. (2013). Noninvasive fractal biomarker of clock neurotransmitter disturbance in humans with dementia. Sci Rep., 3, 2229.
Ibáñez, C., Simó, C., Barupal, D. K., Fiehn, O., Kivipelto, M., Cedazo-Mínguez, A. & Cifuentes, A. (2013). A new metabolomic workflow for early detection of Alzheimer’s disease. J Chromatogr A., 1302, 65-71.
Ibáñez, C., Cifuentes, A. & Simó, C. (2015). Recent Advances and Applications of Metabolomics to Investigate Neurodegenerative Diseases. Int Rev Neurobiol., 122, 95-132.
Iñarrea, P., Alarcia, R., Alava, M. A., Capablo, J. L., Casanova, A., Iñiguez, C., Iturralde, M., Larrodé, P., Martín, J., Mostacero, E. & Ara, J. R. (2014). Mitochondrial Complex Enzyme Activities and Cytochrome c Expression Changes in Multiple Sclerosis. Mol Neurobiol., 49(1), 1-9.
Inoue, T., Kawaji, T. & Tanihara, H. (2013). Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci., 54, 5353-5358.
Irie, Y., Mori, W., Keung, M., Mizushima, Y. & Wakabayashi, K. (2004). Expression of Neuronal Growth Inhibitory Factor (Metallothionein-III) in the Salivary Gland. Physiol. Res., 53, 719-723.
Ishii, K. (2014). PET Approaches for Diagnosis of Dementia. AJNR Am J Neuroradiol., 35(11), 2030-2038.
Jorge, P. J. & Lennart, M. (2010). “Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks.” Nature Neuroscience, 13(7), 812–818.
Kaerst, L., Kuhlmann, A., Wedekind, D., Stoeck, K., Lange, P. & Zerr, I. (2013). Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol., 260(11), 2722-2727.
Kaerst, L., Kuhlmann, A., Wedekind, D., Stoeck, K., Lange, P. & Zerr, I. (2014). Using Cerebrospinal Fluid Marker Profiles in Clinical Diagnosis of Dementia with Lewy Bodies, Parkinson's Disease, and Alzheimer's Disease. J Alzheimers Dis., 38(1), 63-73.
Kang, K., Yoon, U., Lee, J. M. & Lee, H. W. (2013). Idiopathic normal-pressure hydrocephalus, cortical thinning, and the cerebrospinal fluid tap test. J Neurol Sci., 334(1-2), 55-62.
Kapoor, S. (2013). Emerging new biomarkers of Alzheimer’s disease. Int J Geriatr Psychiatry., 28, 880.
Karakaya, T., Fußer, F., Schröder, J. & Pantel, J. (2013). Pharmacological Treatment of MCI as a Prodromal Syndrome of Alzheimer’s Disease. Curr Neuropharmacol., 11, 102-108.
Kim, S., Swaminathan, S., Inlow, M., Risacher, S. L., Nho, K., Shen, L., Foroud, T. M., Petersen, R. C., Aisen, P. S., Soares, H., Toledo, J. B., Shaw, L. M., Trojanowski, J. Q,, Weiner, M. W., McDonald, B. C., Farlow, M. R., Ghetti, B. & Saykin, A. J. (2013). Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One., 8(7), e70269.


Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Roberts, R. O., Boeve, B. F. & Petersen, R. C. (2013). Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With β-Amyloidosis. JAMA Neurol., 70, 1030-1038.
Koehler, N. K., Stransky, E., Shing, M., Gaertner, S., Meyer, M., Schreitmüller, B., Leyhe, T., Laske, C., Maetzler, W., Kahle, P., Celej, M. S., Jovin, T. M., Fallgatter, A. J., Batra, A., Buchkremer, G., Schott, K. & Richartz-Salzburger, E. (2013). Altered Serum IgG Levels to α-Syn in Dementia with Lewy Bodies and Alzheimer’s Disease. PLoS One., 8, e64649.
Kojima, S., Shimada, A., Kodan, A., Kobayashi, K., Morita, T., Yamano, Y. & Umemura, T. (1998). Molecular cloning and expression of the canine metallothionein-III gene. Can J Vet Res., 62, 148-151.
Korczyn, A. D. (2013). Is Alzheimer’s disease a homogeneous disease entity? J Neural Transm., 120(10), 1475-1477.
Kouzuki, M., Asaina, F., Taniguchi, M., Musha, T. & Urakami, K. (2013). The relationship between the diagnosis method of neuronal dysfunction (DIMENSION) and brain pathology in the early stages of Alzheimer’s disease. Psychogeriatrics., 13, 63-70.
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., McMahon, F. J., Turner, R. S. & Innis, R. B. (2013). Biomarkers Consortium PET Radioligand Project Team. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain., 136, 2228-2238.
Kristofikova, Z., Ripova, D., Hegnerová, K., Sirova, J. & Homola, J. (2013). Protein τ-Mediated Effects on Rat Hippocampal Choline Transporters CHT1 and τ-Amyloid β Interactions. Neurochem Res., 38, 949-959.
Kumar, P., Dezso, Z., Mackenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., Bernier, F., Yanagimachi, M., Aoshima, K. & Oda, Y. (2013). Circulating miRNA Biomarkers for Alzheimer’s Disease. PLoS One., 8, e69807.
Laeger, U. (2015). PET with amyloid ligands should not be applied routinely in early diagnostics of Alzheimer's disease. Ugeskr Laeger., 177, 32.
Lamoureux, L., Simon, S. L., Plews, M., Ruddat, V., Brunet, S., Graham, C., Czub, S. & Knox, J. D. (2013). Urine proteins identified by two-dimensional differential gel electrophoresis facilitate the differential diagnoses of scrapie. PLoS One., 8, e64044.
Leandro, G. S., Lobo, R. R., Oliveira, D. V., Moriguti, J. C. & Sakamoto-Hojo, E. T. (2013). Lymphocytes of patients with Alzheimer’s disease display different DNA damage repair kinetics and expression profiles of DNA repair and stress response genes. Int J Mol Sci., 14, 12380-12400.
Lee, S. L., Thomas, P. & Fenech, M. (2015). Genome instability biomarkers and blood micronutrient risk profiles associated with MCI and Alzheimer's disease. Mutat Res., 776, 54-83.
Léger, G. C. & Massoud, F. (2013). Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Rev Clin Pharmacol., 6, 423-442.
Leidinger, P., Backes, C., Deutscher, S., Schmitt, K., Muller, S. C., Frese, K., Haas, J., Ruprecht, K., Paul, F., Stahler, C., Lang, C. J., Meder, B., Bartfai, T., Meese, E. & Keller, A. (2013). A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol., 14, R78.
Leoutsakos, J. M., Bartlett, A. L., Forrester, S. N. & Lyketsos, C. G. (2014). Simulating effects of biomarker enrichment on Alzheimer's prevention trials: Conceptual framework and example. Alzheimers Dement., 10(2), 152-161.
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., Vellas, B., Soininen, H., Wahlund, L. O. & Lovestone, S. (2013). Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One., 8, e64971.
Li, H., Liang, Y., Chen, K., Li, X., Shu, N., Zhang, Z. & Wang, Y. (2013). Different patterns of white matter disruption among amnestic MCI subtypes: relationship with neuropsychological performance. J Alzheimers Dis., 36, 365-376.
Li, Z., Lin, Q., Ma, Q., Lu, C. & Tzeng, C. M. (2014). Genetic predisposition to Parkinson’s disease and cancer. Curr Cancer Drug Targets., 14(3), 310-321.
Lim, Y. Y., Ellis, K. A., Harrington, K., Kamer, A., Pietrzak, R. H., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G., Szoeke, C., Villemagne, V. L., Ames, D. & Maruff, P. (2013). Cognitive consequences of high Aβ amyloid in MCI and healthy older adults: implications for early detection of Alzheimer’s disease. Neuropsychology., 27, 322-332.
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., Snyder, P. J., Bush, A. I., Martins, R. N., Masters, C. L., Rowe, C. C., Nathan, P. J. & Maruff, P. (2013). Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiol Aging., 34, 2457-2464.
Lista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K. & Hampel, H. (2014). CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement., 10(3), 381-392.
Liu, D. & Zhou, X. H. (2013). ROC analysis in biomarker combination with covariate adjustment. Acad Radiol., 20, 874-882.
Liu, L., Zhao, F., Ma, F., Zhang, L., Yang, S. & Xia, N. (2013). Electrochemical detection of β-amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O2 reduction by Aβ(1-16)-heme-modified gold nanoparticles. Biosens Bioelectron., 49, 231-235.
López-de-Ipiña, K., Alonso, J. B., Travieso, C. M., Solé-Casals, J., Egiraun, H., Faundez-Zanuy, M., Ezeiza, A., Barroso, N., Ecay-Torres, M., Martinez-Lage, P. & Martinez de Lizardui, U. (2013). On the selection of non-invasive methods based on speech analysis oriented to automatic Alzheimer disease diagnosis. Sensors (Basel)., 13, 6730-6745.
Luo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Hu, G., Mu, N., Chan, J., Chen, X., Fang, Y., Wu, F., He, H. & Ning, Y. (2013). CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem., 127(5), 681-90.
Manzine, P. R., Barham, E. J., Vale Fde, A., Selistre-de-Araújo, H. S., Iost Pavarini, S. C. & Cominetti, M. R. (2013). Correlation between mini-mental state examination and platelet ADAM10 expression in Alzheimer’s disease. J Alzheimers Dis., 36, 253-260.
Marklund, N., Farrokhnia, N., Hånell, A., Vanmechelen, E., Enblad, P., Zetterberg, H., Blennow, K. & Hillered, L. (2014). Monitoring of β-Amyloid Dynamics after Human Traumatic Brain Injury. J Neurotrauma., 31(1), 42-55
Marutle, A., Gillberg, P. G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L. & Nordberg, A. (2013). ³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. J Neuroinflammation., 10, 90.
Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour-Rainfray, D., Fagan, A. M., Heegaard, N. H., Robin Hsiung, G. Y., Hyman, B., Iqbal, K., Lachno, D. R., Lleó, A., Lewczuk, P., Molinuevo, J. L., Parchi, P., Regeniter, A., Rissman, R., Rosenmann, H., Sancesario, G., Schröder, J., Shaw, L. M., Teunissen, C. E., Trojanowski, J. Q., Vanderstichele, H., Vandijck, M., Verbeek, M. M., Zetterberg, H., Blennow, K. & Käser, S. A. (2013). Alzheimer’s Association QC Program Work Group. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement., 9, 251-261.
Mattsson, N., Insel, P., Nosheny, R., Zetterberg, H., Trojanowski, J. Q., Shaw, L. M., Tosun, D. & Weiner, M. (2013). CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders. Transl Psychiatry., 3, e293.
McClatchey, R., Branson, A., Anjum, A., Bloodsworth, P., Habib, I., Munir, K., Shamdasani, J. & Soomro, K. (2013). neuGRID Consortium. Providing traceability for neuroimaging analyses. Int J Med Inform., 82, 882-894.
Modrego, P. J. & Gazulla, J. (2013). The predictive value of the memory impairment screen in patients with subjective memory complaints: a prospective study. Prim Care Companion CNS Disord., 15(1).
Monge Argilés, J. A., Blanco Cantó, M. A., Leiva Salinas, C., Flors, L., Muñoz Ruiz, C., Sánchez Payá, J., Gasparini Berenguer, R. & Leiva Santana, C. (2014). A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain brain magnetic resonance and cerebrospinal fluid. Neurologia., 29(7), 397-401.
Moore, R. C., Chattillion, E. A., Ceglowski, J., Ho, J., von Känel, R., Mills, P. J., Ziegler, M. G., Patterson, T. L., Grant, I. & Mausbach, B. T. (2013). A randomized clinical trial of Behavioral Activation (BA) therapy for improving psychological and physical health in dementia caregivers: Results of the Pleasant Events Program (PEP). Behav Res Ther., 51, 623-632.
Moran, C., Beare, R., Phan, T. G., Bruce, D. G., Callisaya, M. L. & Srikanth, V. (2015). Alzheimer’s Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology., 85(13), 1123-1130.
Moreth, J., Mavoungou, C. & Schindowski, K. (2013). Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Front Aging Neurosci., 5, 25.
Mroczko, B., Groblewska, M. & Barcikowska, M. (2013). The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in the Pathophysiology of Neurodegeneration: A Literature Study. J Alzheimers Dis., 37(2), 273-283.
Mukaetova-Ladinska, E. B., Abdell-All, Z., Andrade, J., da Silva, J. A., Boksha, I., Burbaeva, G., Kalaria, R. J. & O’Brien, J. T. (2013). Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer's disease: An Explorative Study. Curr Alzheimer Res (in press).
Naudí, A., Cabré, R., Jové, M., Ayala, V., Gonzalo, H., Portero-Otín, M., Ferrer, I. & Pamplona, R. (2015). Lipidomics of Human Brain Aging and Alzheimer’s Disease Pathology. Int Rev Neurobiol., 122,133-89.
Nutu, M., Zetterberg, H., Londos, E., Minthon, L., Nägga, K., Blennow, K., Hansson, O. & Ohrfelt, A. (2013). Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dement Geriatr Cogn Disord., 36, 99-110.
Oh, J., Yoo, G., Chang, Y. W., Kim, H. J., Jose, J., Kim, E., Pyun, J. C. & Yoo, K. H. (2013). A carbon nanotube metal semiconductor field effect transistor-based biosensor for detection of amyloid-beta in human serum. Biosens Bioelectron., 50, 345-350.
Olivieri, F., Rippo, M. R., Procopio, A. D. & Fazioli, F. (2013). Circulating inflamma-miRs in aging and age-related diseases. Front Genet., 4, 121.
Ota, K., Oishi, N., Ito, K., Fukuyama, H. & SEAD-J Study Group, Alzheimer’s Disease Neuroimaging Initiative. (2015). Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. J Neurosci Methods, 256, 168-183.
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Alzheimer’s Disease Neuroimaging Initiative, Minthon, L., Blennow, K. & Olsson, M. (2015). Swedish BioFINDER study group, Hansson O. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology., 85(14), 1240-1249.
Perrin, R. J., Payton, J. E., Malone, J. P., Gilmore, P., Davis, A. E., Xiong, C., et al. (2013), Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation. PLoS ONE, 8(5), e64314.
Plagg, B., Marksteiner, J., Kathrin, M., Kniewallner, K. M. & Humpel, C. (2015). Platelet dysfunction in hypercholesterolemia mice, two Alzheimer’s disease mouse models and in human patients with Alzheimer’s disease. Biogerontology, 16, 543–558.
Podlesniy, P., Figueiro-Silva, J., Llado, A., Antonell, A., Sanchez-Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N. & Trullas, R. (2013). Low CSF concentration of mitochondrial DNA in preclinical Alzheimer’s disease. Ann Neurol. 74(5), 655-668.
Portelius, E., Appelkvist, P., Strömberg, K. & Hoglund, K. (2013). Characterization of the Effect of a Novel γ-Secretase Modulator on Aβ: A Clinically Translatable Model. Curr Pharm Des., 20(15), 2484-2490.
Randall, C., Mosconi, L., de Leon, M. & Glodzik, L. (2013). Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed)., 18, 1150-1173.
Ray, L., Khemka, V. K., Behera, P., Bandyopadhyay, K., Pal, S., Pal, K., Basu, D. & Chakrabarti, S. (2013). Serum Homocysteine, Dehydroepiandrosterone Sulphate and Lipoprotein (a) in Alzheimer's Disease and Vascular Dementia. Aging Dis., 4, 57-64.
Rembach, A., Ryan, T. M., Roberts, B. R., Doecke, J. D., Wilson, W. J., Watt, A. D., Barnham, K. J. & Masters, C. L. (2013). Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. Biomark Med., 7, 641-662.
Richard, E., Schmand, B. A., Eikelenboom, P. & Van Gool, W. A. (2013). Alzheimer’s Disease Neuroimaging Initiative. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer’s disease in patients with MCI: a diagnostic accuracy study. BMJ Open., 3(6).
Rival, T., Page, R. M., Chandraratna, D. S., Sendall, T. J., Ryder, E., Liu, B., Lewis, H., Rosahl, T., et al. (2009). “Fenton chemistry and oxidative stress mediate the toxicity of the β-amyloid peptide in a Drosophila model of Alzheimer's disease.” The European journal of Neuroscience, 29 (7), 1335–1347.
Rongve, A., Arsland, D. & Graff, C. (2013). [Alzheimer's disease and genetics]. Tidsskr Nor Laegeforen., 133, 1449-1452.
Rosén, C., Hansson, O., Blennow, K. & Zetterberg, H. (2013). Fluid biomarkers in Alzheimer’s disease - current concepts. Mol Neurodegener., 8, 20.
Ross, J., Sharma, S., Winston, J., Nunez, M., Bottini, G., Franceschi, M., Scarpini, E., Frigerio, E., Fiorentini, F., Fernandez, M., Sivilia, S., Giardino, L., Calza, L., Norris, D., Cicirello, H., Casula, D. & Imbimbo, B. P. (2013). CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with MCI: A 12-Week, Double-Blind, Placebo- Controlled Study. Curr Alzheimer Res., 10, 742-753.
Rubio-Perez, J. M. & Morillas-Ruiz, J. M. (2013). Serum Cytokines Profile in Alzheimer's Patients after Ingestion of an Antioxidant Beverage. CNS Neurol Disord Drug Targets., 12(8), 1233-1241..
Sabbagh, J. J., Kinney, J. W. & Cummings, J. L. (2013). Alzheimer’s disease biomarkers: correspondence between human studies and animal models. Neurobiol Dis., 56, 116-130.
Sabbagh, J. J, Kinney, J. W. & Cummings, J. L. (2013). Alzheimer's disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis., 2,108-120.
Sancesario, G. M. & Bernardini, S. (2015). How many biomarkers to discriminate neurodegenerative dementia? Crit Rev Clin Lab Sci., 18, 1-13.
Schapira, A. H. (2013). Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol., 26, 395-400.


Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., et al. (1992). “Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.” Nature, 359 (6393), 325–327.
Sharma, S. & Ebadi, M. (2013). Antioxidant Targeting in Neurodegenerative Disorders. Ed. I. Laher, Springer Verlag. Germany. Chapter 85, p 1-85.
Sharma, S, Rais, A., Nel, W., Sandhu, R. & Ebadi, M. (2013a). Clinical significance of Metallothioneins in Cell Therapy and Nanomedicine. Int. J. Nanomedicine., 8, 1477-1488.
Sharma, S. & Ebadi, M. (2014). Charnoly body as universal biomarker of cell injury. Biomarkers & Genomic Medicine., 6, 89-98.
Sharma, S., Carlson, E., Ebadi, M., (2003). The Neuroprotective Actions of Selegiline in Inhibiting 1-Methyl, 4-Phenyl, Pyridinium Ion (MPP+)-Induced Apoptosis in Dopaminergic Neurons. J. Neurocytology, 32, 329-343.
Sharma, S., Kheradpezhou, M., Shavali, S., EI Refaey, H., Eken, J., Hagen, C. & Ebadi, M. (2004). Neuroprotective Actions of Coenzyme Q10 in Parkinson’s Disease. Methods in Enzymology., 382, 488-509.
Sharma, S., Refaey, H. El. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull., 70, 22-32.
Sharma, S. K., Selvamurthy, W. & Dakshinamurti, K. (1993). Effect of environmental neurotoxins in the developing brain. Biometeorology., 2, 447-455.
Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y. & Ebadi, M. (2013a). Biomarkers in Parkinson's disease (recent update). Neurochem Int., 63, 201-129.
Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y. & Ebadi, M. (2013b). Biomarkers in Parkinson's disease (recent update). Neurochem Int., 63, 201-129.
Sharma, S. K., Bolster, B. & Dakshinamurti, K. (1994). Picrotoxin and Pentylene tetrazole induced seizure activity in pyridoxine-deficient rats. J. Neurol. Sci., 121, 1-9.
Sharma, S. K. & Dakshinamurti, K. (1992). Seizure Activity in Pyridoxine-Deficient Adult Rats. Epilepsia., 33, 235–247.
Sharma, S. K. & Dhalla, N. S. (2000). Domoic acid as a tool in Molecular Pharmacology. Pharmacology and therapeutics in New Millenium. Ed. S.K. Gupta. Springer Verlag, Germany. pp. 130-137.
Sharma, S. K. & Dakshinamurti, K. (1992). Seizure Activity in Pyridoxine-Deficient Adult Rats. Epilepsia., 33, 235–247.
Sharma, S. K. & Dakshinamurti, K. (1993). Suppression of domoic acid induced seizures by 8-(OH)-DPAT. J Neural Transm Gen Sect., 93, 87-98.
Sherif, F. F., Zayed, N. & Fakhr, M. (2015). Discovering Alzheimer Genetic Biomarkers Using Bayesian Networks. Adv Bioinformatics., 2015, 639367.
Simonsen, A. H., Kuiperij, B., Ali El-Agnaf, O. M., Engelborghs, S., Herukka, S. K., Parnetti, L., Rektorova, I., Vanmechelen, E., Kapaki, E., Verbeek, M. & Mollenhauer, B. (2016). The utility of α-Syn as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med., 10(1), 19-34.
Sogawa, C. A., Asanuma, M., Sogawa, N., Miyazaki, I., Nakanishi, T., Furuta, H. & Ogawa, N. (2001). Localization, regulation, and function of metallothionein-III/growth inhibitory factor in the brain. Acta Med., 55(1), 1-9.
Soldan, A., Pettigrew, C., Li, S., Wang, M. C., Moghekar, A., Selnes, O. A., Albert, M. & O'Brien, R. (2013). BIOCARD Research Team. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging., 34(12), 2827-2834.
Sood, S., Gallagher, I. J., Lunnon, K., Rullman, E., Keohane, A., Crossland, H., Phillips, B. E., Cederholm, T., Jensen, T., van Loon, L. J., Lannfelt, L., Kraus, W. E., Atherton, P. J., Howard, R., Gustafsson, T., Hodges, A. & Timmons, J. A. (2015). A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. Genome Biol. 16, 185.
Sorensen, K. C., Simonsen, A. H., Holmetoft, U. B., Hasselbalch, S. G. & Heegaard, N. H. (2013). Neprilysin-Like Activity Correlates with CSF-Tau and Phospho-Tau in Patients with Alzheimer's Disease. J Alzheimers Dis., 37(2), 379-387.
Souslova, T., Marple, T. C., Spiekerman, A. M. & Mohammad, A. A. (2013). Personalized medicine in Alzheimer's disease and depression. Contemp Clin Trials., 36(2), 616-623.
Sultana, R., Baglioni, M., Cecchetti, R., Cai, J., Klein, J. B., Bastiani, P., Ruggiero, C., Mecocci, P. & Butterfield, A. D. (2013). Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radic Biol Med., 65, 595-606.
Taverna, M., Straub, T., Hampel, H., Rujescu, D. & Lichtenthaler, S. F. (2013). A New Sandwich Immunoassay for Detection of the α-Secretase Cleaved, Soluble Amyloid-β Protein Precursor in Cerebrospinal Fluid and Serum. J Alzheimers Dis., 37(4), 667-678.
Tew, D. J., Bottomley, Stephen P., Smith, David P., Ciccotosto, Giuseppe D., Babon, Jeffrey., Hinds, Mark G., Masters, Colin L., Cappai, Roberto. & Barnham, Kevin, J. (2008). “Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer’s Disease Amyloid-β Peptide.” Biophysical Journal, 94 (7), 2752–2766.
Thomason, L. A., Smithson, L. J., Hazrati, L. N., McLaurin, J. & Kawaja, M. D. (2013). Reactive astrocytes associated with plaques in TgCRND8 mouse brain and in human Alzheimer brain express phosphoprotein enriched in astrocytes (PEA-15). FEBS Lett, 587, 2448-2454.
Toledo, J. B., Xie, S. X., Trojanowski, J. Q. & Shaw, L. M. (2013). Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol., 126(5), 659-670.
Toombs, J., Paterson, R. W., Lunn, M. P., Nicholas, J. M., Fox, N. C., Chapman, M. D., Schott, J. M. & Zetterberg, H. (2013). Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med., 12, 1-7.
Trushina, E. & Mielke, M. M. (2013). Recent advances in the application of metabolomics to Alzheimer’s Disease. Biochim Biophys Acta., 1842(8), 1232-1239.
Trzepacz, P. T., Yu, P., Sun, J., Schuh, K., Case, M., Witte, M. M., Hochstetler, H. & Hake, A. (2014). Alzheimer’s Disease Neuroimaging Initiative. Comparison of neuroimaging modalities for the prediction of conversion from MCI to Alzheimer’s dementia. Neurobiol Aging., 35(1), 143-151.
Tsitsopoulos, P. P. & Marklund, N. (2013). Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies. Front Neurol., 4, 79.
Tsuruoka, M., Hara, J., Hirayama, A., Sugimoto, M., Soga, T., Shankle, W. R. & Tomita, M. (2013). CE-MS-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis., 34(19), 2865-2872.
Van der Mussele, S., Mariën, P., Saerens, J., Somers, N., Goeman, J., De Deyn, P. P. & Engelborghs, S. (2014). Behavioral Syndromes in MCI and Alzheimer's Disease. J Alzheimers Dis., 38(2), 319-329.
Vasunilashorn, S., Glei, D. A., Lin, Y. H. & Goldman, N. (2013). Apolipoprotein e and measured physical and pulmonary function in older Taiwanese adults. Biodemography Soc Biol., 59, 57-67.
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G.K., Fox, N., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P. & EU/US/CTAD Task Force Members. (2013). Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement., 9, 438-444.
Wahlster, P., Niederländer, C., Kriza, C., Schaller, S. & Kolominsky-Rabas, P. L. (2013). Clinical Assessment of Amyloid Imaging in Alzheimer's Disease: A Systematic Review of the Literature. Front Hum Neurosci., 7, 456.
Wang, L., Brier, M. R., Snyder, A. Z., Thomas, J. B., Fagan, A. M., Xiong, C., Benzinger, T. L, Holtzman, D. M., Morris, J. C. & Ances, B. M. (2013). Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity. JAMA Neurol., 70(10), 1242-1248.
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., Morris, J. C., Petersen, R. C., Saykin, A. J., Schmidt, M. E., Shaw, L., Shen, L., Siuciak, J. A., Soares, H., Toga, A. W. & Trojanowski, J. Q. (2013). Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. S1552-5260(13)02429-1.
Weinstein, G., Beiser, A. S., Decarli, C., Au, R., Wolf, P. A. & Seshadri, S. (2013). Brain Imaging and Cognitive Predictors of Stroke and Alzheimer Disease in the Framingham Heart Study. Stroke., 44(10), 2787-2794.
White, M. T. & Xie, S. X. (2013). Adjustment for measurement error in evaluating diagnostic biomarkers by using an internal reliability sample. Stat Med., 32, 4679-4658.
Xiang, Y., Lam, S. M. & Shui, G. (2015). What can lipidomics tell us about the pathogenesis of Alzheimer disease? Biol Chem., 396(12), 1281-1291.
Yamamoto, T., Uchiyama, T., Higuchi, Y., Asahina, M., Hirano, S., Yamanaka, Y. & Kuwabara, S. (2015). Subthalamic nucleus deep brain stimulation modulate catecholamine levels with significant relation to clinical outcome after surgery in patients with Parkinson’s disease. PLOS Sep, 22.
Yang, A. C., Wang, S. J., Lai, K. L., Tsai, C. F., Yang, C. H., Hwang, J. P., Lo, M. T., Huang, N. E., Peng, C. K. & Fuh, J. L. (2013). Cognitive and neuropsychiatric correlates of EEG dynamic complexity in patients with Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry., 47, 52-61.
Yarchoan, M., Louneva, N., Xie, S. X., Swenson, F. J., Hu, W., Soares, H., Trojanowski, J. Q., Lee, V. M., Kling, M. A., Shaw, L. M., Chen-Plotkin, A., Wolk, D. A. & Arnold, S. E. (2013). Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. J Neurol Sci., 333(1-2), 9-12.
Younesi, E. & Hofmann-Apitius, M. (2013). A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect. J Transl Med., 11, 177.
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M.E., Buchhave, P., Londos, E., et al. (2008). “Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.” Archives of Neurology, 65 (8), 1102–1107.
Zhang, H. Y., Xie, C., Chen, G., Zhang, Z. J., Gao-Jun Teng, G. J. & Li, S. J. (2013). Modular reorganization of brain resting state networks and its independent validation in Alzheimer's disease patients. Front Hum Neurosci, 7, 456.
Zhang, S., Lei, C., Liu, P., Zhang, M., Tao, W., Liu, H. & Liu, M. (2015). Association between variant amyloid deposits and motor deficits in FAD-associated presenilin-1 mutations: A systematic review. Neuroscience & Biobehavioral Reviews, 56, 180–192.
Zhang, A. H., Sun, H. & Wang, X. J. (2013). Recent advances in metabolomics in neurological disease, and future perspectives. Anal Bioanal Chem., 405(25), 8143-8150.
Zhou, X. & Xu, J. (2015). Identification of Alzheimer’s disease-associated long noncoding RNAs. Neurobiol Aging., 36(11), 2925-2931.

Chapter 14

Ajjimaporn, A., Swinscoe, S., Shavali, S., et al. (2005). Metallothionein provides zinc-mediated protective effects against methAmphetamine toxicity in SK-N-SH cells. Brain Res Bull, 67, 466-475.
Ajjimaporn, A., Phansuwan-Pujito, P., Ebadi, M., et al. (2007). Zinc protects SK-N-SH cells from methAmphetamine-induced α-Syn expression. Neurosci Lett., 419, 59-63.
Adams, K. M., Gilman, S., Johnson-Greene, D., et al. (1998). The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolismstudied with positron emission tomography in older Alcoholic patients. Alcohol Clin. Ex.p Res., 22, 105-110.
Adams, K. M., Gilman, S., Koeppe, R. A., et al. (1993). Neuropsychological deficits are correlated with frontal glucose hypometabolism in positron emission tomography studies of older Alcoholic patients. Alcohol Clin Exp Res, 17, 205-210.
Bartzokis, G., Beckson, M., Newton, T., et al. (1999). Selegiline effects on Cocaine-induced changes in medial temporal lobe glucose metabolism and subjective ratings of euphoria. Neuropsychopharmacology, 20, 582-90.
Breier, A., Malhotra, A. K., Pinals, D. A., et al. (1997). Association of Ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry,154, 805-811.
Brody, A. L., Mandelkern, M. A., Lee, G., et al. (2006). Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in Bupropion-treated smokers: a preliminary study. Psychiatry Res, 130, 269-281.
Brody, A. L., Mandelkern, M. A., London, E. D., et al. (2006). Brain metabolic changes during cigarette craving. Arch Gen Psychiatry, 1162-1172.
Buchert, R., Obrocki, J., Thomasius, R., et al. (2006). Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun, 22, 889-897.
Clark, C. M., Li, D., Conry, J., et al. (2006). Structural and functional brain integrity of fetal Alcohol syndrome in nonretarded cases. Pediatrics, 105, 1096-1099.
Dao-Castellana, M. H., Samson, Y., Legault, F., et al. (1998). Frontal dysfunction in neurologically normal chronic Alcoholic subjects: metabolic and neuropsychological findings. Psychol. Med., 28, 1039-1048.
Degrell, I., Berecz, R., Glaub, T., et al. (2006). Use of Positron Emission Tomography in Psychiatry. Orv. Hetil., 143, 1311-1314.
Domino, E. F., Minoshima, S., Guthrie, S. K., et al. (2000). Effects of Nicotine on regional cerebral glucose metabolismin awake resting tobacco smokers. Neuroscience., 101, 277-282.
Ebadi, M., Sharma, S., Wanpen, S., et al. (2004). Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor kappa-B activation. J. Cell Mol. Med., 8, 213-222.
Ebadi, M., Sharma, S., Ghafourifar, P., et al. (2005). Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role fo metallothioneins. Methods in Enzymol, 396, 296-298.
Ebadi, M. & Sharma, S. (2006). Metallothioneins 1 and 2 attenuate peroxynitrite induced oxidative stress in Parkinson’s disease. J. Exp. Biol. & Med., 231, 1576-1583.
Ebadi, M. & Sharma, S. (2007). Vitamin E and Coenzyme Q10 in Parkinson’s Disease. The Encyclopedia of Vitamin E (eds V.R. Preedy and R.R. Watson), CAB International Chapter 39, pp. 461-471.
Fallon, J. H., Keator, D. B., Mbogori, J., et al. (2006). Gender: a major determinant of brain response to Nicotine. Int J Neuropsychopharmacol., 8, 17-26.
Fellgiebel, A., Scheurich, A., Siessmeier, T., et al. (2003). Persistence of disturbed thalamic glucose metabolismin a case of Wernicke-Korsakoff syndrome. Psychiatry Res., 124, 105-112.
Fumal, A., Laureys, S., Di Clemente, L., et al. (2006). Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain, 129, 543-550.
Galynker, I. I., Watras-Ganz, S., Miner, C., et al. (2006). Cerebral glucose metabolism in opiate-dependent subjects: effects of Methadone maintenance. Mt. Sinai. J. Med., 67, 381-387.
George, D. T., Rawlings, R. R., Williams, W. A., et al. (2004). A select group of perpetrators of domestic violence: evidence of decreased glucose metabolism in the right hypothalamus and reduced relationships between cortical/subcortical brain structures in position emission tomography. Psychiatry Res., 130, 11-25.
Gilman, S., Adams, K. M., Johnson-Greene, D., et al. (1996). Koeppe, R.A., Junck, L., Kluin, K.J., Martorello, S., Heumann, M., and Hill, E. Effects of Disulfiram on positron emission tomography and neuropsychological studies in severe chronic Alcoholism. Alcohol Clin. Exp. Res., 20, 1456-1461.
Gilman, S., Koeppe, R. A., Adams, K., et al. (1996). Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic Alcoholics. Ann. Neurol., 40, 163-171.
Goldstein, R. Z. & Volkow, N. D. (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry, 159, 1642-1652.
Goldstein, R. Z., Alia-Klein, N., Leskovjan, A. C., et al. (2005). Anger and depression in Cocaine addiction: association with the orbitofrontal cortex. Psychiatry Res., 138, 13-22.
Goldstein, R. Z., Leskovjan, A. C., Hoff, A. L., et al. (2004). Severity of neuropsychological impairment in Cocaine and Alcohol addiction: association with glucose metabolism in the prefrontal cortex. Neuropsychologia., 42, 1447-1458.
Goldstein, R. Z., Volkow, N. D., Chang, L., et al. (2002). The orbitofrontal cortex in methAmphetamine addiction: involvement in fear. Neuroreport., 13, 2253-2257.
Grant, S., London, E. D., Newlin, D. B., et al. (1996). Activation of memory circuits during cue-elicited Cocaine craving. Proc. Natl. Acad. Sci. U.S.A, 93, 12040-12045.
Hommer, D., Andreasen, P., Rio, D., et al. (1997). Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of Alcoholic and control subjects. J. Neurosc., 17, 2796-2806.
Huang, Y. H., Tsai, S. J., Yu, M. F., et al. (1995). Dose-dependent effects of chronic Amphetamine administration in local cerebral glucose utilization in rat. Neuropsychobiology, 32, 149-155.
Ishii K, Ikerjiri Y, Sasaki M, et al. (1999). Regional cerebral glucose metabolismand blood flow in a patient with Marchiafava-Bignami disease. Am J. Neuroradiol, 20, 1249-1251.
Joyce, E. M., Rio, D. E., Ruttimann, U. E., et al. (1994). Decreased cingulate and precuneate glucose utilization in Alcoholic Korsakoff's syndrome. Psychiatry Res., 54, 225-229.
Kim, S. J., Lyoo, I. K., Hwang, J., et al. (2005). Frontal glucose glucose hypometabolism in abstinent methAmphetamine users. Neuropsychopharmacology., 30, 1383-1391.
Klongpanichapak, S., Govitrapong, P., Sharma, S. K., et al. (2006). Attenuation of Cocaine and MethAmphetamine Neurotoxicity by Coenzyme Q10. Neurochem Res., 31, 303-311.
Lago, J. A. & Kosten, T. R. (1994). Stimulant withdrawal. Addiction., 89,1477-1481.
Liu, X., Vaupel, D. B., Grant, S. & London, E. D. (1998). Effect of Cocaine-related environmental stimuli on the spontaneous electroencephalogram in polydrug abusers. Neuropsychopharmacology, 19, 10-17.
London, E. D. (1989). The effects of drug abuse on glucose metabolism. J. Neuropsychiatry Clin Neurosci., 1, S30-36.
London, E. D., Cascella, N. G., Wong, D. F., et al. (1990). Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [Fluorine-18]-FdG. Arch. Gen. Psychiatry., 47, 567-574.
London, E. D., Simon, S. L., Berman, S. M., et al. (2004). Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methAmphetamine abusers. Arch. Gen. Psychiatry., 61, 73-74.
Martin, P. R., Rio, D., Adinoff, B., et al. (1992). Regional cerebral glucose utilization in chronic organic mental disorders associated with Alcoholism. J. Neuropsychiatry Clin. Neurosci., 4, 159-167.
Montz Andree, R., Jimenez Vicioso, A., Coullaut Jauregui, J., et al. (2002). PET in neurology and psychiatry I. PET with FDG in the study of the CNS. Rev. Esp. Med. Nucl., 21, 370-376.
Morrow, L. A., Callender, T., Lottenberg, S., et al. (1990). PET and neurobehavioral evidence of tetrabromoethane encephalopathy. J. Neuropsychiatry Clin. Neurosci., 2, 431-435.
Murata, T., Omata, N., Fujibayashi, Y., et al. (1999). Dynamic changes in glucose metabolisminduced by Thiamine deficiency and its replenishment as revealed by a positron autoradiography technique using rat living brain slices. J. Neurol. Sci., 164, 29-36.
Nichols, D. E. (2004). Hallucinogens. Pharmacol. Ther., 101, 131-141
Reed, L. J., Lasserson, D., Marsden, P., et al. (2003). FDG-PET findings in the Wernicke-Korsakoff Syndrome. Cortex., 39, 1027-1045.
Samson, Y., Baron, J. C., Feline, A., et al. (1986). Local cerebral glucose utilization in chronic Alcoholics: a positron tomographic study. J. Neurol. Neurosurg. Psychiatry, 49, 1165-1170.
Sharma, S., Kheradpezhou, S., Shavali, S., et al. (2004). Neuroprotective Actions of Coenzyme Q10 in Parkinson’s disease. Methods in Enzymol, 382, 388-3999.
Sharma, S. & Ebadi, M. (2005). Distribution kinetics of 18F-DOPA in Weaver Mutant Mice. Mol. Brain Res., 139, 23-30.
Sharma, S., Refaey, H. E. l. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse models of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull., 70, 22-32.
Sharma, S. & Ebadi, M. (2007). Therapeutic Potential of Metallothioneins in Parkinson’s disease. In Genetics of Parkinson’s Disease, Nova Science Publishers, New York.
Sokoloff, L. (1983). Mapping local functional activity by measurement of local cerebral glucose utilization in the central nervous system of animals and man. Harvey Lect., 79, 77-83.
Soyka, M., Dresel, S., Horak, M., et al. (2000). PET and SPECT findings in Alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. World J. Biol. Psychiatry., 1, 215-218.
Soyka, M., Koch, W. & Tatsch, K. (2005). Thalamic hypofunction in Alcohol hallucinosis: FDG PET findings. Psychiatry Res, 139, 259-262.
Soyka, M., Zetzsche, T., Dresel, S., et al. (2000). FDG-PET and IBZM-SPECT suggest reduced thalamic activity but no dopaminergic dysfunction in chronic Alcohol hallucinosis. J Neuropsychiatry Clin Neurosci, 12, 287-298.
Volkow, N. D., Chang, L., Wang, G. J., et al. (2001). Low level of brain dopamine D2 receptors in methAmphetamine abusers: association with glucose metabolism in the orbitofrontal cortex. Am. J. Psychiatry., 158, 2015-2021.
Volkow, N. D., Chang, L., Wang, G. J., et al. (2001). Higher cortical and lower subcortical glucose metabolism in detoxified methAmphetamine abusers. Am. J. Psychiatry., 158, 383-389.
Volkow, N. D., Fowler, J. S., Wang, G. J., et al. (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal glucose metabolism in Cocaine abusers. Synapse., 14, 169-177.
Volkow, N. D., Fowler, J. S., Wolf, A. P., et al. (1991). Changes in brain glucose metabolismin Cocaine dependence and withdrawal. Am. J. Psychiatry, 148, 621-626.
Volkow, N. D., Hitzemann, R., Wang, G. J., et al. (1992). Fowler, J.S., Burr, G., Pascani, K., Dewey, S.L., and Wolf, A.P. Decreased brain glucose metabolism in neurologically intact healthy Alcoholics. Am. J. Psychiatry., 149, 1016-1022.
Volkow, N. D., Hitzemann, R., Wolf, A. P. et al. (1990). Acute effects of Ethanol on regional brain glucose metabolismand transport. Psychiatry Res., 35, 39-48.
Volkow, N. D., Wang, G. J., Begleiter, H., et al. (1995). Regional brain metabolic response to Lorazepam in subjects at risk for Alcoholism. Alcohol Clin. Exp. Res, 19, 510-516.
Volkow, N. D., Wang, G. J., Fowler, J. S., et al. (2000). Cocaine abusers show a blunted response to Alcohol intoxication in limbic brain regions. Life Sci, 66, PL161-177.
Volkow, N. D., Wang, G. J., Fowler, J. S., et al. (1999). Association of Methylphenidate-induced craving with changes in right striato-orbitofrontal glucose metabolism in Cocaine abusers: implications in addiction. Am. J. Psychiatry., 156,19-26.
Volkow, N. D., Wang, G. J., Fowler, J. S., et al. (1998). Enhanced sensitivity to benzodiazepines in active Cocaine-abusing subjects: a PET study. Am. J. Psychiatry., 155, 200-206.
Volkow, N. D., Wang, G. J., Hitzemann, R., et al. (1993). Decreased cerebral response to inhibitory neurotransmission in Alcoholics. Am. J. Psychiatry, 150, 417-422.
Volkow, N. D., Wang, G. J., Ma, Y., et al. (2005). Activation of orbital and medial prefrontal cortex by Methylphenidate in Cocaine-addicted subjects but not in controls: relevance to addiction. J. Neurosci., 25, 3932-3939.
Volkow, N. D., Wang, G. J., Overall, J. E., et al. (1997). Regional brain metabolic response to Lorazepam in Alcoholics during early and late Alcohol detoxification. Alcohol Clin. Exp. Res., 21, 1278-1284.
Vollenweider, F. X., Leenders, K. L., Oye, I., et al. (1997). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-Ketamine in healthy volunteers using positron emission tomography (PET). Eur. Neuropsychopharmaco., 7, 25-38.
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., et al. (1997). Metabolic hyperfrontality and psychopathology in the Ketamine model of psychosis using positron emission tomography (PET) and [18F]FdG (FDG). Eur. Neuropsychopharmacol., 7, 9-14.
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., et al. (1997). Positron emission tomography and FdG studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology., 16, 357-362.
Voytek, B., Berman, S. M. & Hassid, B. D. (2005). Differences in regional brain glucose metabolism associated with marijuana abuse in methAmphetamine abusers. Synapse., 1, 13-15.
Wang, G. J., Volkow, N. D., Chang, L., et al. (2004). Partial recovery of brain glucose metabolism in methAmphetamine abusers after protracted abstinence. Am. J. Psychiatry.,161, 242-248.
Wang, G. J., Volkow, N. D., Fowler, J. S., et al. (1999). Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci., 64, 775-784.
Wang, G. J., Volkow, N. D., Fowler, J. S., et al. (1998). Regional cerebral glucose metabolism in female Alcoholics of moderate severity does not differ from that of controls. Alcohol Clin. Exp. Res., 22, 1850-1854.
Wang, G. J., Volkow, N. D., Franceschi, D., et al. (2000). Regional brain glucose metabolism during Alcohol intoxication. Alcohol Clin. Exp. Res., 24, 822-829.
Wang, G. J., Volkow, N. D., Hitzemann, R., et al. (1992). Brain imaging of an Alcoholic with MRI, SPECT, and PET. Am. J. Physiol. Imaging, 7,194-198.
Wang, G. J., Volkow, N. D., Roque, C. T., et al. (1993). Functional importance of ventricular enlargement and cortical atrophy in healthy subjects and Alcoholics as assessed with PET, MR imaging, and neuropsychologic testing. Radiology., 186, 59-65.
Williams, W., Reimold, M., Kerich, M., et al. (2004). Glucose utilization in the medial prefrontal cortex correlates with serotonin turnover rate and clinical depression in Alcoholics. Psychiatry Res., 132, 219-224.
Zaplatnikov, K., Menzel, C., Dobert, N., et al. (2004). Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. Br. J. Radiol., 77, 525-527.
Zhu, W., Volkow, N. D., Ma, Y., et al. (2004). Relationship between Ethanol-induced changes in brain regional glucose metabolism and its motor, behavioural and cognitive effects. Alcohol., 39, 53-58.

Chapter 15

Alavi, A., Dann, R., Chawluk, J., Alavi, J., Kushner, M. & Reivich, M. (1986). Positron emission tomography imaging of regional cerebral glucose metabolism. Semin. Nucl. Med., 16, 2-34.


Albin, R. L., Minoshima, S., D’Amato, C. J., Frey, K. A., Kuhl, D. A. & Sima, A. A. (1996). Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology., 47, 462-426.


Antonini, A., Vontobel, P., Psylla, M., Gunther, I., Maguire, P. R., Missimer, J. & Leenders, K. L. (1995). Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol., 52, 1183-1190.


Antonini, A., Leenders, K. L., Vontobel, K. L., Maguire, R. P., Missimer, J., Psylla, M. & Gunther, I. (1997). Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain., 120, 2187-2195.


Antonini, A., Moeller, J. R., Nakamura, T., Spetsieris, P., Dhawan, V. & Eidelberg, D. (1998). The metabolic anatomy of tremor in Parkinson's disease. Neurology., 51, 803-810.


Antonini, A., Kazumata, K., Feigin, A., Mandel, F., Dhawan, V., Margouleff, C. & Eidelberg, D. (1998). Differential diagnosis of parkinsonism with [18F]FdG and PET. Mov. Disord., 13, 268-274.


Arahata, Y., Kato, T., Tadokoro, M. & Sobue, G. (1997). [18F-FdG positron emission tomography in Parkinson's disease]. Nippon. Rinsho., 55, 222-226.


Arahata, Y., Hirayama, M., Ieda, T., Koike, Y., Kato, T., Tadokoro, M., Ikeda, M., Ito, K. & Sobue, G. (1999). Parieto-occipital glucose glucose hypometabolism in Parkinson's disease with autonomic failure. J. Neurol. Sci., 163, 119-126.


Asanuma, K., Ma, Y., Huang, C., Carbon-Correll, M., Edwards, C., Raymond, D., Bressman, S. B., Moeller, J. R. & Eidelberg, D. (2005). The metabolic pathology of dopa-responsive dystonia. Ann. Neurol., 57, 596-600.


Berding, G., Odin, P., Brooks, D. J., Nikkhah, G., Matthies, C., Peschel, T., Shing, M., Kolbe, H., van Den Hoff, J., Fricke, H., Dengler, R., Samii, M. & Knapp, W. H. (2001). Resting regional cerebral glucose metabolismin advanced Parkinson's disease studied in the off and on conditions with [18F]-FDG-PET. Mov. Disord., 16, 1014-1022.


Boecker, H., Weindl, A., Leenders, K., Antonini, A., Kuwert, T., Kruggel, F., Grafin von Einsiedel, H. & Conrad, B. (1996). Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta. Neurol. Scand., 93, 387-392.


Bohnen, N. I., Minoshima, S., Giordani, B., Frey, K. A. & Kuhl, D. E. (1999). Motor correlates of occipital glucose glucose hypometabolism in Parkinson’s disease without dementia. Neurology., 52, 541-546.


Borbely, K. (2001). Functional neuroimaging in movement disorders. Orv. Hetil., 142, 2347-2355.


Bromfield, E. B., Altshuler, L., Leiderman, D. B., Balish, M., Ketter, T. A., Devinsky, O., Post, R. M. & Theodore, W. H. (1992). Cerebral glucose metabolism and depression in patients with complex partial seizures. Arch. Neurol., 49, 617-623.


Broussolle, E., Cinotti, L., Landais, P., Le Bars, D., Galy, G., Lavenne, F., Khalfallah, Y., Chazot, G. & Mauguiere, F. (1993). Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease. Mov. Disord., 8, 459-462.


Brooks, D. J., Frey, K. A., Marek, K. L., Oakes, D., Paty, D., Prentice, R., Shults, C. W. & Stoessl, A. J. (2003). Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp. Neurol., 184, S68-S79.


Brooks, D. J. & Piccini, P. (2006). Imaging in Parkinson’s disease: The roles of Monoamines in Behavior. Biol. Psychiatr, 59, 908-918.


Bryant, C. A. & Jackson, S. H. (1998). Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs. Aging., 13, 211-222.


Cohen, V., Ribeiro, M. J., Nguyen, J. P., Gurruchaga, J. M., Villafane, G., Loc’h, C., Defer, G., Samson, Y., Peschanski, M., Hantraye, P., Cesaro, P. & Remy, P. (2003). Transplantation in Parkinson’s disease: PET changes correlate with the amount of grafted tissue. Mov. Disord, 18, 928-932.


Fuente-Fernandez, de la R., Kishore, A., Calne, D. B., Ruth, T. J. & Stoessl, A. J. (2000). Nigrostriatal dopamine system and motor lateralization. Behav. Brain. Res., 112, 63-68.


Dethy, S., Van Blercom, N., Damhaut, P., Wikler, D., Hildebrand, J. & Goldman, S. (1998). Asymmetry of basal ganglia glucose metabolismand dopa responsiveness in parkinsonism. Mov. Disord., 13, 275-280.


Drouot, X., Oshino, S., Jarraya, B., Besret, L., Kishima, H., Remy, P., Dauguet, J., Lefaucheur, J. P., Dolle, F., Conde, F., Bottlaender, M., Peschanski, M., Keravel, Y., Hantraye, P. & Palfi, S. (2004). Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron., 44, 769-778.


Ebadi, M. & Sharma, S. (2003). Peroxynitrite and mitochondrial dysfunction in the pathogensis of Parkinson’s disease. Antioxid. & Redox Signal., 5, 319-335.


Ebadi, M., Sharma, S., Wanpen, S. & Amornpan, A. (2004). Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J. Cell. Mol. Med., 8, 213-222.


Ebadi, M., Sharma, S., Ghafaurifar, P., Browb-Borg, H. & Refaey, H. El. (2005). Peroxynitrite in the pathogenesis of Parkinson’s disease and the Neurorptective role of Metallothioneins. Methods in Enzymol., 296, 276-298.


Ebadi, M. & Sharma, S. (2006a) Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson’s disease. J. Exp. Biol. & Med., 231, 1576-1583.


Ebadi, M. & Sharma, S. (2006b). Vitamin E and Coenzyme Q10 in Parkinson’s Disease. The Encyclopedia of Viamin E (eds. V. R. Preedy and R. R. Watson), CAB International. U.K.


Eidelberg, D., Moeller, J. R., Dhawan, V. J. J., Sidtis, J. Z.. Ginos, S. C.. Strother, J., Cedarbaum, P., Greene, S. & Fahn, D. A. (1990). Rottenberg, The metabolic anatomy of Parkinson’s disease: complementary [18F]FdG and [18F]fluorodopa positron emission tomographic studies. Mov. Disord. 5, 203-213.


Eidelberg, D., Dhawan, V., Moeller, J. R., Sidtis, J. J., Ginos, J. S., Strother, S. C., Cederbaum, J., Greene, P. & Fahn, S. (1991). Powers, JM. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J. Neurol. Neurosurg. Psychiatry., 54, 856-862.


Eidelberg, D., Takikawa, S., Wilhelmsen, K., Dhawan, V., Chaly, T., Robeson, W., Dahl, R., Margouleff, D., Greene, P. & Hunt, A. (1993). Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism. Ann. Neurol., 34, 185-191.


Eidelberg, D., Takikawa, S., Moeller, J. R., Dhawan, V., Redington, K., Chaly, T., Robeson, W., Dahl, J. R., Margouleff, D. & Fazzini, E. (1993). Striatal glucose hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann. Neurol., 33, 518-527.


Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D. & Przedborski, S. (1994a). The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab., 14, 783-801.


Eberling, J. L., Richardson, B. C., Reed, B. R., Wolfe, N. & Jagust, W. J. (1994b). Cortical glucose metabolismin Parkinson's disease without dementia. Neurobiol. Aging., 15, 329-335.


Eidelberg, D., Moeller, J. R., Ishikawa, T., Dhawan, V., Spetsieris, P., Chaly, T., Belakhlef, A., Mandel, F., Przedborski, S. & Fahn, S. (1995). Early differential diagnosis of Parkinson's disease with 18F-FdG and positron emission tomography. Neurology., 45, 1995-2004.


Eidelberg, D., Moeller, J. R., Ishikawa, T., Dhawan, V., Spetsieris, P., Chaly, T., Robeson, W., Dahl, J. R. & Margouleff, D. (1995). Assessment of disease severity in parkinsonism with fluorine-18-FdG and PET. J. Nucl. Med., 36, 378-383.


Eidelberg, D., Moeller, J. R., Ishikawa, T., Dhawan, V., Spetsieris, V., Silbersweig, P. D., Stern, E., Woods, R. P., Fazzini, E., Dogali, M. & Beric, A. (1996). Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson’s disease. Ann. Neurol., 39, 450-459.


Eidelberg, D., Moeller, J. R., Kazumata, K., Antonini, A., Sterio, D., Dhawan, V., Spetsieris, P., Alterman, R., Kelly, P. J., Dogali, M., Fazzini, E. & Beric, A. (1997). Metabolic correlates of pallidal neuronal activity in Parkinson’s disease. Brain., 120, 1315-1324.


Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M. F., Feigin, A. S. & Eidelberg, D. (2005). FDG-PET in the differential diagnosis of parkinsonian disorders. Neuroimage., 26, 912-921.


Feigin, A., Fukuda, M., Dhawan, V., Przedborski, S., Jackson-Lewis, V., Mentis, M. J., Moeller, J. R. & Eidelberg, D. (2001). Metabolic correlates of levodopa response in Parkinson’s disease. Neurology., 57, 2083-2088.
Fowler, J. S., Volkow, N. S., Wang, G. J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Wolf, A. P., Warner, D., Cilento, R. & Zezulkova, I. (1998). Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J. Addict. Dis., 17, 23-34.


Fukuda, M., Edwards, C. & Eidelberg, D. (2001). Functional brain networks in Parkinson's disease. Parkinsonism. Relat. Disord., 8, 91-94.


Fukuda, M., Mentis, M. J., Ma, Y., Dhawan, V., Antonini, A., Lang, A. E., Lozano, A. M., Hammerstad, J., Lyons, K., Koller, W. C., Moeller, J. R. & Eidelberg, D. (2001). Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain., 124, 1601-1609.


Ghaemi, M., Rudolf, J., Schmulling, S., Bamborschke, S. & Heiss, W. D. (2000). FDG- and DOPA-PET in postencephalitic parkinsonism. J. Neural. Transm., 107, 1289-1295.


Ghaemi, M., Hilker, R., Rudolf, J., Sobesky, J. & Heiss, W. D. (2002). Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J. Neurol. Neurosurg. Psychiatry., 73, 517-523.


Ghaemi, M., Raethjen, J., Hilker, R., Rudolf, J., Sobesky, J., Deuschl, G. & Heiss, W. D. (2002). Monosymptomatic resting tremor and Parkinson’s disease: a multi tracer positron emission tomographic study. Mov. Disord., 17, 782-788.


Goodman, M. M., Clinton, D. K., Keil, R., Shi, B., Martarello, L., Xing, D., Votaw, J., Ely, T. D., Lambert, P., Owens, M. J., Camp, V. M., Malveaux, E. & Hoffman, J. M. (2000). 18F-Labelled FECNT: A selective radioligand for PET imaging of brain dopamine transporters. Nuclear Med. & Biol., 27, 1-12.


Hanakawa, T., Fukuyama, H., Akiguchi, I., Kato, M., Kimura, J. & Shibasaki, H. (1996). A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study. Rinsho Shinkeigaku., 36, 655-660.


Henselmans, J. M., de Jong, B. M., Pruim, J., Staal, M. J., Rutgers, A. W. & Haaxma, R. (2000). Acute effects of thalamotomy and pallidotomy on regional cerebral glucose metabolism, evaluated by PET. Clin. Neurol. Neurosurg., 102, 84-90.


Herholz, K. (1995). FDG PET and differential diagnosis of dementia. Alzheimer. Dis. Assoc. Disord., 9, 6-16.


Hilker, R., Voges, J., Thiel, A., Ghaemi, M., Herholz, K., Sturm, V. & Heiss, W. D. (2002). Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson’s disease: measuring the on- and off-conditions with FDG-PET. J. Neural. Transm., 109, 1257-1264.


Hilker, R., Voges, J., Weisenbach, S., Kalbe, E., Burghaus, L., Ghaemi, M., Lehrke, R. A., Koulousakis, K., Sturm, H. V. & Heiss, W. D. (2004). Subthalamic nucleus stimulation restores glucose metabolismin associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease. J. Cereb. Blood. Flow. Metab., 24, 7-16.


Hirato, M., Ishihara, J., Horikoshi, S., Shibazaki, T. & Ohye, C. (1995). Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording. Acta. Neurochir. Suppl., 64, 5-8. 1995.


Holthoff-Detto, V. A., Kessler, J., Herholz, K., Bonner, H., Pietrzyk, U., Wurker, M., Ghaemi, M., Wienhard, K., Wagner, R. & Heiss, W. D. (1997). Functional effects of striatal dysfunction in Parkinson disease. Arch. Neurol., 54, 145-150.


Hu, M. T., Taylor-Robinson, S. D., Chaudhuri, K. R., Bell, J. D., Labbe, C., Cunningham, V. J., Koepp, M. J., Hammers, A., Morris, R. G., Turjanski, N. & Brooks, D. J. (2000). Cortical dysfunction in non-demented Parkinson’s disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain., 123, 340-352.


Hu, M. T., Chaudhuri, K. R., Jarosz, J., Yaguez, L. & Brooks, D. J. (2002). An imaging study of parkinsonism among African-Caribbean and Indian London communities. Mov. Disord., 17, 1321-1328.


Imamura, T., Ishii, K., Hirano, N., Hashimoto, M., Tanimukai, S., Kazui, H., Hanihara, T., Sasaki, M. & Mori, E. (2001). Occipital glucose metabolismin dementia with lewy bodies with and without Parkinsonism: a study using positron emission tomography. Dement. Geriatr.Cogn. Disord., 12, 194-197.


Ishikawa, T., Dhawan, V., Kazumata, K., Chaly, T., Mandel, F., Neumeyer, J., Margouleff, C., Babchyck, B., Zanzi, I. & Eidelberg, D. (1996). Comparative nigrostriatal dopaminergic imaging with Iodine-123-βCIT-FP/SPECT and Fluorine-18-FDOPA/PET. J. Nucl. Med., 37, 1760-1765.


Jankovic, J. & Kapadia, A. S. (2001). Functional decline in Parkinson disease. Arch. Neurol., 58, 1611-1615.


Juh, R., Kim, J., Moon, D., Choe, B. & Suh, T. (2004). Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur. J. Radiol., 51, 223-233.


Juh, R., Pae, C. U., Lee, C. U., Yang, D., Chung, Y., Suh, T. & Choe, B. (2005). > Voxel based comparison of glucose metabolismin the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci. Res., 52, 211-221.


Kaasinen, V., Maguire, R. P., Hundemer, H. P. & Leenders, K. L. (2005). Corticostriatal covariance patterns of 6-[(18)F]fluoro-L-dopa and [(18)F]FdG PET in Parkinson's disease. J. Neurol., 253, 340-348.


Karbe, H., Holthoff, V., Huber, M., Herholz, K., Wienhard, K., Wagner, R. & Heiss, W. D. (1992). Positron emission tomography in degenerative disorders of the dopaminergic system. J. Neural. Transm. Park. Dis. Dement. Sect., 4, 121-130.


Kassubek, J., Juengling, F. D., Hellwig, B., Knauff, M., Spreer, J. & Lucking, C. H. (2001). Hyperglucose metabolism in the ventrolateral thalamus in unilateral Parkinsonian resting tremor: a positron emission tomography study. Neurosci. Lett., 304, 17-20.


Kato, M. (1990). Positron emission tomography and basal ganglia functions. No. To. Shinkei., 42, 450-460.


Kazumata, K., Antonini, A., Dhawan, V., Moeller, J. R., Alterman, R. L., Kelly, P., Sterio, D., Fazzini, E., Beric, A. & Eidelberg, D. (1997). Preoperative indicators of clinical outcome following stereotaxic pallidotomy. Neurology., 49, 1083-1090.


Khan, N. L., Giunti, P., Sweeney, M. G., Scherfler, C., Brien, M. O., Piccini, P., Wood, N. W. & Lees, A. J. (2005). Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov. Disord., 20, 1115-1119.


Klein, R. C., de Jong, B. M. J. J. & de Vries., Leenders, K. L. (2005). Direct comparison between regional cerebral glucose metabolism in progressive supranuclear palsy and Parkinson’s disease. Mov. Disord., 20, 1021-1030.


Kuhl, D. E., Metter, E. J. & Riege, W. H. (1984). Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]FdG method. Ann. Neurol., 15, 419-424.


Kuhl, D. E., Metter, E. J., Riege, W. H. & Markham, C. H. (1984). Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann. Neurol., 15 Suppl, S119-125.


Kuhl, D. E., Markham, C. H., Metter, E. J., Riege, W. H., Phelps, M. E. & Mazziotta, J. C. (1985). Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res. Publ. Assoc. Res. Nerv. Ment. Dis., 63, 199-209.


Kuhl, D. E., Minoshima, S., Fessler, J. A., Frey, K. A., Foster, N. L., Ficaro, E. P., Wieland, D. M. & Koeppe, R. A. (1996). In vivo mapping of Cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol., 40, 399-410.


Kume, A., Shiratori, M., Takahashi, A., Kato, T., Ito, K., Tadokoro, M. & Sakuma, S. (1992). Hemi-parkinsonism in multiple system atrophy: a PET and MRI study. J. Neurol. Sci., 110, 37-45.


Lang, A. E. (1995). Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Mov. Disord., 10, 489-495.


Laureys, S., Salmon, E., Garraux, G., Peigneux, P., Lemaire, C., Degueldre, C. & Franck, G. (1999). Fluorodopa uptake and glucose metabolismin early stages of corticobasal degeneration. J. Neurol., 246, 1151-1158.


Leger, G., Gjedde, A., Kuwabara, H., Guttman, M. & Cumming, P. (1998). Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse., 30, 351-361.


Lozza, C., Marie, P. M. & Baron, J. C. (2002). The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson’s disease. Neuroimage., 17, 688-699.


Lozza, C., Baron, J. C., Eidelberg, D., Mentis, M. J., Carbon, M. & Marie, R. M. (2004). Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum. Brain. Mapp., 22, 236-245.


Momose, T. (2002). Measurement of brain function by positron emission tomography: from mapping to synaptic function. No. To. Shinkei., 54, 967-974.


Martin, W. R., Stoessl, A. J., Adam, M. J., Ammann, W., Bergstrom, M., Harrop, R., Laihinen, A., Rogers, J. R., Ruth, T. J. & Sayre, C. I. (1987). Positron emission tomography in Parkinson's disease: glucose and DOPA glucose metabolism. Adv. Neurol., 45, 95-98.


Mayberg, H. S., Starkstein, S. E., Peyser, C. E., Brandt, J., Dannals, R. F. & Folstein, S. E. (1992). Paralimbic frontal lobe glucose hypometabolism in depression associated with Huntington’s disease. Neurology., 42, 1791-1797.


Mentis, M. J., McIntosh, A. R., Perrine, K., Dhawan, V., Berlin, B., Feigin, A., Edwards, C., Mattis, P. & Eidelberg, D. (2002). Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am. J. Psychiatry, 159, 746-754.


Metter, E. J., Riege, W. H., Kameyama, M., Kuhl, D. E. & Phelps, M. E. (1984). Cerebral metabolic relationships for selected brain regions in Alzheimer’s, Huntington’s, and Parkinson’s diseases. J. Cereb. Blood. Flow. Metab., 4, 500-506.


Metter, E. J. & Hanson, W. R. (1986). Clinical and acoustical variability in hypokinetic dysarthria. J. Commun. Disord., 19, 347-366.


Metter, E. J., Kuhl, D. E. & Riege, W. H. (1990). Brain glucose metabolismin Parkinson’s disease. Adv. Neurol., 53, 135-139.


Mishina, M., Ishii, K., Mitani, K., Ohyama, M., Yamazaki, M., Ishiwata, K., Senda, M., Kobayashi, S., Kitamura, S. & Katayama, Y. (2002). Midbrain glucose hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta. Neurol. Scand., 110, 128-135.
Mochizuki, A. & Shimizu, T. (1997). Striatonigral degeneration. Nippon. Rinsho., 55, 123-126.


Moeller, J. R. & Strother, S. C. (1991). A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J. Cereb. Blood. Flow. Metab., 11, 21-35.


Moeller, J. R., Ishikawa, T., Dhawan, V., Spetsieris, P., Mandel, F., Alexander, G. E., Grady, C., Pietrini, P. & Eidelberg, D. (1996). The metabolic topography of normal aging. J. Cereb. Blood. Flow. Metab., 16, 385-398.


Moeller, J. R. & Eidelberg, D. (1997). Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain., 120, 2197-2206.


Moeller, J. R., Nakamura, T., Mentis, M. J., Dhawan, V., Spetsieres, P., Antonini, A., Missimer, J., Leenders, K. L. & Eidelberg, D. (1999). Reproducibility of regional metabolic covariance patterns: comparison of four populations. J. Nucl. Med., 40, 1264-1269.


Morrish, P. K., Sawle, G. V. & Brooks, D. J. (1996). Regional changes in [18F]dopa glucose metabolism in the striatum in Parkinson's disease. Brain., 119, 2097-2103.


Nakagawa, M., Kuwabara, Y., Taniwaki, T., Sasaki, M., Koga, H., Kaneko, K., Hayashi, K., Kira, J. & Honda, H. (2005). PET evaluation of the relationship between D2 receptor binding and glucose metabolismin patients with parkinsonism. Ann. Nucl. Med., 19, 267-275.


Nagano-Saito, A., Kato, T., Arahata, Y., Washimi, Y., Nakamura, A., Abe, Y., Yamada, T., Iwai, K., Hatano, K., Kawasumi, Y., Kachi, T., Dagher, A. & Ito, K. (2004). Cognitive- and motor-related regions in Parkinson's disease: F-DOPA and FDG PET studies. Neuroimage, 22, 553-561.


Nagano-Saito, A., Washimi, Y., Arahata, Y., Iwai, K., Kawatsu, S., Ito, K., Nakamura, A., Abe, Y., Yamada, T., Kato, T. & Kachi, T. (2004). Visual hallucination in Parkinson's disease with FDG PET. Mov. Disord., 19, 801-806.
Okada, J., Peppard, R. & Calne, D. B. (1989). Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia. Nippon. Igaku. Hoshasen. Gakkai. Zasshi., 49, 643-656.


Otsuka, M., Kuwabara, Y., Ichiya, Y., Hosokawa, S., Sasaki, M., Yoshida, T., Fukumura, T., Kato, M. & Masuda, K. (1997). Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-DOPA and 18F-FDG. Ann. Nucl. Med., 11, 251-257.


Otsuka, M. & Taniwaki, T. (1999). Functional imaging for disorders of basal ganglia]. Rinsho. Shinkeigaku., 39, 30-32.


Perani, D., Bressi, S., Testa, D., Grassi, F., Cortelli, P., Gentrini, S., Savoiardo, M., Caraceni, T. & Fazio, F. (1995). Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F-18 positron emission tomographic study. Arch. Neurol., 52, 179-185.


Picard, F., Hirsch, E., Salmon, E., Marescaux, C. & Collard, M. (1996). Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-DOPA. Rev. Neurol. (Paris)., 152, 267-271.


Piccini, P., Pavese, N. & Brooks, D. J. (2003). Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann. Neurol., 53, 647-653.


Piert, M., Koeppe, R. A., Giordani, B., Minoshima, S. & Kuhl, D. E. (1996). Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J. Nucl. Med., 37, 1115-122.


Przedborski, S., Goldman, S., Levivier, M., Giladi, N., Bidaut, L. M., Hildebrand, J., Stanus, E., Labar, D. & Luxen, A. (1993). Brain glucose metabolismand dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome. Mov. Disord., 8, 391-395.


Przedborski, S., Giladi, N., Takikawa, S., Ishikawa, T., Dhawan, V., Spetsieris, P., Chaly, T. S., Fahn, A. & Eidelberg, D. (1994). Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome. Neurology., 44, 1622-1628.


Przedborski, S., Goldman, S., Giladi, N., Dhawan, V., Takikawa, S., Hildebrand, J., Fahn, S. & Eidelberg, D. (1993). Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. Adv. Neurol., 60, 501-505.


Racette, B. A., Antenor, J. A., McGee-Minnich, L., Moerlein, S. M., Videen, T. O., Kotagal, V. & Perlmutter, J. S. (2005). [18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov. Disord, 20, 492-496.


Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., Gwinn-Hardy, K., McFarland, H., Innis, R., Katz, R. G., Kieburtz, K., Kish, S. J., Lange, N., Langston, J. W., Marek, K., Morin, L., Moy, C., Murphy, D., Oertel, W. H., Oliver, G., Palesch, Y., Powers, W., Seibyl, J., Sethi, K. D., Shults, C. W., Sheehy, P., Stoessl, A. J. & Holloway, R. (2005). The role of radiotracer imaging in Parkinson disease. Neurology, 64, 208-215.


Remy, P. (2006). Is functional imaging useful in the clinical evaluation of Parkinson’s disease?]. Rev. Neurol. (Paris)., 159, 357-361.


Rinne, J. O., Ruottinen, H., Bergman, J., Haaparanta, M., Sonninen, P. & Solin, O. (1999). Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry., 67, 737-741.


Rougemont, D., Baron, J. C., Collard, P., Bustany, P., Comar, D. & Agid, Y. (1984). Local cerebral glucose utilization in treated and untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry., 47, 824-830.


Sasaki, M., Ichiya, Y., Hosokawa, S., Otsuka, M., Kuwabara, Y., Fukumura, T., Kato, K. M., Goto, I. & Masuda, K. (1992). Regional cerebral glucose metabolismin patients with Parkinson’s disease with or without dementia. Ann. Nucl. Med., 6, 241-246.


Sharma, S. & Ebadi, M. (2003). Metallothionein attenuates 3-morpholinosydnonimine (SIN-1) induced oxidative stress in dopaminergic neurons. Antioxid. & Redox Signal., 5, 251-264.


Sharma, S., Kheradpezhou, M., Shavali, S., Refaey, H. El., Eken, J., Hagen, C. & Ebadi, M. (2004a). Neuroprotective Actions of Coenzyme Q10 in Parkinson’s Disease. Methods in Enzymol., 382, 488-509.


Sharma, S. & Ebadi, M. (2004b). An Improved Method For Analyzing Coenzyme Q Homologues and Multiple Detection of Rare Biological Samples. J. Neurosci. Methods., 137, 1-8.


Sharma, S. & Ebadi, M. (2005). Distribution Kinetics of 18F-DOPA in Weaver Mutant Mice. Mol. Brain Res., 139, 23-30.


Sharma, S., Refaey, E. Il. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse models of Parkinson’s disease and the Neurorptective role of Coenzyme Q10. Brain Res. Bull., 70, 22-32.


Shibasaki, T. (1997). Glucose metabolismand blood flow studies in 2 cases with juvenile Parkinson’s disease. Nippon. Rinsho., 55, 95-100.


Snow, B. J. (1992). Positron emission tomography in Parkinson’s disease. Can. J. Neurol. Sci., 19(1 Suppl), 138-141

.
Spetsieris, P. G., Moeller, J. R., Dhawan, V., Ishikawa, T. & Eidelberg, D. (1995). Visualizing the evolution of abnormal metabolic networks in the brain using PET. Comput. Med. Imaging. Graph., 19, 295-306.


Su, P. C., Ma, Y., Fukuda, M., Mentis, M. J., Tseng, H. M., Yen, R. F., Liu, H. M., Moeller, J. R. & Eidelberg, D. (2001). Metabolic changes following subthalamotomy for advanced Parkinson’s disease. Ann. Neurol., 50, 514-520.


Tatlidil, R., New, P. & Mayberg, H. (2000). FDG positron emission tomography in diffuse Lewy body disease: a case report. Clin. Nucl. Med., 25, 1004-1006.


Trost, M., Su, P. C., Barnes, A., Su, S. L., Yen, R. F., Tseng, H. M., Ma, Y. & Eidelberg, D. (2003). Evolving metabolic changes during the first postoperative year after subthalamotomy. J. Neurosurg., 99, 872-878.


Turjanski, N. & Brooks, D. J. (1997). PET and the investigation of dementia in the parkinsonian patient. J. Neural. Transm. Suppl., 51, 37-48.


Vander Borght, T., Laloux, P., Maes, A., Salmon, E., Goethals, I. & Goldman, S. (2001). Guidelines for brain radionuclide imaging. Perfusion single photon computed tomography (SPECT) using Tc-99m RPs and brain glucose metabolism positron emission tomography (PET) using F-18 FdG. The Belgian Society for Nuclear Medicine. Acta. Neurol. Belg., 101, 196-209.


Vander, T., Borght, S., Minoshima, S., Giordani, B., Foster, N. L., Frey, K. A., Berent, S., Albin, R. L., Koeppe, R. A. & Kuhl, D. E. (1997). Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J. Nucl. Med., 38, 797-802.


Weder, B. J., Leenders, K. L., Vontobel, P., Nienhusmeier, M., Keel, A., Zaunbauer, W., Vonesch, T. & Ludin, H. P. (1999). Impaired somatosensory discrimination of shape in Parkinson’s disease: association with caudate nucleus dopaminergic function. Hum. Brain. Mapp., 8, 1-12.


Wu, R. M., Shan, D. E., Sun, C. M., Liu, R. S., Hwu, W. L., Tai, C. H., Hussey, J., West, A., Gwinn-Hardy, K., Hardy, J., Chen, J., Farrer, M. & Lincoln, S. (2002). Clinical, 18F-DOPA- PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. Mov. Disord, 1, 670-675.


Wu, J. C., Iacono, R., Ayman, M., Salmon, E., Lin, S. D., Carlson, D., Keator, D., Lee, A., Najafi, A. & Fallon, J. (2000). Correlation of intellectual impairment in Parkinson's disease with FDG PET scan. Neuroreport., 11, 2139-2144.


Zhao, Y. B., Sun, B. M., Li, D. Y. & Wang, Q. S. (2004). Effects of bilateral subthalamic nucleus stimulation on resting-state cerebral glucose metabolismin advanced Parkinson's disease. Chin. Med. J. (Engl)., 117, 1304-1308.

Chapter 16

Bourgeois, A. C., Warren, L. A., Chang, T. T., Embry, S., Hudson, K. & Bradley, Y. C. (2013). Role of positron emission tomography/computed tomography in breast cancer. Radiol Clin North Am., 51(5), 781-798.
Bravatà, V., Stefano, A., Cammarata, F. P., Minafra, L., Russo, G., Nicolosi, S., Pulizzi, S., Gelfi, C., Gilardi, M. C. & Messa, C. (2013). Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research. J Exp Clin Cancer Res., 32, 23.
Breeman, W. A., de Blois, E., Sze Chan, H., Konijnenberg, M., Kwekkeboom, D. J. & Krenning, E. P. (2011). (68)Ga-labeled DOTA-peptides and (68)Ga-labeled RPs for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med., 41(4), 314-3121.
Chiesa, C., Castellani, R., Mira, M., Lorenzoni, A. & Flux, G. D. (2013). Dosimetry in 131I-mIBG therapy: moving toward personalized medicine. Q J Nucl Med Mol Imaging., 57(2), 161-170.
Choyke, P., Kurdziel, K. A., Mena, E. & Lindenberg, M. L. (2013). Meeting the challenges of PET-based molecular imaging in cancer. Expert Rev Mol Diagn., 13(7), 671-680.
Clark, A. S., McDonald, E., Lynch, M. C. & Mankoff, D. (2014). Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer. Oncology (Williston Park)., 28(5), 424-430.
Cole, E. L., Stewart, M. N., Littich, R., Hoareau, R., Scott, P. J. (2014). Radiosyntheses using fluorine-18: the art and science of late stage fluorination. Curr Top Med Chem., 14(7), 875-900.
Fani, M., André, J. P. & Maecke, H. R. (2008). 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET- RPs. Contrast Media Mol Imaging., 3(2), 67-77.
Fischer, G., Seibold, U., Schirrmacher, R., Wängler, B. & Wängler, C. (2013). (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules., 18(6), 6469-6490.
Garcia, C., Gebhart, G. & Flamen, P. (2012). New PET imaging agents in the management of solid cancers. Curr Opin Oncol., 24(6), 748-755.
Geets, X., Sterpin, E., Wanet, M., Di Perri, D. & Lee, J. (2014). Metabolic imaging in non-small-cell lung cancer radiotherapy. Cancer Radiother., 18(5-6), 402-405.
Gillings, N. (2013). Radiotracers for positron emission tomography imaging. MAGMA., 26(1), 149-158.
Halmos, G. B., Bruine de Bruin, L., Langendijk, J. A., van der Laan, B. F., Pruim, J. & Steenbakkers, R. J. (2014). Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Clin Nucl Med., 39(1), 44-48.
Hendrikse, N. H., Luurtsema, G., van der Veldt, A. A. & Lubberink, M. (2008). Positron emission tomography for modeling pathophysiological processes in vivo. Curr Opin Drug Discov Devel., 11(5), 717-725.
Hight, M. R., Cheung, Y. Y., Nickels, M. L., Dawson, E. S., Zhao, P., Saleh, S., Buck, J. R., Tang, D., Washington, M. K., Coffey, R. J. & Manning, H. C. (2014). A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res., 20(8), 2126-2135.
Hsiao, Y. M., Mathias, C. J., Wey, S. P., Fanwick, P. E. & Green, M. A. (2009). Synthesis and biodistribution of lipophilic and monocationic gallium RPs derived from N, N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga. Nucl Med Biol., 36(1), 39-45.
Jadvar, H. (2013). Molecular imaging of prostate cancer with PET. J Nucl Med., 54(10), 1685-1788.
Khan, M. U., Khan, S., El-Refaie, S., Win, Z., Rubello, D. & Al-Nahhas, A. (2009). Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol., 35(6), 561-567.
Kist, J. W., de Keizer, B., Stokkel, M. P., Hoekstra, O. S., Vogel, W. V. & THYROPET study group. (2014). Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. BMC Cancer., 14, 405.
Långström, B., Karimi, F. & Watanabe, Y. (2013). Endogenous compounds labeled with radionuclides of short half-life-some perspectives. J. Labelled Comp. Radiopharm., 56(3-4), 251-262.
Marzola, M. C. & Rubello, D. (2015). Molecular Imaging in Hereditary Succinate Dehydrogenase Mutation-Related Paragangliomas. Clin Nucl Med., 40(6), e313-318.
Moteki, H., Suzuki, M., Naito, Y., Fujiwara, K., Oguchi, K., Nishio, S. Y., Iwasaki, S. & Usami, S. (2014). Evaluation of cortical processing of language by use of positron emission tomography in hearing loss children with congenital cytomegalovirus infection. Int J Pediatr Otorhinolaryngol., 78(2), 285-289.
Nakhoda, Z., Torigian, D. A., Saboury, B., Hofheinz, F. & Alavi, A. (2013). Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies. Hell J Nucl Med., 16(1), 19-24.
Miller, N. R. & Pozo, M. A. (2011). Non-FDG PET in oncology. Clin. Transl. Oncol., Nov, 13(11), 780-786.
Prata, M. I. (2012). Gallium-68: a new trend in PET radiopharmacy. Curr Radiopharm., 5(2), 142-149.
Rice, S. L., Roney, C. A., Daumar, P. & Lewis, J. S. (2011). The next generation of positron emission tomography RPs in oncology. Semin Nucl Med., 41(4), 265-282.
Riss, P. J., Burchardt, C. & Roesch, F. (2011). A methodical 68Ga-labelling study of DO2A-(butyl-L-Tyrosine)2 with cation-exchanger post-processed 68Ga: practical aspects of radiolabelling. Contrast Media Mol Imaging., 6(6), 492-498.
Roesch, F. & Riss, P. J. (2010). The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr Top Med Chem., 10(16), 1633-1668.
Rösch, F. (2013). Past, present and future of 68Ge/68Ga generators. Appl Radiat Isot., Jun, 76, 24-30.
Sánchez-Jurado, R., Devis, M., Sanz, R., Aguilar, J. E., del Puig Cózar, M. & Ferrer-Rebolleda, J. (2014). Whole-body PET/CT studies with lowered 18F-FDG doses: the influence of body mass index in dose reduction. J Nucl Med Technol., 42(1), 62-67.
Shokeen, M. & Anderson, C. J. (2009). Molecular imaging of cancer with copper-64 RPs and positron emission tomography (PET). Acc Chem Res., 42(7), 832-841.
Velikyan, I. (2011). Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem., 7(5), 345-379.
Velikyan, I. (2013). Prospective of 68Ga-radiopharmaceutical development. Theranostics., 4(1), 47-80.
Velikyan, I. (2013). The diversity of 68Ga-based imaging agents. Recent Results Cancer Res., 194, 101-131.
Wadsak, W. & Mitterhauser, M. (2010). Basics and principles of RPs for PET/CT. Eur J Radiol., 73(3), 461-469.
Wang, L., Tang, K., Zhang, Q., Li, H., Wen, Z., Zhang, H. & Zhang, H. (2013). Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. Biomed Res Int., 2013, 102819.
Win, Z., Al-Nahhas, A., Rubello, D. & Gross, M. D. (2007). Somatostatin receptor PET imaging with Gallium-68 labeled peptides. Q J Nucl Med Mol Imaging., 51(3), 244-250.
Wu, P., Zhang, Y., Sun, Y., Shi, X., Li, F. & Zhu, Z. (2013). Clinical applications of 18F-FDG PET/CT in monitoring anti-cancer therapies. Curr Pharm Biotechnol., 14(7), 658-68.

Chapter 17

Alibaz-Oner, F. & Direskeneli, H., (2015). Update on Takayasu’s arteritis. Presse Med., 44(6 Pt 2), e259-65.
Amariglio, R. E., Mormino, E. C., Pietras, A. C., Marshall, G. A., Vannini, P., Johnson, K. A., Sperling, R. A. & Rentz, D. M. (2015). Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology., 85(1), 56-62.
Apostolova, L. G., Hwang, K. S., Avila, D., Elashoff, D., Kohannim, O., Teng, E., Sokolow, S., Jack, C. R., Jagust, W. J., Shaw, L.,Trojanowski, J. Q., Weiner, M. W. & Thompson, P. M., ADNI. (2015). Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology., 84(7), 729-737.
Appel, L., Jonasson, M., Danfors, T., Nyholm, D., Askmark, H., Lubberink, M. & Sörensen, J. (2015). Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med., 56(2), 234-242.
Arbizu, J., García-Ribas, G., Carrió, I., Garrastachu, P., Martínez-Lage, P. & Molinuevo, J. L. (2015). Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Rev Esp Med Nucl Imagen Mol., 34(5), 303-313.
Ariza, M., Kolb, H.C., Moechars, D., Rombouts, F. & Andrés, J. I. (2015). Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. J Med Chem., 58(11), 4365-4382.
Arraes, A. E., de Souza, A. W., Mariz, H. A., Silva, N. P., Torres, I. C., Pinto, P. N., Lima, E. N. & Sato, E. I. (2015). [18F-FdG positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu’s arteritis]. Rev Bras Reumatol., Jul 30. pii: S0482-5004(15)00093-5.
Asadi-Pooya, A. A. (2015). Neurobiological origin of psychogenic nonepileptic seizures: A review of imaging studies. Epilepsy Behav., 52(Pt A), 256-259.
Auning, E., Selnes, P., Grambaite, R., Šaltytė Benth, J., Haram, A., Løvli Stav, A., Bjørnerud, A., Hessen, E., Hol, P. K., Muftuler, L. A., Fladby, T. & Aarsland, D. (2015). Neurobiological correlates of depressive symptoms in people with subjective and MCI. Acta Psychiatr Scand., 131(2), 139-147.
Aydin, S. Z., Merkel, P. A. & Direskeneli, H. (2015). Outcome measures for Takayasu’s arteritis. Curr Opin Rheumatol., 27(1), 32-37.
Baldarçara, L., Currie, S., Hadjivassiliou, M., Hoggard, N., Jack, A., Jackowski, A. P., Mascalchi, M., Parazzini, C., Reetz, K., Righini, A., Schulz, J. B., Vella, A., Webb, S. J. & Habas, C. (2015). Consensus paper: radiological biomarkers of cerebellar diseases. Cerebellum., 14(2), 175-196.
Banzo, S. I. R., Quircea, R., Martínez-Rodríguez, I., Jiménez-Bonilla, J., Portilla-Quattrociocchi, H., Medina-Quiroz, P., Ortegaa, F., Rodríguez, E., Mateo, I., Vázquez-Higuera, J. L., de Arcochaa, M. & Carril, J. M. (2011). Molecular Neuroimaging in the Study of Cognitive Impairment: Contribution of the Cerebral Blood Flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT. Rev. Esp. Med. Nucl., 30, 301–306.
Baril, P., Martin-Duque, P. & Vassaux, G. (2010). Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. British Journal of Pharmacology, 159(4), 761–771.
Baschnagel, A. M., Wobb, J. L., Dilworth, J. T., Williams, L., Eskandari, M., Wu, D., Pruetz, B. L. & Wilson, G. D. (2015). The association of 18F-FDG PET and glucose metabolismbiomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiother Oncol., Aug 29.
Bazzola, L., Foroni, C., Andreis, D., Zanoni, V. R., Cappelletti, M., Allevi, G., Aguggini, S., Strina, C., Milani, M., Venturini, S., Ferrozzi, F., Giardini, R., Bertoni, R., Turley, H., Gatter, K., Petronini, P. G., Fox, S. B., Harris, A. L., Martinotti, M., Berruti, A., Bottini, A., Reynolds, A. R. & Generali, D. (2015). Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br J Cancer., 112(1), 52-60.
Bei, L., Shui, Y. B., Bai, F., Nelson, S. K., Van Stavern, G. P. & Beebe, D. C. (2015). A test of lens opacity as an indicator of preclinical Alzheimer Disease. Exp Eye Res., 140, 117.
Berti, V., Murray, J., Davies, M., Spector, N., Tsui, W. H., Li, Y., Williams, S., Pirraglia, E., Vallabhajosula, S., McHugh, P., Pupi, A., de Leon, M. J. & Mosconi, L. (2015). Nutrient patterns and brain biomarkers of AD in cognitively normal individuals. J. Nutr. Health Aging., 19(4), 413-423.
Besson, F. L., La Joie, R., Doeuvre, L., Gaubert, M., Mézenge, F., Egret, S., Landeau, B., Barré, L., Abbas, A., Ibazizene, M., de La Sayette, V., Desgranges, B., Eustache, F. & Chételat, G. (2015). Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical AD. J Neurosci., 35(29), 10402-10411.
Biermann, M., Kråkenes, J., Brauckhoff, K., Haugland, H. K., Heinecke, A., Akslen, L. A., Varhaug, J. E. & Brauckhoff, M. (2015). Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity. Acta Radiol., 56(11), 1350-1356.
Bilgel, M., Jedynak, B., Wong, D. F., Resnick, S. M. & Prince, J. L. (2015). Temporal Trajectory and Progression Score Estimation from Voxelwise Longitudinal Imaging Measures: Application to Amyloid Imaging. Inf Process. Med. Imaging., 24, 424-436.
Blanchet, E. M., Taieb, D., Millo, C., Martucci, V., Chen, C. C., Merino, M., Herscovitch, P. & Pacak, K. (2015). 18F-FLT PET/CT in the evaluation of pheochromocytomas and paragangliomas: A pilot study. J Nucl Med., 56(12), 1849-1854.
Blanchet, E., Taieb, D., Millo, C., Martucci, V., Chen, C.C., Merino, M., Herscovitch, P., Pacak, K., Blennow, K., Mattsson, N., Schöll, M., Hansson, O. & Zetterberg, H. (2015). Amyloid biomarkers in AD. Trends Pharmacol Sci., 36(5), 297-309.
Blum, K., Liu, Y., Wang, W., Wang, Y., Zhang, Y., Oscar-Berman, M., Smolen, A., Febo, M., Han, D., Simpatico, T., Cronjé, F. J., Demetrovics, Z. & Gold, M. S. (2015). rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgrad Med., 127(2), 232-241.
Bocchetta, M., Galluzzi, S., Kehoe, P. G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J. F., de Mendonça, A., Didic, M., Eriksdotter, M., Félician, O., Frölich, L., Gertz, H. J., Hallikainen, M., Hasselbalch, S. G., Hausner, L., Heuser, I., Jessen, F., Jones, R. W., Kurz, A., Lawlor, B., Lleo, A., Martinez-Lage, P., Mecocci, P., Mehrabian, S., Monsch, A., Nobili, F., Nordberg, A., Rikkert, M. O., Orgogozo, J. M., Pasquier, F., Peters, O., Salmon, E., Sánchez-Castellano, C., Santana, I., Sarazin, M., Traykov, L., Tsolaki, M., Visser, P. J., Wallin, Å. K.,Wilcock, G., Wilkinson, D., Wolf, H., Yener, G., Zekry, D. & Frisoni, G. B. (2015). The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement., 11(2), 195-206.
Bocheva, Y., Bochev, P. & Ivanov, S. (2015). [Ca-125] in diagnosis and monitoring of patients with ovarian cancer]. Akush Ginekol (Sofiia)., 54(1), 11-17.
Boellaard, R., Delgado-Bolton, R., Oyen, W. J., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., Stroobants, S., Delbeke, D., Donohoe, K. J., Holbrook, S., Graham, M. M., Testanera, G., Hoekstra, O. S., Zijlstra, J., Visser, E., Hoekstra, C. J., Pruim, J., Willemsen, A., Arends, B., Kotzerke, J., Bockisch, A., Beyer, T., Chiti, A. & Krause, B. J. (2015). FDG PET/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging., 42(2), 328-354.
Boers-Sonderen, M. J., Desar, I. M., Fütterer, J. J., Mulder, S. F., Geus-Oei, L. F., Mulders, P. F., VAN DER Graaf, W. T., Oyen, W. J. & VAN Herpen, C. M. (2015). Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Res., 35(10), 5601-5606.
Bourgeat, P., Villemagne, V. L., Dore, V., Brown, B., Macaulay, S. L., Martins, R., Masters, C. L., Ames, D., Ellis, K., Rowe, C. C., Salvado, O., Fripp, J. & AIBL Research Group. (2015). Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging., 36 Suppl 1, S159-166.
Boutin, H., Murray, K., Pradillo, J., Maroy, R., Smigova, A., Gerhard, A., Jones, P. A. & Trigg, W. (2015). 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging., 42(3), 503-511.
Boychak, O., Vos, L., Makis, W., Buteau, F.A., Pervez, N., Parliament, M., McEwan, A. J. & Usmani, N. (2015). Role for (11)C-Choline PET in active surveillance of prostate cancer. Can Urol Assoc J., 9(3-4), E98-E103.
Bradshaw, T. J., Bowen, S. R., Deveau, M. A., Kubicek, L., White, P., Bentzen, S. M., Chappell, R. J., Forrest, L. J. & Jeraj, R. (2015). Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines. Int J Radiat Oncol Biol Phys., 91(4), 787-795.
Burnham, S. C., Raghavan, N., Wilson, W., Baker, D., Ropacki, M. T., Novak, G., Ames, D., Ellis, K., Martins, R. N., Maruff, P., Masters, C. L., Romano, G., Rowe, C. C., Savage, G., Macaulay, S. L. & Narayan, V. A. (2015). Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal AD Trials: An AIBL Study. J Alzheimers Dis., 46(4), 1079-1089.
Burroni, L., Borsari, G., Pichierri, P., Polito, E., Toscano, O., Grassetto, G., Al-Nahhas, A., Rubello, D. & Vattimo, A. G. (2012). Preoperative diagnosis of orbital cavernous hemangioma: a 99mTc-RBC SPECT study. Clin Nucl Med., 37(11), 1041-1046.
Campbell, M. C., Koller, J. M., Snyder, A. Z., Buddhala, C., Kotzbauer, P. T. & Perlmutter, J. S. (2015). CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology., 84(24), 2413-2421.
Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C.,Wall, A. E., Carter, S. F., Schöll, M., Choo, I. H., Grimmer, T., Redolfi, A., Nordberg, A., Scheltens, P., Drzezga, A. & Frisoni, G. B. ADNI. (2015). MCI with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology., 84(5), 508-515.
Caroppo, P., Habert, M. O., Durrleman, S., Funkiewiez, A., Perlbarg, V., Hahn, V., Bertin, H., Gaubert, M., Routier, A., Hannequin, D., Deramecourt, V., Pasquier, F., Rivaud-Pechoux, S., Vercelletto, M., Edouart, G., Valabregue, R., Lejeune, P., Didic, M., Corvol, J. C., Benali, H., Lehericy, S., Dubois, B., Colliot, O., Brice, A. & Le Ber, I. (2015). Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease? J Alzheimers Dis., 47(3), 751-759.
Catalano, O. A., Gee, M. S., Nicolai, E., Selvaggi, F., Pellino, G., Cuocolo, A., Luongo, A., Catalano, M., Rosen, B. R., Gervais, D., Vangel, M. G., Soricelli, A. & Salvatore, M. (2015). Evaluation of Quantitative PET/MR Enterography Biomarkers for Discrimination of Inflammatory Strictures from Fibrotic Strictures in Crohn Disease. Radiology., 5, 150566.
Chalkidou, A., O’Doherty, M. J. & Marsden, P. K. (2015). False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review. PLoS One., 4, 10(5):e0124165.
Chan, L. T., Lynch, W., De May, M., Horton, J. C., Miller, B. L. & Rabinovici, G. D. (2015). Prodromal posterior cortical atrophy: clinical, neuropsychological, and radiological correlation. Neurocase., 21(1), 44-55.
Chang, J. H., Joon L. D., Davis, I. D., Lee, S. T., Hiew, C. Y., Esler, S., Gong, S. J., Wada, M., Clouston, D., O’Sullivan, R., Goh, Y. P., Bolton, D., Scott, A. M. & Khoo, V. (2015). Comparison of [(11)C]Choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions. Int J Radiat Oncol Biol Phys., 92(2), 438-445.
Chen, K., Roontiva, A., Thiyyagura, P., Lee, W., Liu, X., Ayutyanont, N., Protas, H., Luo, J. L., Bauer, R., Reschke, C., Bandy, D., Koeppe, R. A., Fleisher, A. S., Caselli, R. J., Landau, S., Jagust, W., Weiner, M. W. & Reiman, E. M. ADNI. (2015). Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med., 56(4), 560-566.
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L. & Hill, A. F. (2015). Prognostic serum miRNA biomarkers associated with AD shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry., 20(10), 1188-1196.
Chiba, Y., Fujishiro, H., Ota, K., Kasanuki, K., Arai, H., Hirayasu, Y., Sato, K. & Iseki, E. (2015). Clinical profiles of dementia with Lewy bodies with and without Alzheimer’s disease-like hypometabolism. Int J Geriatr Psychiatry., 30(3), 316-323.
Christensen, T. E., Ahtarovski, K. A., Bang, L. E., Holmvang, L., Søholm, H., Ghotbi, A. A., Andersson, H., Vejlstrup, N., Ihlemann, N., Engstrøm, T., Kjær, A. & Hasbak, P. (2015). Basal hyperaemia is the primary abnormality of perfusion in Takotsubo cardiomyopathy: a quantitative cardiac perfusion positron emission tomography study. Eur Heart J Cardiovasc Imaging., 16(10), 1162-1169.
Chui, H. C. & Ramirez-Gomez, L. (2015). Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther., 7(1), 21.
Cimitan, M., Evangelista, L., Hodolič, M., Mariani, G., Baseric, T., Bodanza, V., Saladini, G., Volterrani, D., Cervino, A. R., Gregianin, M., Puccini, G., Guidoccio, F., Fettich, J. & Borsatti, E. (2015). Gleason score at diagnosis predicts the rate of detection of 18F-Choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med., 56(2), 209-215.
Connolly, R. M., Leal, J. P., Goetz, M. P., Zhang, Z., Zhou, X. C., Jacobs, L. K., Mhlanga, J. H., Carpenter, J., Storniolo, A. M., Watkins, S., Fetting, J. H., Miller, R. S., Sideras, K., Jeter, S. C., Walsh, B., Powers, P., Zorzi, J., Boughey, J. C., Davidson, N. E., Carey, L. A., Wolff, A. C., Khouri, N., Gabrielson, E., Wahl, R. L. & Stearns, V. (2015). TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med., 56(1), 31-37.
Cortadellas, T., Córdoba, O., Gascón, A., Haladjian, C., Bernabeu, A., Alcalde, A., Esgueva, A., Rodriguez-Revuelto, R., Espinosa-Bravo, M., Díaz-Botero, S., Xercavins, J., Rubio, I. T. & Gil-Moreno, A. (2015). Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. Eur J Surg Oncol., 41(5), 635-640.
Coutinho, A. M., Porto, F. H., Duran, F. L., Prando, S., Ono, C. R., Feitosa, E. A., Spíndola, L., de Oliveira, M. O., do Vale, P. H., Gomes, H. R,, Nitrini, R, Brucki, S. M. & Buchpiguel, C. A. (2015). Brain glucose metabolism and cerebrospinal fluid biomarkers profile of non-amnestic MCI in comparison to amnestic MCI and normal older subjects. Alzheimers Res Ther., 7(1), 58.
Dani, M., Edison, P. & Brooks, D. J. (2016). Imaging biomarkers in tauopathies. Parkinsonism Relat Disord., 22 Suppl 1, S26-28.
Del Gobbo, A., Pellegrinelli, A., Gaudioso, G., Castellani, M., Zito Marino, F., Franco, R., Palleschi, A., Nosotti, M., Bosari, S., Vaira, V. & Ferrero, S. (2015). Analysis of NSCLC tumor heterogeneity, proliferative and 18F-FDG PET indexes reveals Ki67 prognostic role in adenocarcinomas. Histopathology., Aug 14.
Dhawan, V., Robeson, W., Bjelke, D., Chaly, T., Graf, K., Hellman, M., Zhuo, L., Mackay, M. & Eidelberg, D. (2015). Human Radiation Dosimetry for the N-Methyl-D-Aspartate Receptor Radioligand 11C-CNS5161. J Nucl Med., 56(6), 869-872.
Di Gioia, D., Stieber, P., Schmidt, G. P., Nagel, D., Heinemann, V. & Baur-Melnyk, A. (2015). Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumor marker increase. Br J Cancer., 112(5), 809-818.
Differding, S., Hanin, F. X. & Grégoire, V. (2015). PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging., 42(4), 613-622.
DiFrancesco, J. C., Touat, M., Caulo, M., Gallucci, M., Garcin, B., Levy, R., Uncini, A. & Piazza, F. (2015). Recurrence of Cerebral Amyloid Angiopathy-Related Inflammation: A Report of Two Cases from the iCAβ International Network. J Alzheimers Dis., 46(4), 1071-1077.
Dong, A., Zhang, H., Wang, Y., Gong, J., Zuo, C., Yang, J. & Lu, J. (2015). Malignant nonepithelial prostate tumors: FDG PET/CT findings with MRI and CT correlation. Clin Nucl Med., 40(1), 14-20.
Dowling, N. M., Johnson, S. C., Gleason, C. E. & Jagust, W. J. ADNI. (2015). The mediational effects of FDG glucose hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage., 105, 357-368.
Dubroff, J. G. & Nasrallah, I. M., (2015). Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia? Acad Radiol., 22(8), 988-994.
Duff, K., Horn, K. P., Foster, N. L. & Hoffman, J. M. (2015). Short-Term Practice Effects and Brain Glucose hypometabolism: Preliminary Data from an FDG PET Study. Arch Clin Neuropsychol., 30(3), 264-270.
Ehlgen, A., Bylock, A., Kreuzer, J., Koslowski, M., Gantner, F. & Niessen, H. G. (2015). Clinical imaging in anti-atherosclerosis drug development. Drug Discov Today., 20(11), 1317-1327.
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F. P., Kübler, H., Haberhorn, U., Eisenhut, M., Wester, H. J., Gschwend, J. E. & Schwaiger, M. (2015). Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med., 56(5), 668-674.
Eichendorff, S., Svendsen, P., Bender, D., Keiding, S., Christensen, E.I., Deleuran, B. & Moestrup, S. K. (2015). Biodistribution and PET imaging of a novel [68Ga]-anti-CD163-antibody conjugate in rats with collagen-induced arthritis and in controls. Mol Imaging Biol., 17(1), 87-93.
Elboga, U., Karaoglan, H., Sahin, E., Kalender, E., Demir, H. D., Basıbuyuk, M., Celen, Z. Y., Yilmaz, M. & Ozkaya M. (2015). F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience. Eur Rev Med Pharmacol Sci., 19(3), 396-401.
English, S. J., Piert, M. R., Diaz, J. A., Gordon, D., Ghosh, A., DʼAlecy, L. G., Whitesall, S. E, Sharma, A. K., DeRoo, E. P., Watt, T., Su, G., Henke, P. K., Eliason, J. L., Ailawadi, G. & Upchurch, G. R. Jr. (2015). Increased 18F-FDG uptake is predictive of rupture in a novel rat abdominal aortic aneurysm rupture model. Ann Surg., 261(2), 395-404.
Eschbach, R. S., Fendler, W. P., Kazmierczak, P. M., Hacker, M., Rominger, A., Carlsen, J., Hirner-Eppeneder, H., Schuster, J., Moser, M., Havla, L., Schneider, M. J., Ingrisch, M., Spaeth, L., Reiser, M. F., Nikolaou, K. & Cyran, C. C. (2015). Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring Rgorafenil therapy in experimental colon carcinomas with immunohistochemical validation. PLoS One., 10(2), e0115543.
Evangelista, L., Bertagna, F., Bertoli, M., Stela, T., Saladini, G. & Giubbini, R. (2015). Diagnostic And Prognostic Value Of 18FdG PET/CT in Male Breast Cancer: Results From A Bicentric Population. Curr Radiopharm., 2015 May 28.
Even, A. J., van der Stoep, J., Zegers, C. M., Reymen, B., Troost, E. G., Lambin, P., van Elmpt, W., Even, A. J. G., Stoep, J. V. D., Zegers, C. M. L, Reymen, B., Troost, E. G. C., Lambin, P. & Elmpt, W. V. (2015). PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiother Oncol., 116(2), 281-286.
Farid, K., Carter, S. F., Rodriguez-Vieitez, E., Almkvist, O., Andersen, P., Wall, A., Blennow, K., Portelius, E., Zetterberg, H. & Nordberg, A. (2015). Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. J Alzheimers Dis., 47(3), 661-667.
Farjah, F., Madtes, D. K., Wood, D. E., Flum, D. R., Zadworny, M. E., Waworuntu, R., Hwang, B. & Mulligan, M. S. (2015). Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer. J Thorac Cardiovasc Surg., 150(4), 796-803.
Ferda, J., Ferdová, E., Baxa, J., Kreuzberg, B., Daum, O., Třeška, V. & Skalický, T. (2015). The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography. Anticancer Res., 35(4), 2241-2246.
Fink, J. R., Muzi, M., Peck, M. & Krohn, K. A. (2015). Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. J Nucl Med., 56(10), 1554-1561.
Firbank, M. J., Lloyd, J., Williams, D., Barber, R., Colloby, S. J., Barnett, N., Olsen, K., Davison, C., Donaldson, C., Herholz, K. & O’Brien, J. T. (2015). An evidence-based algorithm for the utility of FDG-PET for diagnosing AD according to presence of medial temporal lobe atrophy. Br J Psychiatry. Jun 4. pii: bjp. bp.114.160804.
Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L., Domarkas, J., Lord, S., Baldry, C. & Gilbert, F. J. (2015). Imaging tumor hypoxia with positron emission tomography. Br J Cancer., 112(2), 238-250.
Frederiksen, K. S., Hasselbalch, S., Law, I., Højgaard, L. & Waldemar, G. (2015). [Biomarkers for early diagnosis of AD]. Ugeskr Laeger., 8, 177(24).
Furka, I., Németh, N. & Mikó, I. (2013). [The spleen in experimental surgery]. Magy Seb., 66(3), 156-160.
Furukawa, T., Yuan, Q., Jin, Z. H., Aung, W., Yoshii, Y., Hasegawa, S., Endo, H., Inoue, M., Zhang, M. R., Fujibayashi, Y. & Saga, T. (2015). A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone]. Oncol Rep., 34(3), 1379-1387.
Gao, L., Liu, H., Sun, X., Gao, D., Zhang, C., Jia, B., Zhu, Z., Wang, F. & Liu, Z. (2015). Molecular imaging of post-Src-inhibition tumor signatures for guiding Dasatinib combination therapy. J Nucl Med., 2015 Sep 17.
Gardener, S. L., Rainey-Smith, S. R., Barnes, M. B., Sohrabi, H. R., Weinborn, M., Lim, Y. Y., Harrington, K., Taddei, K., Gu, Y., Rembach, A., Szoeke, C., Ellis, K. A., Masters, C. L., Macaulay, S. L., Rowe, C. C., Ames, D., Keogh, J. B., Scarmeas, N., Martins, R. N.. (2015). Dietary patterns and cognitive decline in an Australian study of ageing. Mol Psychiatry., 20(7), 860-866.
George, N., Gean, E. G., Nandi, A., Frolov, B., Zaidi, E., Lee, H., Brašić, J. R. & Wong, D. F. (2015). Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. CNS Drugs., 29(4), 313-330.
Ghouri, Y. A., Krishna, S. G., Kundu, U. R., Bhutani, M. S., Lee, J. H. & Ross, W. A. (2015). A case series and literature review of Merkel cell carcinoma metastasizing to pancreas. Dig Dis Sci., 60(6), 1805-1812.
Gidicsin, C. M., Maye, J. E., Locascio, J. J., Pepin, L. C., Philiossaint, M., Becker, J. A., Younger, A. P., Dekhtyar, M., Schultz, A. P., Amariglio, R. E., Marshall, G. A., Rentz, D. M., Hedden, T., Sperling, R. A. & Johnson, K. A. (2015). Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology., 85(1), 48-55.
Gooding, M. A., Atkinson, J. L., Duncan, I. J., Niel, L. & Shoveller, A. K. (2015). Dietary fat and carbohydrate have different effects on body weight, energy expenditure, glucose homeostasis and behaviour in adult cats fed to energy requirement. J Nutr Sci., Jan 22, 4, e2.
Goos, J. A., de Cuba, E. M., Coupé, V. M., Diosdado, B., Delis-Van, Diemen, P. M., Karga, C., Beliën, J. A., Menke-Van der, Houven., van Oordt, C. W., Geldof, A. A., Meijer, G. A., Hoekstra, O. S., Fijneman, R. J. & the DeCoDe PET Group. (2016). Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Ann Surg., 263(1), 138-145.
Goos, J. A., Verbeek, J., Geldof, A. A., Hiemstra, A. C., van de Wiel, M. A., Adamzek, K. A., Delis-Van Diemen, P. M., Stroud, S. G., Bradley, D. P., Meijer, G. A., Hoekstra, O. S., Fijneman, R. J. & Windhorst, A. D. (2015). Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). Nucl Med Biol., Sep 11.. pii: S0969-8051(15)00161-4.
Gorla, R., Erbel, R., Kuehl, H., Kahlert, P., Tsagakis, K., Jakob, H., Mahabadi, A. A., Schlosser, T., Bockisch, A., Eggebrecht, H., Bossone, E. & Jánosi, R. A. (2015). Prognostic value of 18F-FdG PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. Int J Cardiovasc Imaging., 31(8), 1677-1685.
Groheux, D., Sanna, A., Majdoub, M., de Cremoux, P., Giacchetti, S., Teixeira, L., Espié, M., Merlet, P., de Roquancourt, A., Visvikis, D., Hatt, M., Resche-Rigon, M. & Hindié, E. (2015). Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. J Nucl Med., 56(6), 824-831.


Growdon, M. E., Schultz, A. P., Dagley, A. S., Amariglio, R. E., Hedden, T., Rentz, D. M., Johnson, K. A., Sperling, R. A., Albers, M. W. & Marshall, G. A. (2015). Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology., 84(21), 2153-60.
Grüninger, F. (2015). Invited review: Drug development for tauopathies. Neuropathol Appl Neurobiol., 41(1), 81-96.
Gupta, V. B., Wilson, A. C., Burnham, S., Hone, E., Pedrini, S., Laws, S. M., Lim, W. L., Rembach, A., Rainey-Smith, S., Ames, D., Cobiac, L., Macaulay, S. L., Masters, C. L., Rowe, C. C., Bush, A. I., Martins, R. N. & AIBL Research Group. (2015). Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkersand Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther., 7(1), 16.
Habermeier, A., Graf, J., Sandhöfer, B. F., Boissel, J. P., Roesch, F. & Closs, E. I. (2015). System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-Tyrosine (FET). Amino Acids., 47(2), 335-344.
Hager, B. M. & Keshavan, M. S. (2015). Neuroimaging Biomarkers for Psychosis. Curr Behav Neurosci Rep., 2015, 1-10.
Hake, A., Trzepacz, P. T., Wang, S., Yu, P., Case, M., Hochstetler, H., Witte, M. M., Degenhardt, E. K. & Dean, R. A. ADNI. (2015). Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimers Dement., 11(8), 986-993.
Haldorsen, I. S., Popa, M., Fonnes, T., Brekke, N., Kopperud, R., Visser, N. C., Rygh, C. B., Pavlin, T., Salvesen, H. B., McCormack, E. & Krakstad, C. (3025). Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoSOne., 7, 10(8), e0135220.
Haris, M., Yadav, S. K., Rizwan, A., Singh, A., Cai, K., Kaura, D., Wang, E., Davatzikos, C., Trojanowski, J. Q., Melhem, E. R., Marincola, F. M. & Borthakur, A. (2015). T1rho MRI and CSF biomarkers in diagnosis of AD. Neuroimage Clin., 7, 598-604.
Harrington, K. D., Lim, Y. Y., Gould, E. & Maruff, P. (2015). Amyloid-beta and depression in healthy older adults: a systematic review. Aust N Z J Psychiatry., 49(1), 36-46.
Hasselbalch, S. G. (2015). [PET with amyloid ligands should not be applied routinely in early diagnostics of AD]. Ugeskr Laeger., Aug 3, 177(32).
Hazari, P. P., Prakash, S., Meena, V. K., Jaswal, A., Khurana, H., Mishra, S. K., Bhonsle, H. K., Singh, L. & Mishra, A. K. (2015). LAT1 targeted delivery of methionine based imaging probe derived from M(III) metal ions for early diagnosis of proliferating tumors using molecular imaging modalities. Curr Cancer Drug Targets., 14(9), 817-831.
Henderson, N. C. & Sheppard, D. (2013). Integrin-mediated regulation of TGFβ in fibrosis. Biochimica et Biophysica Acta, 1832(7), 891–896.
Herrmann, K., Lapa, C., Wester, H. J., Schottelius, M., Schiepers, C., Eberlein, U., Bluemel, C., Keller, U., Knop, S., Kropf, S., Schirbel, A., Buck, A. K. & Lassmann, M. (2015). Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-Pentixafor. J Nucl Med., 56(3), 410-416.
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., Advani, R. H. & Hoppe, R. T. (2015). Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the Rituximab era. Int J Radiat Oncol Biol Phys., 92(1), 99-106.
Hollands, S., Lim, Y. Y., Buckley, R., Pietrzak, R. H., Snyder, P. J., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N., Martins, R. N., Masters, C. L., Villemagne, V. L., Rowe, C. C. & Maruff, P. (2015). Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis., 43(2), 677-686.
Hooper, C. E., Lyburn, I. D., Searle, J., Darby, M., Hall, T., Hall, D., Morley, A., White, P., Rahman, N. M., De Winton, E., Clive, A., Masani, V., Arnold, D. T., Dangoor, A., Guglani, S., Jankowska, P., Lowndes, S. A., Harvey, J. E., Braybrooke, J. P. & Maskell, N. A. (2015). The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer., 112(7), 1175-1182.
Hu, C., Cheng, L., Sepulcre, J., Johnson, K. A., Fakhri, G. E., Lu, Y. M. & Li, Q. (2015). A spectral graph regression model for learning brain connectivity of AD. PLoS One., 10(5), e0128136.
Huang, E. P., Wang, X. F., Choudhury, K. R., McShane, L. M., Gönen, M., Ye, J., Buckler, A. J., Kinahan, P. E., Reeves, A. P., Jackson, E. F., Guimaraes, A. R. & Zahlmann, G. (2015). Meta-Analysis Working Group. Meta-analysis of the technical performance of an imaging procedure: guidelines and statistical methodology. Stat Methods Med Res., 24(1), 141-174.
Huang, S. H., Chang, C. C., Lui, C. C., Chen, N. C., Lee, C. C., Wang, P. W. & Jiang, C. F. (2015).

Cortical metabolic and nigrostriatal abnormalities associated with clinical stage-specific dementia with Lewy bodies. Clin Nucl Med., 40(1), 26-31.
Humbert, O., Cochet, A. & Coudert, B. (2015). Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist., 20(2), 94-104.
Humbert, O., Riedinger, J. M., Charon-Barra, C. & Berriolo-Riedinger, A. (2015). Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F. Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer. Clin. Cancer Res., 21(24), 5460-8.
Husby, J. A., Reitan, B. C., Biermann, M., Trovik, J., Bjørge, L., Magnussen, I. J., Salvesen, Ø. O., Salvesen, H. B. & Haldorsen, I. S. (2015). Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients. J Nucl. Med., 56(8), 1191-1198.
Hutterer, M., Hattingen, E., Palm, C., Proescholdt, M. A. & Hau, P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol., 2015 Jun, 17(6), 784-800.
Hyslop, A., Miller, I., Bhatia, S., Resnick, T., Duchowny, M. & Jayakar, P. Minimally resective epilepsy surgery in MRI-negative children. Epileptic Disord., 17(3), 263-74.
Illés, Á., Simon, Z., (2015). [New trends and novel possibilities in the diagnosis of lymphomas]. Magy Onkol. 59(1), 73-78.
Ishi, K. & Tamaoka, A. (2015). [Ten-years records of organic arsenic (diphenylarsinic acid) poisoning: epidemiology, clinical feature, glucose metabolism, and toxicity]. Brain Nerve., 67(1), 5-18.
Isobe, M. & Tezuka, D. (2015). Isolated cardiac sarcoidosis: clinical characteristics, diagnosis and treatment. Int J Cardiol., 182, 132-140.
Ito, K., Yokoyama, J., Miyata, Y., Toyohara, J., Okasaki, M., Minamimoto, R., Morooka, M., Ishiwata, K. & Kubota, K. (2015). Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma. Nucl Med Commun., 36(3), 219-225.
Jagust, W. J., Landau, S. M., Koeppe, R. A., Reiman, E. M., Chen, K., Mathis, C. A., Price, J. C., Foster, N. L. & Wang, A. Y. The ADNI 2 PET Core: 2015. Alzheimers Dement., 2015, Jul, 11(7), 757-771.
James, M. L., Belichenko, N. P., Nguyen, T. V., Andrews, L. E., Ding, Z., Liu, H., Bodapati, D., Arksey, N., Shen, B., Cheng, Z., Wyss-Coray, T., Gambhir, S. S., Longo, F. M. & Chin, F. T. (2015). PET imaging of translocator protein (18 kDa) in a mouse model of AD using N-(2, 5-dimethoxybenzyl)-2-18F-fluoro-N-(2-phenoxyphenyl)acetamide. J Nucl Med., 56(2), 311-316.
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey F. R., Visser, P. J. & Amyloid Biomarker Study Group. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA., 313(19),1924-1938.
Jentsch, C., Beuthien-Baumann, B., Troost, E. G. & Shakirin, G. (2015). Validation of functional imaging as a biomarker for radiation treatment response. Br J Radiol., 88(1051), 20150014.
Jeong, C. J., Lee, H. Y., Han, J., Jeong, J. Y., Lee, K. S., Choi, Y. L. & Choi, J. Y. (2015). Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma. Clin Nucl Med., 40(1), e34-9.
Joutsa, J., Voon, V., Johansson, J., Niemelä, S., Bergman, J. & Kaasinen, V. (2015). Dopaminergic function and inter-temporal choice. Transl Psychiatry., 5, e491.
Kanazawa, M., Ohba, H., Harada, N., Kakiuchi, T., Muramatsu, S. I. & Tsukada, H. (2015). Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PETStudy with β-11-L-DOPA and 18F-FDOPA in Parkinson’s Disease Monkeys. J Nucl Med., 2015 Nov 12.
Kandel, B. M., Avants, B. B., Gee, J. C., Arnold, S. E. & Wolk, D. A. (2015). Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in MCI. J Alzheimers Dis., 46(4), 901-912.
Kang, T. H., Han, S. H. & Park, S. J. (2015). Development of Seven Microsatellite Markers Using Next Generation Sequencing for the Conservation on the Korean Population of Dorcus hopei (E. Saunders, 1854) (Coleoptera, Lucanidae)., 16(9), 21330-21341.
Karami, A., Eyjolfsdottir, H., Vijayaraghavan, S., Lind, G., Almqvist, P., Kadir, A., Linderoth, B., Andreasen, N., Blennow, K., Wall, A., Westman, E., Ferreira, D., Kristoffersen Wiberg, M., Wahlund, L. O., Seiger, Å., Nordberg, A., Wahlberg, L, Darreh-Shori, T. & Eriksdotter, M. (2015). Changes in CSF Cholinergic biomarkers in response to cell therapy with NGF in patients with AD. Alzheimers Dement., 11(11), 1316-1328.
Karlsson, F., Antonodimitrakis, P. C. & Eriksson, O. (2015). Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers. Nucl Med Biol., 42(10), 762-769.
Kemna, M. J., Vandergheynst, F., Vöö, S., Blocklet, D., Nguyen, T., Timmermans, S. A., van Paassen, P., Cogan, E., van Kroonenburgh, M. J. & Tervaert, J. W. (2015). Positron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis. Medicine (Baltimore)., 94(20), e747.
Kendi, A. T., Corey, A., Magliocca, K. R., Nickleach, D. C., Galt, J., Switchenko, J. M., El-Deiry, M. W., Wadsworth, J. T., Hudgins, P. A., Saba, N. F. & Schuster, D. M. (2015). 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers? Eur J Radiol., 84(6), 1171-1176.
Kerbler, G. M., Fripp, J., Rowe, C. C., Villemagne, V. L., Salvado, O., Rose, S. & Coulson, E. J. ADNI. (2014). Basal forebrain atrophy correlates with amyloid β burden in AD. Neuroimage Clin., 7, 105-113.
Keshari, K. R., Wilson, D. M., Van Criekinge, M., Sriram, R., Koelsch, B. L., Wang, Z. J., VanBrocklin, H. F., Peehl, D. M., O’Brien, T., Sampath, D., Carano, R. A. & Kurhanewicz, J. (2015). Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate., 75(14), 1601-1609.
Khan, T. K. & Alkon, D. L. A. D. (2015). Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. J Alzheimers Dis., 46(4), 817-836.
Khan, T. K. & Alkon, D. L. (2015). Peripheral biomarkers of AD. J Alzheimers Dis., 44(3), 729-744.
Kim, C. Y., Jeong, S. Y., Chong, G. O., Son, S. H., Jung, J. H., Kim, D. H., Lee, S. W., Ahn, B. C. & Lee, J. (2015). Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol., 136(3), 498-504.
Kim, J. W., Oh, J. S., Roh, J. L., Kim, J. S., Choi, S. H., Nam, S. Y. & Kim, S. Y. (2015). Prognostic significance of standardized uptake value and metabolic tumor volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging., 42(9), 1353-1361.
Kim, J. Y., Lee, S. H., Kim, S., Kang, T. & Bae, Y. T. (2015). Tumor 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol., 25(4), 1172-1181.
Kim, Y. H., Lee, J. A., Baek, J. M., Sung, G. Y., Lee, D. S. & Won, J. M. (2015). The clinical significance of standardized uptake value in breast cancer measured using 18F-FdG positron emission tomography/computed tomography. Nucl Med Commun., 36(8), 790-794.
Kincses, Z. T., Király, A., Veréb, D. & Vécsei, L. (2015). Structural Magnetic Resonance Imaging Markers of AD and Its Retranslation to Rodent Models. J Alzheimers Dis., 47(2), 277-290.
Kiviniemi, A., Gardberg, M., Frantzén, J., Pesola, M., Vuorinen, V., Parkkola, R., Tolvanen, T., Suilamo, S., Johansson, J., Luoto, P., Kemppainen, J., Roivainen, A. & Minn, H. (2015). Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res., 5, 25.
Knudsen, A., Hag, A. M., Loft, A., von Benzon, E., Keller, S. H., Møller, H. J., Lebech, A. M., Ripa, R. S. & Kjær, A. (2015). HIV infection and arterial inflammation assessed by (18)F-FdG (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol., Apr, 22(2), 372-380.
Koo, H. J., Chae, E. J., Kim, J. E., Kim, E. Y., Oh, S. Y., Hwang, H. J., Lee, H. J. & Do, K. H. (2015). Presence of macronodules in thoracic sarcoidosis: prevalence and computed tomographic findings. Clin Radiol., 70(8), 815-821.
Kümler, I., Balslev, E., Poulsen, T. S., Nielsen, S. L., Nygård, S. B., Rømer, M. U., Christensen, I. J., Høgdall, E., Moreira, J., Nielsen, D. L., Brünner, N. & Stenvang, J. (2015). Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer. Int J Cancer., 137(8), 2000-2006.
Kwak, W., Ha, Y. S., Soni, N., Lee, W., Park, S. I., Ahn, H., An, G. I., Kim, I. S., Lee, B. H. & Yoo, J. (2015). Apoptosis imaging studies in various animal models using radio-iodinated peptide. Apoptosis., 20(1), 110-121.
Lakhman, Y., Nougaret, S., Miccò, M., Scelzo, C., Vargas, H. A., Sosa, R. E., Sutton, E. J., Chi, D. S., Hricak, H. & Sala, E. (2015). Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies. Radiographics., 35(4),1295-1313.
Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M. & Jagust, W. (2015). Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med., 56(4), 567-574.
Ledig, C., Heckemann, R. A., Hammers, A., Lopez, J. C., Newcombe, V. F., Makropoulos, A., Lötjönen, J., Menon, D. K. & Rueckert, D. (2015). Robust whole-brain segmentation: application to traumatic brain injury. Med Image Anal., 21(1), 40-58.
Lee, G. I. H., Kim, S. J., Pak, K., Cho, J. S., Jeong, Y. J., Lee, C. H. & Chang, S. (2015). Initial Experience of 18F-FDG PET/MRI in Thymic Epithelial Tumors: Morphologic, Functional, and Metabolic Biomarkers. Clin Nucl Med., 41(1), 8-14.
Leifert, W. R., Nguyen, T., Rembach, A., Martins, R., Rainey-Smith, S., Masters, C. L., Ames, D., Rowe, C. C., Macaulay, S. L., François, M. & Fenech, M. F. (2015). Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkersof AD Risk. J Alzheimers Dis., 48(2), 443-452.
Leijenaar, R. T., Nalbantov, G., Carvalho, S., van Elmpt, W. J., Troost, E. G., Boellaard, R., Aerts, H. J., Gillies, R. J. & Lambin, P. (2015). The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep., 5, 11075.
Leite, J., Hespanhol, R. & Buchpiguel, C. A. (2015). Molecular imaging in genetics. Neuroimaging. Clin N Am., 25(1), 17-29.
Lenihan, M. W. & Jordan, B. D. (2015). The clinical presentation of chronic traumatic encephalopathy. Curr Neurol Neurosci Rep., 15(5), 23.
Leuzy, A., Carter, S. F., Chiotis, K., Almkvist, O., Wall, A. & Nordberg, A. (2015). Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with MCI and AD. J Alzheimers Dis., 45(4), 1077-1088.
Lewczuk, P., Mroczko, B., Fagan, A. & Kornhuber, J. (2015). Biomarkers of AD and MCI: a current perspective. Adv Med Sci., 60(1), 76-82.
Li, F., Tran, L., Thung, K. H., Ji, S., Shen, D. & Li, J. (2015). A Robust Deep Model for Improved Classification of AD/MCI Patients. IEEE J Biomed Health Inform., 19(5), 1610-1616.
Li, Q. X., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A., Laughton, K. M., Pertile, K. K., Fowler, C. J., Rumble, R. L., Trounson, B. O., Taddei, K., Rainey-Smith, S. R., Laws, S. M., Robertson, J. S., Evered, L. A., Silbert, B., Ellis, K. A., Rowe, C. C. & Macaulay, S. L. J Alzheimers Dis., 48(1), 175-187.
Li, X. & Zhang, Z. J. (2015). Neuropsychological and Neuroimaging Characteristics of Amnestic MCI Subtypes: A Selective Overview. CNS Neurosci Ther., 21(10), 776-783.
Li, Y., Tsui, W., Rusinek, H., Butler, T., Mosconi, L., Pirraglia, E., Mozley, D., Vallabhajosula, S., Harada, R., Furumoto, S., Furukawa, K., Arai, H., Kudo, Y., Okamura, N. & de Leon, M. J. (2015). Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med., 56(2), 270-273.
Liang, S. H., Southon, A. G., Fraser, B. H., Krause-Heuer, A. M., Zhang, B., Shoup, T. M., Lewis, R., Volitakis, I., Han, Y.,Greguric, I., Bush, A. I. & Vasdev, N. (2015). Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of AD. ACS Med Chem Lett., 6(9), 1025-1029.
Liikanen, I., Koski, A., Merisalo-Soikkeli, M., Hemminki, O., Oksanen, M., Kairemo, K., Joensuu, T., Kanerva, A. & Hemminki, A. (2015). Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology., 4(3), e989771.
Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., Snyder, P. J., Martins, R. N., Masters, C. L., Rowe, C. C., Maruff, P. & Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. (2015). APOE ε4 moderates amyloid-related memory decline in preclinical AD. Neurobiol Aging., 36(3), 1239-1244.
Liszkay, G. (2015). [Advancements in the diagnosis of melanoma]. Magy Onkol., 59(1), 68-72.
Liu, C. H. (2015). Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging. Future Neurol., 10(1), 49-65.
Liu, Y., Tan, L., Wang, H. F., Liu, Y., Hao, X. K., Tan, C. C., Jiang, T., Liu, B., Zhang, D. Q. & Yu, J. T. ADNI. (2015). Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across AD Spectrum. Mol Neurobiol., 2015 Aug 23.
Liu, Y., Yuan, H., Kersey, F. R., Register, J. K., Parrott, M. C. & Vo-Dinh, T. (2015). Plasmonic gold nanostars for multi-modality sensing and diagnostics. Sensors (Basel)., 15(2), 3706-3720.
Lopci, E., Franzese, C., Grimaldi, M., Zucali, P. A., Navarria, P., Simonelli, M., Bello, L., Scorsetti, M. & Chiti, A. (2015). Imaging biomarkers in primary brain tumors. Eur J Nucl Med Mol Imaging., 42(4), 597-612.
Mäkitalo, S., Mellgren, Å., Borgh, E., Kilander, L., Skillbäck, T., Zetterberg, H. & Gisslén, M. (2015). The cerebrospinal fluid biomarker profile in an HIV-infected subject with AD. AIDS Res Ther., 12, 23.
Mäntylä, T., Mantere, O., Raij, T. T., Kieseppä, T., Laitinen, H., Leiviskä, J., Torniainen, M., Tuominen, L., Vaarala, O. & Suvisaari, J. (2015). Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis. PLoSOne., 10(5), e0125112.
Martín, A., Szczupak, B., Gómez-Vallejo, V., Domercq, M., Cano, A., Padro, D., Muñoz, C., Higuchi, M., Matute, C. & Llop, J. (2015). In vivo PET imaging of the α4β2 nicotinic acetylCholine receptor as a marker for brain inflammation after cerebral ischemia. J Neurosci., 35(15), 5998-6009.
Martínez-Torteya, A., Treviño, V. & Tamez-Peña, J. G. (2015). Improved Diagnostic Multimodal Biomarkers for AD and MCI. Biomed Res Int., 2015, 961314.
Matías-Guiu, J. A., Cabrera-Martín, M. N., Moreno-Ramos, T., Valles-Salgado, M., Fernandez-Matarrubia, M., Carreras, J. L. & Matías-Guiu, J. (2015). Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol., 262(6), 1463-1472.
Matrone, F., Sivolella, S., Bellavita, R., Casciola, L., Cristallini, E. G. & Aristei, C. (2015). Use of 18F-Choline positron emission tomography/CT in high-risk prostate cancer: a case of solitary adrenal metastasis. Tumori., 101(1), e21-3.
Maurovich-Horvat, P., Kallianos, K., Engel, L. C., Szymonifka, J., Schlett, C. L., Koenig, W., Hoffmann, U. & Truong, Q. A. (2015). Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers. Obesity (Silver Spring). 23(6), 1178-1184.
McConathy, J. & Sheline, Y. I. (2015). Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry., 77(8), 685-692.
Medina, R. A, Mariotti, E., Pavlovic, D., Shaw, K. P., Eykyn, T. R., Blower, P. J. & Southworth, R. (2015). 64Cu-CTS: A Promising Radiopharmaceutical for the Identification of Low-Grade Cardiac Hypoxia by PET. J Nucl Med., 56(6), 921-926.
Meignan, M., Gallamini, A., Haioun, C., Barrington, S., Itti, E., Luminari, S. & Polliack, A. (2015). Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014. Leuk Lymphoma., 56(5), 1229-1232.
Meignan, M. (2015). FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis. Hematol Oncol., 33 Suppl 1, 38-41.
Mendler, C. T., Friedrich, L., Laitinen, I., Schlapschy, M., Schwaiger, M., Wester, H. J. & Skerra, A. (2015). High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs., 7(1), 96-109.
Minoshima, S. (2015). Establishing Amyloid PET Imaging Biomarkers: Ongoing Efforts. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. Am J Neuroradiol., 36(7), 1245-1246.
Molinari, C., Matteucci, F., Caroli, P. & Passardi, A. (2015). Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Clin Colorectal Cancer., 14(4), 227-238.
Mongillo, P., Bertotto, D., Pitteri, E., Stefani, A., Marinelli, L. & Gabai, G. (2015). Peripheral leukocyte populations and oxidative stress biomarkers in aged dogs showing impaired cognitive abilities. Age (Dordr)., 37(3), 9778.
Moreau, S., DaSilva, J. N., Valdivia, A. & Fernando, P. (2015). N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy. Nucl Med Biol., 42(2), 192-197.
Müller, M. L., Bohnen, N. I., Kotagal, V., Scott, P. J., Koeppe, R. A., Frey, K. A. & Albin, R. L. (2015). Clinical markers for identifying Cholinergic deficits in Parkinson’s disease. Mov Disord., 30(2), 269-273.
Nensa, F., Beiderwellen, K., Heusch, P. & Wetter, A. (2014). Clinical applications of PET/MRI: current status and future perspectives. Diagn Interv Radiol., 20(5), 438–447.
Niccolini, F., Haider, S., Reis Marques, T., Muhlert, N., Tziortzi, A. C., Searle, G. E., Natesan, S., Piccini, P., Kapur, S., Rabiner, E. A., Gunn, R. N., Tabrizi, S. J. & Politis, M. (2015). Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease. Brain., 138(Pt 10), 3016-3029.
Nishio, J., Iwasaki, H., Aoki, M., Nabeshima, K. & Naito, M. (2015). FDG PET/CT and MR imaging of CD34-negative soft-tissue solitary fibrous tumor with NAB2-STAT6 fusion gene. Anticancer Res., 35(2), 967-971.
Nordberg, A., Kadir, A., Andreasen, N., Almkvist, O., Wall, A., Långström, B. & Zetterberg, H. (2015). Correlations between AD Cerebrospinal Fluid Biomarkers and Cerebral Glucose metabolismafter 12 Months of Phenserine Treatment. J Alzheimers Dis., 47(3), 691-704.
Novelli, S., Briones, J., Flotats, A. & Sierra, J. (2015). PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. Adv Clin Exp Med., 24(2), 325-330.
O’Brien, J. T. & Herholz, K. (2015). Amyloid imaging for dementia in clinical practice. BMC Med., 13, 163.
Ocak, M., Gillman, A. G., Bresee, J., Zhang, L., Vlad, A. M., Müller, C., Schibli, R., Edwards, W. B., Anderson, C. J. & Gach, H. M. (2015). Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model. Mol Pharm., 12(2), 542-553.
O’Connor, J. P., Rose, C. J., Waterton, J. C., Carano, R. A., Parker, G. J. & Jackson, A. (2015). Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res., 21(2), 249-257.
Olivotto, I., d’Amati, G., Basso, C., Van Rossum, A., Patten, M., Emdin, M., Pinto, Y., Tomberli, B., Camici, P. G. & Michels, M. (2015). Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovasc Res., 105(4), 409-423.
Oosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Oude Munnink, T. H., Lub-de Hooge, M. N., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., Scherer, S. J., Sluiter, W. J., Dierckx, R. A., Bongaerts, A. H., Gietema, J. A. & de Vries, E. G. (2015). 89Zr-Bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med., 56(1), 63-69.
Ordonez, A. A., Pokkali, S., DeMarco, V. P., Klunk, M., Mease, R. C., Foss, C. A., Pomper, M. G. & Jain, S. K. (2015). Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother., 59(1), 642-649.
Ortiz, R., Ulrich, H., Zarate, C. A. Jr. & Machado-Vieira, R. (2015). Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry., 57, 117-131.
Ota, K., Oishi, N., Ito, K. & Fukuyama, H. (2015). SEAD-J Study Group; ADNI. Effects of imaging modalities, brain atlases and feature selection on prediction of AD. J Neurosci Methods., 256, 168-183.
Ozkan, Z. G., Kuyumcu, S., Uzum, A. K., Gecer, M. F., Ozel, S., Aral, F. & Adalet, I. (2015). Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun., 36(3), 242-250.
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., ADNI., Minthon, L., Blennow, K., Olsson, M., Swedish BioFINDER study group. & Hansson, O. (2015). Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology., 85(14), 1240-1249.
Pan, Y., Liu, S., Wu, H., Lv, J., Xu, X., et al. (2013). Baculovirus as an Ideal Radionuclide Reporter Gene Vector: A New Strategy for Monitoring the Fate of Human Stem Cells In Vivo. PLoS ONE, 8(4), e61305.
Park, B. N., Kim, J. H., Lee, K. & Park, S. H. (2015). An YS.

Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT. Eur Radiol., 25(5), 1487-1496.
Park, J. W., Jung, K. H., Lee, J. H., Quach, C. H., Moon, S. H., Cho, Y. S. & Lee, K. H. (2015). 18F-FDG PET/CT monitoring of β3 agonist-stimulated brown adipocyte recruitment in white adipose tissue. J Nucl Med., 56(1), 153-158.
Pedersen, S. F., Sandholt, B. V., Keller, S. H., Hansen, A. E., Clemmensen, A. E., Sillesen, H., Højgaard, L., Ripa, R. S. & Kjær, A. (2015). 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy. Arterioscler Thromb Vasc Biol., 35(7), 1696-703.
Pedraz-Cuesta, E., Christensen, S., Jensen, A. A., Jensen, N. F., Bunch, L., Romer, M. U., Brünner, N., Stenvang, J. & Pedersen, S. F. (2015). The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer., 15, 411.
Perani, D., Cerami, C., Caminiti, S. P., Santangelo, R., Coppi, E., Ferrari, L., Pinto, P., Passerini, G., Falini, A., Iannaccone, S., Cappa, S. F., Comi, G., Gianolli, L. & Magnani, G. (2015). Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging., 2015 Sep 4.
Perng, P., Marcus, C. & Subramaniam, R. M. (2015). (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. AJR Am J Roentgenol., 205(2), 259-270.
Persson, M., Nedergaard, M., Brandt-Larsen, M., Skovgaard, D., Jørgensen, J. T., Michaelsen, S. R., Madsen, J., Lassen, U., Poulsen, H. S. & Kjaer, A. (2015) uPAR is a Promising New Imaging Biomarker in Glioblastoma. J Nucl Med., Oct 1.
Peter, J., Houshmand, S., Werner, T. J., Rubello, D. & Alavi, A. (2015). Applications of global quantitative 18F-FDG-PET analysis in temporal lobe epilepsy. Nucl Med Commun., 2015 Nov 19.
Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L., Lambin, P., Ward, C., Meehan, J., Kunkler, I. H., Langdon, S. P., Ree, A. H., Flatmark, K., Lyng, H., Calzada, M. J., Peso, L. D., Landazuri, M. O., Görlach, A., Flamm, H., Kieninger, J., Urban, G.,Weltin, A., Singleton, D. C., Haider, S., Buffa, F. M., Harris, A. L., Scozzafava, A., Supuran, C. T., Moser, I., Jobst, G., Busk, M., Toustrup, K., Overgaard, J., Alsner, J., Pouyssegur, J., Chiche, J., Mazure, N., Marchiq, I., Parks, S., Ahmed, A., Ashcroft, M., Pastorekova, S., Cao, Y., Rouschop, K. M., Wouters, B. G., Koritzinsky, M., Mujcic, H. & Cojocari, D. (2015). Targeting tumor hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem., 30(5), 689-721.
Picchio, M., Mapelli, P., Panebianco, V., Castellucci, P., Incerti, E., Briganti, A., Gandaglia, G., Kirienko, M., Barchetti, F., Nanni, C., Montorsi, F., Gianolli, L. & Fanti, S. (2015). Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging., 42(4), 644-655.
Pietrzak, R. H., Lim, Y. Y., Ames, D., Harrington, K., Restrepo, C., Martins, R. N., Rembach, A., Laws, S. M., Masters, C. L.,Villemagne, V. L., Rowe, C. C. & Maruff, P. Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group., (2015). Trajectories of memory decline in preclinical AD: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging., 36(3), 1231-1238.
Polito, E., Burroni, L., Pichierri, P., Loffredo, A. & Vattimo, A. G. (2005). Technetium tc 99m-labeled red blood cells in the preoperative diagnosis of cavernous hemangioma and other vascular orbital tumors. Arch Ophthalmol., 123(12), 1678-1683.
Portelius, E., Lashley, T., Westerlund, A., Persson, R., Fox, N. C., Blennow, K., Revesz, T. & Zetterberg, H. (2015). Brain amyloid-beta fragment signatures in pathological ageing and AD by hybrid immunoprecipitation mass spectrometry. Neurodegener Dis., 15(1), 50-57.
Prasai, B., Silvers, W. C. & McCarley, R. L. (2015). Oxidoreductase-Facilitated Visualization and Detection of Human Cancer Cells. Anal Chem., 87(12), 6411-6418.
Prestia, A., Caroli, A., Wade, S. K., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E.,Wall, A., Carter, S. F., Schöll, M., Choo, I. H., Nordberg, A., Scheltens, P. & Frisoni, G. B. (2015). Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement., 2015 Jan 31.
Rafii, M. S., Wishnek, H., Brewer, J. B., Donohue, M. C., Ness, S., Mobley, W. C., Aisen, P. S. Rissman, R. A. (2015). The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of AD biomarkers in down syndrome. Front Behav Neurosci., 9, 239.
Rasmussen, G. B., Vogelius, I. R., Rasmussen, J. H., Schumaker, L., Ioffe, O., Cullen, K., Fischer, B. M., Therkildsen, M. H., Specht, L. & Bentzen, S. M. (2015). Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta Oncol., Aug. 9, 1-8.
Rehani, M. M. & Sharma, S. K. (1980). Site of Tc-99m binding to the red blood cell: concise communication. J Nucl Med., 21(7), 676-678.
Reilmann, R., Lippross, V., Hölzner, E., Gigengack, F., Bohlen, S., Kugel, H., Deppe, M., Osada, N., Lücke, M., Riess, O., Nguyen, H. P., Von Hörsten, S., Schäfers, K., Schäfers, M., Jacobs, A. H. & Hermann, S. (2015). FDG μPET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington’s Disease – A 15 Months Follow-up Study. J Huntingtons Dis., 4(1), 37-47.
Reis, C., Wang, Y., Akyol, O., Ho, W. M., Ii, R. A., Stier, G., Martin, R. & Zhang, J. H. (2015). What’s New in Traumatic Brain Injury: Update on Tracking, Monitoring and Treatment. Int J Mol Sci., 16(6), 11903-11965.
Resnick, S. M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M. C., Thambisetty, M., Prince, J. L., Zhou, Y., Soldan, A.,Wong, D. F., O’Brien, R. J., Ferrucci, L. & Albert, M. S. (2015). Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging., 36(8), 2333-2339.
Risacher, S. L., Kim, S., Nho, K., Foroud, T., Shen, L., Petersen, R. C., Jack, C. R. Jr. Beckett, L. A., Aisen, P. S., Koeppe, R. A., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W. & Saykin, A. J. ADNI (ADNI). (2015). APOE effect on AD biomarkers in older adults with significant memory concern. Alzheimers Dement., 2015 May 7.
Rischpler, C., Nekolla, S. G., Kunze, K. P. & Schwaiger, M. (2015). PET/MRI of the heart. Semin Nucl Med., 45(3), 234-247.
Ritter, A. & Cummings, J. (2015). Fluid Biomarkers in Clinical Trials of AD Therapeutics. Front Neurol., 6, 186.
Romano, A., Parrinello, N. L., Vetro, C., Forte, S., Chiarenza, A., Figuera, A., Motta, G., Palumbo, G. A., Ippolito, M., Consoli, U. & Di Raimondo, F. (2015). Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol., 168(5), 689-700.
Rowe, S. P., Gage, K. L., Faraj, S. F., Macura, K. J., Cornish, T. C., Gonzalez-Roibon, N., Guner, G., Munari, E., Partin, A. W., Pavlovich, C. P., Han, M., Carter, H. B., Bivalacqua, T. J., Blackford, A., Holt, D., Dannals, R. F., Netto, G. J., Lodge, M. A., Mease, R. C., Pomper, M. G. & Cho, S. Y. (2015). Author information18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med., 56(7), 1003-1010.
Ruan, Q., Yu, Z., Chen, M., Bao, Z., Li, J. & He, W. (2015). Cognitive frailty, a novel target for the prevention of elderly dependency. Ageing Res Rev., Mar, 20, 1-10.
Sah, B. R., Burger, I. A., Schibli, R., Friebe, M., Dinkelborg, L., Graham, K., Borkowski, S., Bacher-Stier, C., Valencia, R., Srinivasan, A., Hany, T. F., Mu, L., Wild, P. J. & Schaefer, N. G. (2015). Dosimetry and first clinical evaluation of the new 18F-radiolabeled Bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med., 56(3), 372-378.
Saiyin, H., Ardito-Abraham, C. M., Wu, Y., Wei, Y., Han, X., Li, J., Zhou, P., Yi, Q., Maitra, A., Liu, J. O., Tuveson, D. A., Lou, W. & Yu, L. (2015). Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol., 236(2), 142-154.
Sakalihasan, N., Nienaber, C. A., Hustinx, R., Lovinfosse, P., El Hachemi, M., Cheramy-Bien, J. P., Seidel, L., Lavigne, J. P., Quaniers, J., Kerstenne, M. A., Courtois, A., Ooms, A., Albert, A., Defraigne, J. O. & Michel, J. B. (2015). (Tissue PET) Vascular metabolic imaging and peripheral plasma biomarkers in the evolution of chronic aortic dissections. Eur Heart J Cardiovasc Imaging., 16(6), 626-633.
Sakamoto, R., Okada, T., Kanagaki, M., Yamamoto, A., Fushimi, Y., Kakigi, T., Arakawa, Y., Takahashi, J. C., Mikami, Y. & Togashi, K. (2015). Estimation of proliferative potentiality of central neurocytoma: correlational analysis of minimum ADC and maximum SUV with MIB-1 labeling index. Acta Radiol., 56(1), 114-120.
Sampedro, F., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M. B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V., Falcón, C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A. & Fortea, J. ADNI (2015). APOE-by-sex interactions on brain structure and glucose metabolism in healthy elderly controls. Oncotarget., 6(29), 26663-266674.
Sasagawa, Y., Akai, T., Tachibana, O. & Iizuka, H. (2015). Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol., 121(1), 177-183.
Sauter, A. W., Schwenzer, N., Divine, M. R., Pichler, B. J. & Pfannenberg, C. (2015). Image-derived biomarkers and multimodal imaging strategies for lung cancer management. Eur J Nucl Med Mol Imaging., 42(4), 634-643.
Savonenko, A. V., Melnikova, T., Wang, Y., Ravert, H., Gao, Y., Koppel, J., Lee, D., Pletnikova, O., Cho, E., Sayyida, N., Hiatt, A., Troncoso, J., Davies, P., Dannals, R. F., Pomper, M. G. & Horti, A. G. (2015). Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PLoS One., 10(6), e0129618.
Schaffer, C., Sarad, N., DeCrumpe, A., Goswami, D., Herrmann, S., Morales, J., Patel, P. & Osborne, J. (2015). Biomarkers in the Diagnosis and Prognosis of AD. J Lab Autom., 20(5), 589-600.
Schilson, S. S., Keul, P., Shaikh, R. S., Schäfers, M., Levkau, B. & Haufe, G. (2015). Synthesis of new ligands for targeting the S1P1 receptor. Bioorg Med Chem., 23(5), 1011-1026.
Schroeter, M. L., Tiepolt, S., Marschhauser, A., Thöne-Otto, A., Hoffmann, K. T., Barthel, H., Obrig, H. & Sabri, O. (2015). Dissociation of amyloid biomarkers in PET and CSF in AD: a case report. BMC Neurol., 15, 152.
Schwartz, D. L., Harris, J., Yao, M., Rosenthal, D. I., Opanowski, A., Levering, A., Ang, K. K., Trotti, A. M., Garden, A. S., Jones, C. U., Harari, P., Foote, R., Holland, J., Zhang, Q. & Le, Q. T. (2015). Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys., 91(4), 721-729.
Schwedt, T. J. & Chong, C. D. (2015). Functional imaging and migraine: new connections? Curr Opin Neurol., 28(3), 265-270.
Sharma, S. (2016a). Charnoly Body as a Novel Biomarker of Zika Virus Induced Microcephaly. Proceedings of the Drug Discovery and Therapy World Congress (Track: CNS Drug Discovery & Therapy) 22nd to 25th August. Boston, USA.
Sharma, S. (2016b). Monoamine Oxidase Inhibitors: Clinical Pharmacology, Therapeutic Applications, and Adverse Effects. Nova Science Publishers, New York.
Shi, S., Ji, S., Qin, Y., Xu, J., Zhang, B., Xu, W., Liu, J., Long, J., Liu, C., Liu, L., Ni, Q. & Yu, X. (2015). Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett., 360(2), 227-233.
Shih, I. L., Yen, R. F., Chen, C. A., Chen, B. B., Wei, S. Y., Chang, W. C., Sheu, B. C., Cheng, W. F., Tseng, Y. H., Chen, X. J., Chen, C. H., Wei, L. H., Chiang, Y. C., Torng, P. L., Yen, M. L. & Shih, T. T. (2015). Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated whole-body PET/MR: Correlation with pathological prognostic factors. J. Magn. Reson. Imaging., Apr 27. doi: 10.1002/jmri.24932.
Siva, S., Deb, S., Young, R. J., Hicks, R. J., Callahan, J., Bressel, M., Mileshkin, L., Rischin, D., Bernshaw, D. & Narayan, K. (2015). (18)F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. Eur J Nucl Med Mol Imaging., 42(12), 1825-1832.
Skaliczki, G., Weszl, M., Schandl, K., Major, T., Kovács, M., Skaliczki, J., Redl, H., Szendrői, M., Szigeti, K., Máté, D., Dobó-Nagy, C. & Lacza, Z. (2012). Compromised bone healing following spacer removal in a rat femoral defect model. Acta Physiol Hung., 99(2), 223-232.
Skeoch, S., Williams, H., Cristinacce, P., Hockings, P., James, J., Alexander, Y., Waterton, J. & Bruce, I. (2015). Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-FdG PET-CT and MRI: a pilot study. Lancet., 385 Suppl 1, S91.
Su, Z., Roncaroli, F., Durrenberger, P. F., Coope, D. J., Karabatsou, K., Hinz, R., Thompson, G., Turkheimer, F. E., Janczar, K., Du Plessis, D., Brodbelt, A., Jackson, A., Gerhard, A. & Herholz, K. (2015). The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med., 56(4), 512-517.
Suchorska, B., Jansen, N. L., Linn, J., Kretzschmar, H., Janssen, H., Eigenbrod, S., Simon, M., Pöpperl, G., Kreth, F. W., la Fougere, C., Weller, M. & Tonn, J. C. German Glioma Network., (2015). Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology., 84(7), 710-719.
Sun, Y., Duan, Q., Wang, S., Zeng, Y. & Wu, R. (2015). Diagnosis of pancreatic cancer using 18F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics. J BUON., 20(2), 452-459.
Tan, T. C., Neilan, T. G., Francis, S., Plana, J. C. & Scherrer-Crosbie, M. (2015). Anthracycline-Induced Cardiomyopathy in Adults. Compr Physiol., 5(3), 1517-1540.
Tateno, A., Sakayori, T., Kawashima, Y., Higuchi, M., Suhara, T., Mizumura, S., Mintun, M. A., Skovronsky, D. M., Honjo, K., Ishihara, K., Kumita, S., Suzuki, H. & Okubo, Y. (2015). Comparison of imaging biomarkers for AD: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Int J Geriatr Psychiatry., 30(5), 505-513.
Territo, P. R., Maluccio, M., Riley, A. A., McCarthy, B. P., Fletcher, J., Tann, M., Saxena, R. & Skill, N. J. (2015). Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med Imaging., 15, 15.
Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., Maruff, P. & Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. (2015). Amyloid-Related Memory Decline in Preclinical AD Is Dependent on APOE ε4 and Is Detectable over 18-Months. PLoS One., 10(10), e0139082.
Thomas, L., Lapa, C., Bundschuh, R. A., Polat, B., Sonke, J. J. & Guckenberger, M. (2015). Tumor delineation in oesophageal cancer - A prospective study of delineation inPET and CT with and without endoscopically placed clip markers. Radiother Oncol., 116(2), 269-275.
Tiepolt, S., Patt, M., Hoffmann, K.T., Schroeter, M.L., Sabri, O. & Barthel, H. (2015). AD FDG PET Imaging Pattern in an Amyloid-Negative MCI Subject. J Alzheimers Dis., 47(3), 539-543.
Tillmanns, J., Schneider, M., Fraccarollo, D., Schmitto, J. D., Länger, F., Richter, D., Bauersachs, J. & Samnick, S. (2015). PET imaging of cardiac wound healing using a novel [68Ga]-labeled NGR probe in rat myocardial infarction. Mol Imaging Biol., 17(1), 76-86.
Tőkés, T., Szentmártoni, G., Torgyík, L., Kajáry, K., Lengyel, Z., Györke, T., Molnár, B. Á., Tőkés, A. M., Kulka, J. & Dank, M. (2015). Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. Croat Med J., 56(2), 128-138.
Toledo, J. B., Bjerke, M., Chen, K., Rozycki, M., Jack, C. R. Jr. Weiner, M. W., Arnold, S. E., Reiman, E. M., Davatzikos, C., Shaw, L. M. & Trojanowski, J. Q. (2015). ADNI. Collaborators (266) Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. Neurology., 85(2), 144-153.
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C. Jr. Weiner, M., Davatzikos, C., Shaw, L. M. & Trojanowski, J. Q. (2015). Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurol., 72(5), 571-581.
Ueda, M., Hisada, H., Temma, T., Shimizu, Y., Kimura, H., Ono, M., Nakamoto, Y., Togashi, K. & Saji, H. (2015). Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Mol Imaging Biol., 17(1), 102-110.
Uppal, A., White, M. G., Nagar, S., Aschebrook-Kilfoy, B., Chang, P. J., Angelos, P., Kaplan, E. L. & Grogan, R. H. (2015). Benign and Malignant Thyroid Incidentalomas Are Rare in Routine Clinical Practice: A Review of 97,908 Imaging Studies. Cancer Epidemiol Biomarkers Prev., 24(9), 1327-1331.
Val-Laillet, D., Aarts, E., Weber, B., Ferrari, M., Quaresima, V., Stoeckel, L. E., Alonso-Alonso, M., Audette, M., Malbert, C. H. & Stice, E. (2015). Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin., 8, 1-31.
van Dijk, L. K., Boerman, O. C., Franssen, G. M., Kaanders, J. H. & Bussink, J. (2015). 111In-Cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med., 56(2), 287-292.
van Dijk, L. K., Boerman, O. C., Kaanders, J. H. & Bussink, J. (2015). PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. Clin Cancer Res., 21(16), 3602-3609.
VanItallie, T. B. (2015). Biomarkers, ketone bodies, and the prevention of AD. Glucose metabolism., 64(3 Suppl 1), S51-57.
Vargas, H. A, Grimm, J. F., Donati, O., Sala, E. & Hricak, H. (2015). Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol., 25(5), 1294-302.
Varley, J., Brooks, D. J. & Edison, P. (2015). Imaging neuroinflammation in AD and other dementias: Recent advances and future directions. Alzheimers Dement., 11(9), 1110-1120.
Vatankulu, B., Yilmaz Aksoy, S., Asa, S., Sager, S., Sayman, H. B., Halac, M. & Sonmezoglu, K. (2015). Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Rev Esp Med Nucl Imagen Mol., Aug 7.
Velikyan, I. (2015). Continued rapid growth in (68) Ga applications: update 2013 to June 2014. J Labelled Comp Radiopharm., 58(3), 99-121.
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L. & Rowe, C. C. (2015). Tau imaging: early progress and future directions. Lancet Neurol., 14(1), 114-124.
Visanji, N. P., Marras, C., Kern, D. S., Al Dakheel, A., Gao, A., Liu, L. W., Lang, A. E. & Hazrati, L. N. (2015). Colonic mucosal α-Syn lacks specificity as a biomarker for Parkinson disease. Neurology., 84(6), 609-616.
Volkow, N. D., Koob, G. & Baler, R. (2015). Biomarkers in substance use disorders. ACS Chem Neurosci., 6(4), 522-525.
Vos, S. J., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., Frisoni, G. B., Drzezga, A., Didic, M., van Berckel, B. N., Simmons, A., Soininen, H., Kłoszewska, I., Mecocci, P.,Tsolaki, M., Vellas, B., Lovestone, S., Muscio, C., Herukka, S. K., Salmon, E., Bastin, C., Wallin, A., Nordlund, A., de Mendonça, A., Silva, D., Santana, I., Lemos, R., Engelborghs, S., Van der Mussele, S., ADNI, Freund-Levi, Y., Wallin, Å. K., Hampel, H., van der Flier, W., Scheltens, P. & Visser, P. J. (2015). Prevalence and prognosis of AD at the MCI stage. Brain., 138(Pt 5), 1327-1338.
Watt, A. D., Perez, K. A., Ang, C. S., O’Donnell, P., Rembach, A., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Faux, N. G., Masters, C. L., Villemagne, V. L. & Barnham, K. J. (2015). Peripheral α-defensins 1 and 2 are elevated in AD. J Alzheimers Dis., 44(4), 1131-1143.
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Luthman, J., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Shen, L., Schwarz, A., Toga, A. W. & Trojanowski, J. Q. ADNI. (2015). Update of the ADNI: A review of papers published since its inception. Alzheimers Dement., 11(6), e1-120.
Weiner, M. W. & Veitch, D. P. (2015). Introduction to special issue: Overview of ADNI. Alzheimers Dement., 11(7), 730-733.
Weise, D., Tiepolt, S., Awissus, C., Hoffmann, K. T., Lobsien, D., Kaiser., Barthel, H., Sabri, O. & Gertz, H. J. (2015). Critical Comparison of Different Biomarkers for AD in a Clinical Setting. J Alzheimers Dis., 48(2), 425-432.
Welsh, L., Panek, R., McQuaid, D., Dunlop, A., Schmidt, M., Riddell, A., Koh, D. M., Doran, S., Murray, I., Du, Y., Chua, S., Hansen, V., Wong, K. H., Dean, J., Gulliford, S., Bhide, S., Leach, M. O., Nutting, C., Harrington, K. & Newbold, K. (2015). Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study. Radiat Oncol., 10(1), 112.
Whisenant, J. G., McIntyre, J. O., Peterson, T. E., Kang, H., Sánchez, V., Manning, H. C., Arteaga, C. L. & Yankeelov, T. E. (2015). Utility of [18 F]FLT-PET to assess treatment response in Tratsumab-resistant and Tratsumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol., 17(1), 119-128.
Whitwell, J. L., Duffy, J. R., Strand, E. A., Machulda, M. M., Senjem, M. L., Schwarz, C. G., Reid, R., Baker, M. C., Perkerson, R. B., Lowe, V. J., Rademakers, R., Jack, C. R. Jr. & Josephs, K. A. (2015). Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang., 142, 45-53.
Wiltfang, J. (2015). [Cerebrospinal fluid markers in early diagnosis of Alzheimer dementia]. Ther Umsch., 72(4), 271-278.
Withofs, N., Signolle, N., Somja, J., Lovinfosse, P., Nzaramba, E. M., Mievis, F., Giacomelli, F., Waltregny, D., Cataldo, D., Gambhir, S. S. & Hustinx, R. (2015). 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology. J Nucl Med., 56(3), 361-364.
Wondergem, M. J., Rizvi, S. N., Jauw, Y., Hoekstra, O. S., Hoetjes, N., van de Ven, P. M., Boellaard, R., Chamuleau, M. E., Cillessen, S. A., Regelink, J. C., Zweegman, S. & Zijlstra, J. M. (2015). 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med., 56(2), 216-221.
Wong, A. L., Lim, J. S., Sinha, A., Gopinathan, A., Lim, R., Tan, C. S., Soh, T., Venkatesh, S., Titin, C., Sapari, N. S., Lee, S. C., Yong, W. P., Tan, D. S., Pang, B., Wang, T. T., Zee, Y. K., Soong, R., Trnkova, Z., Lathia, C.,Thiery, J. P., Wilhelm, S., Jeffers, M. & Goh, B. C. (2015). Tumor pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with Rgorafenil. J. Transl. Med., 13, 57.
Wu, A. J. & Goodman, K. A. (2015). Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol., 6(1), 53-59.
Wu, C., Li, F. & Niu, G. (2013). Chen X. PET Imaging of Inflammation Biomarkers. Theranostics, 3, 448-466.
Wu, X., Zhou, X., Zhang, S., Zhang, Y., Deng, A., Han, J., Zhu, L., Kung, H. F. & Qiao, J. (2015). Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain. Nucl Med Biol., 42(7), 630-636.
Wurtman, R. (2015). Biomarkers in the diagnosis and management of AD. Glucose metabolism., 64(3 Suppl 1), S47-50.
Xie, J., Chen, K., Huang, J., Lee, S., Wang, J., Gao, J., Li, X. & Chen, X. (2010). (PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials., 31(11), 3016-3022.
Yamada, M. (2015). Cerebral amyloid angiopathy: emerging concepts. J Stroke., Jan, 17(1), 17-30.
Yang, J., Wong, A., Wang, Z., Liu, W., Au, L., Xiong, Y., Chu, W. W., Leung, E. Y., Chen, S., Lau, C., Chan, A. Y., Lau, A. Y., Fan, F., Ip, V., Soo, Y., Leung, T., Ho, C. L., Wong, L. K. & Mok, V. C. (2015). Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimers Dement., 11(1), 16-23.
Ye, T., Zu, C., Jie, B., Shen, D. & Zhang, D. ADNI. (2015). Discriminative multi-task feature selection for multi-modality classification of AD. Brain Imaging Behav., 2015 Aug 27.
Yokobori, Y., Toyoda, M., Sakakura, K., Kaira, K., Tsushima, Y. & Chikamtsu, K. (2015). 18F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Otolaryngol., 135(5), 494-499.
Yoon, R. G., Kim, S. J., Kim, H. S., Choi, C. G., Kim, J. S., Oh, J., Chung, S. J. & Lee, C. S. (2015). The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson’s disease: correlation with 18F-flurodeoxyglucose positron-emission tomography. Neurosci. Lett., 584, 296-301.
Yu, E. Y., Duan, F., Muzi, M., Deng, X., Chin, B. B., Alumkal, J. J., Taplin, M. E., Taub, J. M., Herman, B., Higano, C. S., Doot, R. K., Hartfeil, D., Febbo, P. G. & Mankoff, D. A. (2015). Castration-resistant prostate cancer bone metastasis response measured by 18F-Fluoride PET after treatment with Dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med., 56(3), 354-360.
Yue, Y., Cui, X., Bose, S., Audeh, W., Zhang, X. & Fraass, B. (2015). Stratifying triple-negative breast cancer prognosis using 18F-FdG-PET/CT imaging. Breast Cancer Res Treat., 153(3), 607-616.
Zhang, Y., Xu, H., Wang, H., Yu, W., Zhao, X. & Xue, Y. (2015). Fluorine-18-deoxyglucose positron emission tomography/computed tomography with Ki67 and GLUT-1 immunohistochemistry for evaluation of the radiosensitization effect of oleanolic acid on C6 rat gliomas. Nucl Med Commun., 36(1), 21-27.
Zhou, Y., Yu, F. & Duong, T. Q. ADNI., (2015). White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in MCI and early AD patients. J Magn Reson Imaging., 41(1), 102-109.
Zukotynski, K. A., Kim, C. K., Gerbaudo, V. H., Hainer, J., Taplin, M. E., Kantoff, P., den Abbeele, A. D., Seltzer, S. & Sweeney, C. J. (2015). (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging., 5(1), 72-82. eCollection 2015.

Chapter 18

Anonymous, (2003). Iometopane: (123)I beta-CIT, dopascan injection, GPI 200, RTI 55. Drugs R D., 4, 320-322.
Banzo, I., Quirce, R., Martínez-Rodríguez, I., Jiménez-Bonilla, J., Portilla-Quattrociocchi, H., Medina-Quiroz, P., Ortega, F., Rodríguez, E., Mateo, I., Vázquez-Higuera, J. L., de Arcocha, M. & Carril, J. M. (2011). Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan. Rev. Esp. Med., Nucl., 30, 301-306.
Burroni, L., Borsari, G., Pichierri, P., Polito, E., Toscano, O., Grassetto, G., Al-Nahhas, A., Rubello, D. & Vattimo, A. G. (2012). Preoperative diagnosis of orbital cavernous hemangioma: a 99mTc-RBC SPECT study. Clin. Nucl Med., 37, 1041-46.
Chabenne, A., Moon, C., Ojo, C., Khogali, A., Nepal, B. & Sharma, S. (2014). Biomarkers in Fetal Alcohol Syndrome (Recent Update). Biomarkers and Genomic Medicine, 6, 12-22.
Cheng, D., Rusckowski, M., Wang, Y., Liu, Y., Liu, G., Liu, X. & Hnatowich, D. (2011). A brief evaluation of tumor imaging in mice with 99mTc-Glucarate including a comparison with 18F-FDG. Curr Radiopharm., 4, 5-9.
Cheng, D., Wang, Y., Liu, X., Pretorius, P. H., Liang, M., Rusckowski, M. & Hnatowich, D. J. (2010). Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice. Bioconjug Chem., 21, 1565-1570.
Cheng, D., Rusckowski, M., Pretorius, P. H., Chen, L., Xiao, N., Liu, Y., Liu, G., Liang, M., Liu, X., Dou, S. & Hnatowich, D. J. (2011). Improving the quantitation accuracy in noninvasive small animal single photon emission computed tomography imaging. Nucl Med Biol., 38, 843-48.
Cunha, L., Horvath, I., Ferreira, S., Lemos, J., Costa, P., Vieira, D., Veres, D. S., Szigeti, K., Summavielle, T., Máthé, D. & Metello, L. F. (2014). Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Ther., 18(2), 153-173.
Czernin, J., Ta, L. & Herrmann, K. (2014). Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med., 55(Suppl-2), 59S-62S.
Desmyter, S., van Heeringen, C. & Audenaert, K. (2011). Structural and functional neuroimaging studies of the suicidal brain. Prog Neuropsychopharmacol Biol. Psychiatry., 35, 796-808.
Ebadi, M. & Sharma, S. (2006). Vitamin E and Coenzyme Q10 in Parkinson’s disease. The Encyclopedia of Vitamin E, (Eds V.R. Preedy and R.R. Watson) 439-449.
Ebadi, M., Brown-Borg, H., Refaey, H. El., Singh, B., Garratt, S., Shavali, S. & Sharma, S. (2005). Metallothionein-Mediated Neuroprotection in Genetically-Engineered Mouse Models of Parkinson’s disease. Mol. Brain Res., 134, 67-75.
Ebadi, M., Sharma, S. K., Ghafaurifar, P., Brown-Borg, H. & Refaey, H. El. (2005). Peroxynitrite in the pathogenesis of Parkinson’s disease and the Neuroprotective role of Metallothioneins. Method. In Enzymol., 396, 276-298.
Ebadi, M. & Sharma, S. (2006). Metallothioneins 1 and 2 Attenuate Peroxynitrite-Induced Oxidative Stress in Parkinson’s disease. Exp. Biol. Med., 231, 1576-1583.
Eckelman, W. C., Reba, R. C. & Kelloff, G. J. (2008). Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discovery Today., 13, 748–759.
Erritzoe, D., Talbot, P., Frankle, W. G. & Abi-Dargham, A. (2003). Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clin. N. Am., 13, 817-832.
Furka, I., Németh, N. & Mikó, I. (2013). The spleen in experimental surgery. Magy Seb., 66, 156-160.
Garrood, T., Blades, M., Haskard, D. O., Mather, S. & Pitzalis, C. (2009). A novel model for the pre-clinical imaging of inflamed human synovial vasculature. von Guggenberg. Rheumatology., (Oxford). 48, 926-31.
Gould, R. W., Duke, A. N. & Nader, M. A. (2014). PET studies in nonhuman primate models of Cocaine abuse: translational research related to vulnerability and neuroadaptations. Neuropharmacology., 84, 138-151.
Gualdi, G. F., Colaiacomo, M. C., Bertini, L., Melone, A., Rojas, M. & Di Biasi, C. (2004). Neuroimaging of Alzheimer disease: current role and future potential. Clin Ter., 155, 429-438.
Gueguen, B., Touchon, J. & Campion, D. (1997). Memory disorders in the elderly: complementary examinations--for whom? Therapie., 52, 499-502.
Hampel, H., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C., Bakardjian, H., Drzezga, A., Colliot, O., Epelbaum, S., Broich, K., Lehéricy, S., Brice, A., Khachaturian, Z. S., Aisen, P. S. & Dubois, B. (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020. Biochem Pharmacol., 88, 426-449.
Hargreaves, R. J. & Rabiner, E. A. (2014). Translational PET imaging research. Neurobiol Dis., 61, 32-38.
John, A. E., Luckett, J. C., Tatler, A. L., Awais, R. O., Desai, A., Habgood, A., Ludbrook, S., Blanchard, A. D., Perkins, A. C., Jenkins, R. G. & Marshall, J. F. (2013). Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl. Med., 54, 2146-52.
Jupp, B. & Dalley, J. W. (2014). Behavioral endophenotypes of drug addiction: Etiological insights from neuroimaging studies. Neuropharmacology., 76, 487-497.
Kersemans, V., Thompson, J., Cornelissen, B., Woodcock, M., Allen, P. D., Buls, N., Muschel, R. J., Hill, M. A. & Smart, S. C. (2011). Micro-CT for anatomic referencing in PET and SPECT: radiation dose, biologic damage, and image quality. J Nucl Med., 52, 1827-33.
Keunen, O., Taxt, T., Grüner, R., Lund-Johansen, M., Tonn, J. C., Pavlin, T., Bjerkvig, R., Niclou, S. P. & Thorsen, F. (2014). Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev., 76, 98-115.
Klongpanichapak, S., Govitropong, P., Sharma, S. & Ebadi, M. (2006). Attenuation of Cocaine and MethAmphetamine Neurotoxicity by Coenzyme Q10. Neurochem. Res., 31, 303-3111.
Le Foll, B., Wilson, A. A., Graff, A., Boileau, I. & Di Ciano, P. (2014). Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol., 5, 161.
Li, Y., Zhang, W., Wu, H. & Liu, G. (2014). Advanced Tracers in PET Imaging of Cardiovascular Disease. Biomed Res Int., 2014, 504532.
Liang, M., Liu, X., Cheng, D., Liu, G., Dou, S., Wang, Y., Rusckowski, M. & Hnatowich, D. J. (2010). Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem., 21, 1385-88.
Lin, K. J., Wu, C. C., Pan, Y. H., Chen, F. H., Fu, S. Y., Chiang, C. S., Hong, J. H. & Lo, J. M. (2012). In vivo imaging of radiation-induced tissue apoptosis by (99m)Tc(I)-his (6)-annexin A5. Ann. Nucl. Med., 26, 272-280.
Liu, S., Pan, Y., Lv, J., Wu, H., Tian, J. & Zhang, Y. (2013). Feasibility of baculovirus-mediated reporter gene delivery for efficient monitoring of islet transplantation in vivo. Nucl. Med. Biol., 41(2), 171-178.
Malaney, P., Nicosia, S. V. & Davé, V. (2014). One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett., 344, 1-12.
Manzardo, C., Del Mar Ortega, M., Sued, O., García, F., Moreno, A. & Miró, J. M. (2005). Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J. Neurovirol., Suppl 3, 72-82.
Massoud, T. F. & Gambhir, S. S. (2007). Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends in Molecular Medicine., 13, 183–191.
Mathe, D., Balogh Polyak, A., Keraly, R., Pawlak, D., Zakunun, J., Pillai, M. R. A. & Janoki, G. A. (2010). Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl. Med. Biol., 37, 215-226.
Morano, G. N. & Seibyl, J. P. (2003). Technical overview of brain SPECT imaging: improving acquisition and processing of data. J. Nucl. Med. Technol., 31, 191-195.
Nader, M. A. & Banks, M. L. (2014). Environmental modulation of drug taking: Nonhuman primate models of Cocaine abuse and PET neuroimaging. Neuropharmacology., 76, 510-517.
Neuner, I., Arrubla, J., Felder, J. & Shah, N. J. (2014). Simultaneous EEG-fMRI acquisition at low, high and ultra-high magnetic fields up to 9.4T: Perspectives and challenges. Neuroimage., 102P1, 71-79.
Pan, Y., Liu, S., Wu, H., Lv, J., Xu, X. & Zhang, Y. (2013). Baculovirus as an ideal radionuclide reporter gene vector: a new strategy for monitoring the fate of human stem cells in vivo. PLoS One., 8, e61305.
Pilecki, S., Gierach, M., Gierach, J., Serafin, Z., Sulima, N., Grzela, A., Olejarz, E., Wałek, S., Lasek, W., Kałużny, J. & Junik, R. (2008). Single photon emission computed tomography (SPECT) in the diagnosis of orbital cavernous hemangioma. Pol. J. Radiol., 73, 59-62.
Polyák, A., Hajdu, I., Bodnár, M., Trencsényi, G., Pöstényi, Z., Haász, V., Jánoki, G., Jánoki, G. A., Balogh, L. & Borbély, J. (2013). (99m)Tc-labelled nanosystem as tumor imaging agent for SPECT and SPECT/CT modalities. Int. J. Pharm., 449, 10-17.
Rehani, M. M. & Sharma, S. K. (1980). Site of Tc-99m binding to the red blood cells. J Nuclear Medicine, 22, 676-78.
Rossmeisl, J. H. Jr. Garcia, P. A., Daniel, G. B., Bourland, J. D., Debinski, W., Dervisis, N. & Klahn, S. (2014). Neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound., 55, 115-132.
Saricicek, A., Esterlis, I., Maloney, K. H., Mineur, Y. S., Ruf, B. M., Muralidharan, A., Chen, J. I., Cosgrove, K. P., Kerestes, R., Ghose, S., Tamminga, C. A., Pittman, B., Bois, F., Tamagnan, G., Seibyl, J., Picciotto, M. R., Staley, J. K. & Bhagwagar, Z. (2012). Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am. J. Psychiatry., 169, 851-859.
Schillaci, O., Travascio, L., Bruni, C., Bazzocchi, G., Testa, A., Garaci, F. G., Melis, M., Floris, R. & Simonetti, G. (2009). Molecular imaging and magnetic resonance imaging in early diagnosis of Alzheimer’s disease. A literature review. Neuroradiol. J., 21, 755-771.
Seibyl, J. P. (2008). Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med., 38, 274-286.
Sharma, S. & Ebadi, M. (2008). Therapeutic Potential of Metallothioneins in Parkinson’s disease. In New Research on Parkinson’s Disease. Eds T.M Hahn and Julian Werner, Chapter- 1 pp. 1–41. Nova Science Publishers USA.
Sharma, S. (2015). Synthetic and Herbal Monoamine Oxidase inhibitors. Monoamine Oxidase Inhibitors. Cinical Pharmacology, Benefits, and Potential Health Risks. Nova Science Publishers, New York, U.S.A. Chapter 2, pp. 33-78.
Sharma, S. & Ebadi, M. (2014). Antioxidant Targeting in Neurodegenerative Disorders. Ed. I. Laher, Springer Verlag. Germany. Chapter 85, p. 1-30.
Sharma, S. & Ebadi, M. (2014). Charnoly body as a Universal Biomarker of Cell Injury. Biomarkers and Genomic Medicine., 6, 89-98.
Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y. & Ebadi, M. (2013a). Biomarkers of Parkinson’s Disease (Recent Update). Neurochemistry International., 63, 201-229.
Sharma, S., Rais, A., Sandhu. R. & Nel, W. (3013b). Ebadi M. Clinical significance of metallothioneins in cell therapy and nanomedicine. International Journal of Nanomedicine., 8, 1477–1488.
Sharma, S. & Ebadi, M. (2013c). In-Vivo Molecular Imaging in Parkinson’s Disease. In Parkinson’s Disease. Eds. RF. Pfeiffer, ZK Wszolek, M. Ebadi. IInd Edition, Chapter 58, CRC Press Taylor & Francis Group. Boca Rotan, FL, USA. 2013, pp. 787-80.
Sharma, S. & Ebadi, M. (2014b). Significance of Metallothioneins in Aging Brain. Neurochemistry International., 65, 40-48.
Sharma, S. & Ebadi, M. (2008). SPECT Neuroimaging in Translational Research of CNS Disorders. Neurochem Internat., 52, 352-362.
Sharma, S., Gawande, S., Jagtap, A., Abeulela, R. & Salman, Z. Fetal Alcohol Syndrome; Prevention, Diagnosis, & Treatment. In Alcohol Abuse: Prevalence, Risk Factors. Nova Science Publishers, New York, U.S.A. Ed Jeffrey Raines, Chapter 3, pp. 39-94.
Sharma, S., Refaey, H. El. & Ebadi, M. (2006). Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull., 70, 22-32.
Sharma, S. (2014). Molecular Pharmacology of Environmental Neurotoxins. In Kainic Acid: Neurotoxic Properties, Biological Sources, and Clinical Applications. Nova Science Publishers. New York. P1-47.
Sharma, S. & Ebadi, M. (2005). Distribution Kinetics of 18F-DOPA in Weaver Mutant Mice. Molecular Brain Research., 139, 23-30.
Sharma, S. (2014). Nanotheranostics in Evidence Based Personalized Medicine. Current Drug Targets., 15, 915-930.
Shyam babu, C., Satishchandra, P., Mahadevan, A., Pillai Shibu, V., Ravishankar, S., Sidappa, N., Udaykumar, R., Ravi, V. & Shankar, S. K. (2013). Usefulness of stereotactic biopsy and neuroimaging in management of HIV-1 Clade C associated focal brain lesions with special focus on cerebral toxoplasmosis. Clin Neurol Neurosurg., 115, 995-02.
Silverman, D. H., Small, G. W. & Phelps, M. E. (1999). Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer’s Disease. Clin Positron Imaging., 2, 119-130.
Skaliczki, G., Weszl, M., Schandl, K., Major, T., Kovács, M., Skaliczki, J., Redl, H., Szendrői, M., Szigeti, K., Máté, D., Dobó-Nagy, C. & Lacza, Z. (2012). Compromised bone healing following spacer removal in a rat femoral defect model. Acta Physiol Hung., 99, 223-32.
van de Watering, F. C., Rijpkema, M., Perk, L., Brinkmann, U., Oyen, W. J. & Boerman, O. C. (2014). Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int., 2014, 203601.
Villemagne, V. L., Ng, S., Cappai, R., Barnham, K. J., Fodero-Tavoletti, M. T., Rowe, C., Masters, C. L. & Attesa, L. L. (2006). Towards a molecular approach to neuroimaging and therapeutics in Alzheimer’s disease. Neuroradiol. J., 19, 453-474.
von Guggenberg, E., Sallegger, W., Helbok, A., Ocak, M., King, R., Mather, S. J. & Decristoforo, C. (2009). Cyclic Minigastrin analogs for gastrin receptor scintigraphy with Technetium-99m: preclinical evaluation. J. Med. Chem., 52, 4786-93.
Wang, C., Schroeder, F. A. & Hooker, J. M. (2014). Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques. Neuroscience., 264, 186-197.
Xie, J., Chen, K., Huang, J., Lee, S., Wang, J., Gao, J., Li, X. & Chen, X. (2010). PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials., 31, 3016–3022.

Chapter 20

Ajjimaporn, A., Swinscoe, J., Shavali, S. & Ebadi, M. (2005). Metallothionein provides zinc-mediated protective effects against methAmphetamine toxicity in SK-N-SH cells. Brain Res. Bull., 67, 466-475.
Antonini, A. & DeNotaris, R. (2004). PET and SPECT functional imaging in Parkinson’s disease. Sleep Med., 5, 201-206.
Bastos Leite, A. J., Scheltens, P. & Barkhof, F. (2004). Pathological aging of the brain: an overview. Top. Magn. Reson. Imaging, 15, 369-389.
Belanger, H. G., Vanderploeg, R. D., Curtis, G. & Warden, D. L. (2007). Recent neuroimaging techniques in mild traumatic brain injury. J. Neuropsychiatry Clin. Neurosci., 19, 5-20.
Brathen, G., Ben-Menachem, E., Brodtkorb, E., Galvin, R., Garcia-Monco, J. C., Halasz, P., Hillborn, M., Leone, M. A. & Young, A. B. (2005). The EFNS Task force on diagnosis and treatment of Alcohol-related seizures. Eur. J. Neurol., 12, 575-581.
Brockhuis, B., (2006). Cerebral blood flow changes in patients with dementia with Lewy bodies (DLB). A study of 6 cases. Nucl. Med. Rev. Cent. East Eur., 9, 114-118.
Brust, P., Scheffel, U. & Szabo, Z. (1999). Radioligands for the study of the 5-HT transport in-vivo. Drugs, 2, 129-145.
Cowan, R. L. (2007). Neuroimaging research in human MDMA users: a review. Psychopharmacology, 189, 539-556.
Cunha, P. J. & Novaes, M. A. (2004). Neurocognitive assessment in Alcohol abuse and dependence: implications for treatment. Rec. Bras Psiquiatr, 26, S23-27.
de Mendelssohn, A., Kasper, S. & Tauscher, J. (2004). Neuroimaging in substance abuse disorders. Nervenarzt, 75, 651-662.
Decata, A., Intiso, D., Bernal, M., Molinaro, F., Mazzoccoli, G., D’Alessandro, V., Greco, A., Curci, S., Sperandeo, M., Frusciante, V., Fanularo, G., Dallapiccola, B., Vendemiale, G., (2007). Int. J. Immunopathol. Pharmacol., 20, 91-96.
Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kinsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., Werling, J., Kipp, J., Rabinow, B. E. & Gendelman, H. E. (2006). Development of a macrophage-based Nanoparticle plateform for antiretroviral drug delivery. Blood, 108, 2827-2835.
Ebadi, M., Sharma, S., (2006). Metallothioneins 1 and 2 Attenuate Peroxynitrite-Induced Oxidative Stress in Parkinson’s Disease. Jr. Exp. Bio & Med. 231, 1576-1583.
Ebadi, M., Sharma. S., Ghafourifar, P., Brown-Borg, H. & Refaey, H. El. (2005). Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role of metallothioneins. Methods in Enzymol., 396, 276-298.
Ebadi, M., Brown-Borg, H., Garrett, S., Singh, B., Shavali, S. & Sharma, S. (2005). etallothionein-Mediated Neuroprotection in Genetically-Engineered Mice Models of Parkinson’s Disease and Aging. Mol. Brain Res., 134, 67-75.
Hurley, R. A., Reneman, L., & Taber, K. H. (2002). Ecstasy in the brain: a model for neuroimaging. J. Neuropsychiatry Clin. Neurosci., 14, 125-129.
Elkashef, A. & Vocci, F. (2003). Biological markers of Cocaine addiction: implications for medications development. Addict. Biol., 8, 123-139.
Ernst, M., Kimes, A. S. & Jazbec, S. (2003). Neuroimaging and mechanisms of drug abuse: interface of molecular imaging and molecular genetics. Neuroimaging Clin. N. Am., 13, 833-840.
Fong, T. G., Bogardus, S. T., Jr, Daftary., A., Auerbach, E., Blumentfeld, H., Modur, S., Leo-Summers, L., Seibyl, J. & Inouye, S. K. (2006). Cerebral perfusion changes in older delirious patients using 99mTc-HMPAO SPECT. J. Gerontol A Biol. Sci. Med. Sci., 61, 1294-1299.
Fong, T. G., Borgardus, S. T., Jr, Daftary, A., Auerbach, E., Blumenfeld, H., Modur, S., Leo-Summers, L., Seibyl, J. & Inouye, S. K. (2006). Cerebral perfusion changes in older delirious patients using 99mTc-HMPAO SPECT. J. Gerontol A. Biol. Sci. Med. Sci., 61, 1294-1299.
Gatley, S. J., Volkow, N. D., Wang, G. D., Fowler, J. S., Logan, J., Ding, Y. S. & Gerasimov, M. (2005). PET imaging in clinical drug abuse research. Curr Pharm. Des. 11, 3203-3219.
Gundisch, D., Koren, A. O., Horti, A. G., Pavlova, O. A., Kimes, A. S., Mukhin, A. G. & London, E. D. (2005). In vitro characterization of 6-[18F]fluoro-A-8530, a high affinity ligand for alpha4beta-2 nicotinic acetylCholine receptors. Synapse, 55, 89-97.
Halldin, C., Gulyas, B., Langer, O. & Farde, L. (2001). Brain radioligands-state of the art and new trends. Q. J. Nucl. Med., 45, 139-152.
Hamano, T., Tsuchida, T., Hirayama, M., Fujiyama, J., Mutoh, T., Yonekura, Y. & Kuriyama, M. (2000). Dopamine transporter SPECT in patients with Parkinson’s disease. Kaku Igaku, 37, 125-129.
Hummerich, R., Reischl, G., Ehrlichmann, W., Machulla, H. J, Heinz, A. & Schloss, P. (2004). DASB-in vitro binding characteristics on human recombinant monoamine transporters with regards to its potential as positron emission tomography (PET) tracer. J. Neurochem., 90, 1218-1226.
Ishii, K., Ikerjiri, Y., Sasaki., M., Kitagaki, H., Mori, E., (1999). Regional cerebral glucose metabolismand blood flow in a patient with Marchiafava-Bignami disease. Am. J. Neuroradiol., 20, 1249-1251.
Iyo, M., Sekine, Y. & Mori, N. (2004). Neuromechanism of developing methAmphetamine psychosis: a neuroimaging study. Ann. N.Y. Acad. Sci., 1025, 288.295.
Jia, S. W., Wang, W., Liu, Y. & Wu, Z. M. (2005). Neuroimaging studies of brain corpus striatum changes among heroin-dependent patients treated with herbal medicine. U’finer Capsule. Addict. Biol., 10, 293-297.
Jia, S. W., Wang, W., Liu, Y. & Wu, Z. M. (2005). Neuroimaging studies of brain corpus striatum changes among heroin-dependent patients treated with herbal medicine, U’finer capsule. Addict. Biol., 10, 293-297.
Johnson, B. A., Devous, M. D. Ruitz, P. & Ait-Daoud, N. (2001). Treatment advances for Cocaine ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. Am. J. Psychiatry, 158, 1191-1198.
Kim, S. E., Lee, W. Y., Choe, Y. S. & Kim, J. H. (1999). SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson’s disease: correlation with symptom severity. Neurol Res., 21, 255-261.
Klongpanichapak, S., Govitrapong, P., Sharma, S. & Ebadi, M. (2006). Attenuation of Cocaine and MethAmphetamine Neurotoxicity in SK-N-SH Neurons by Coenzyme Q10. Neurochemical Res., 31, 303-311.
Konkol, R. J., Tikofsky, R. S., Wells, R., Hellman, R. S., Nemeth, P., Walsch, D. J., Heimler, R., & Sty, J. R. (1994). Normal high-resolution cerebral 99mTc-HMPAO SPECT scans in symptomatic neonates exposed to Cocaine. J. Clin. Neurol., 9, 278-283.
Kostel, T. R., Malison, R. & Wallace, E. (1996). Neuropsychological abnormalities in Cocaine abusers: possible correlates in SPECT neuroimaging. NIDA Res. Monogr., 163, 175-192.
Kosten, T. R., Gottschalk, P. C., Tucker, K., Rinder, C. S., Dey, H. M. & Rinder, H. M. (2003). Aspirin or amiloride for cerebral perfusion defects in Cocaine dependence. Drug Alcohol Depend., 71, 187-194.
Krause, K. H., Dresel, S. H., Krause, J., La Fougere, C. & Ackenhell, M. (2003). The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev., 27, 605-613.
Lang, C. J. (2000). The use of neuroimaging techniques for clinical detection of neurotoxicity: a review. Neurotoxicol., 21, 847-855.
Langstrom, B., Andren, P. E., Lindhe, O., Svedberg, M. & Hall, H. (2007). In-vitro Techniques in Neurodegenerative diseases. Mol. Imaging. Biol., 9(4), 61-75.
Ligford-Hughes, A. R., Acton, P. D., Gacinovic, S., Boddington, S. J., Costa, D. C., Pilowsky, L. S., Ell, P. J., Marshall, E. J. & Kerwin, R. W. (2000). Levels of gamma-aminobutyric acid-benzodiazepine receptors in abstinent, Alcohol-dependent women: preliminary findings from an 123I-iomazenil single photon emission tomography study. Alcohol Clin. Exp. Res., 24, 1449-1455.
Lingford-Hughes, A. (2005). Human brain imaging and substance abuse. Curr. Opin Pharmacol., 5, 42-46.
Lingford-Hughes, A. R., Davies, S. J., McIver, S., Williams, T. M., Daglish, M. R. & Nutt, D. J. (2003). Drugs and The Future Addiction. Brain Science Addiction and Society. Br. Med. Bull., 65, 209-222.
MacLaren, D. C., Toyokuni, T., Cherry, S. R., Barrio, J. R., Phelps, M. E., Herschman, H. R. & Ghambhir, S. S. (2000). PET imaging in transgene expression. Biol. Psychiatry, 48, 337-348.
Maharajan, P., Maharajan, V., Ravagnan, G. & Paino, G. (2001). The weaver mutant mouse: a model to study the ontogeny of dopamine transmission system and their role in drug addiction. Prog. Neurobiol., 64, 269-276.
Mann, K., Ackermann, K., Croissant, B., Mundle, G., Nakovics, H. & Dielh, A. (2005). Neuroimaging of gender differences in Alcohol dependence are women more vulnerable?, Alcohol Clin. Exp. Res., 29, 896-901.
Mann, K., Mundle, G., Strayle, M. & Wakat, P. (1995). Neuroimaging in Alcoholism: CT and MRI and clinical correlates. J. Neural. Transm., 99, 145-155.
Masters, C. L., Cappai, R., Barhham, K. J. & Villmagne, V. L. (2006). Molecular mechanisms for Alzheimer’s disease: implications for neuroimaging and therapeutics. J. Neurochem., 97, 1700-1725.
McConathy, J., Kilts, C. D. & Goodman, M. M. (2001). Radioligands for PET and SPECT imaging of the central noradrenergic system. CNS Spectr., 6, 704-709.
Moreno-Iniguez, M., Ortuno, F., Bonelli, R. M., Millan, M., Soutullo, C. A. & Cervera-Enguiz, S. (2007). Perseverative error in schizophrenia: correlation with cortical blood flow by SPECT. Actas Esp Psiquiar, 35, 20-28.
Nikolaus, S., Antke, C., Beu, M., Kley, K., Larisch, R., Wirrwar, A. & Muller, H. W. (2007). In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT. Nucl. Med. Commun., 28, 207-213.
Nikolaus, S., Larisch, R., Wirrwar, A., Jamdjeu-Noune, M., Antke, C., Beu, M., Schramm, N. & Muller, H. W. (2005). [123I] Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine-an in vivo imaging study with a dedicated small animal SPECT. Eur. J. Nucl. Med. Mol. Imaging., 32, 1305-1310.
O’Carroll, R. (1993). Neuropsychological and neuroimaging aspects of latent hepatic encephalopathy (LHE). Alcohol Alcohol Suppl., 2, 191-195.
Pakrasi, S., Collby, S. J., Firbank, M. J., Perry, E. K., Wyper, D. J., Owens, J., McKeith, I. G., Willams, E. D. & O’brien, J. T. (2007). Muscrinic actylCholine receptor status in Alzheimer’s disease using (R, R) 123I-QNB SPECT. J. Neurol., 254(7), 907-913.
Reneman, L., deWin, M. M., van den Brink, W., Booij, J., den Heeten, G. J., (2006). Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Psychopharmacol., 20, 164-175.
Schlaepfer, T. E., Strain, E. C., Greenberg, B. D., Preston, K. L., Lancaster, E., Bigelow, G. E., Barta, P. E. & Pearlson, G. D. (1998). Site of opioid action in the human brain: mu and kappa agonists subjective and cerebral blood flow effects. Am. J. Psychiatry, 155, 470-473.
Schuh-Hofer, S., Richter, M., Geworski, L., Villringer, A., Israel, H., Wenzel, R., Munz, D. L., Arnold, G., (2007). Increased serotonin transporter availability in the brain stem of migraineurs. J. Neurol., 254, 789-796.
Sharma, S. & Ebadi, M. (2008). SPECT Neuroimaging in Translationa Research of CNS Disorders. Neurochemistry Int., 52, 352-362.
Sharma, S., Krause, G. & Ebadi, M., (2006). Radiation Safety and Quality Control in the Cyclotron Laboratory. Radiation Protection Dosimetry, 118, 431-439.
Sharma, S., Refaey, H. EI. & Ebadi, M. (2006). Complex-1 Activity and 18F-DOPA Uptake in Genetically-Engineered Mouse Model of Parkinson’s Disease and the Neuroprotective Role of Coenzyme Q10. Brain Res. Bullet., 70, 22-32.
Sharma, S. & Ebadi, M. (2005). Distribution Kinetics of 18F-DOPA in Weaver Mutant Mice. Mol. Brain Res., 139, 23-30.
Shih, M. C., Felicio, A. C., deOliveira Godeiro-Junior, C., de Carvalho Aguiar, P., de Andrade, L. A., Ferraz, H. B. & Bressan, R. A. (2007). Molecular imaging in hereditary forms of Parkinsonism. Eur. J. Neurol., 14, 359-368.
Shimazono, Y. & Matsushima, E. (1995). Behavioral and neuroimaging studies on schizopherenia in Japan. Psychiatry Clin. Neurosci., 49, 3-11.
Smith, D. F. & Jacobson, S. (2007). Stereoselective neuroimaging in vivo. Eur. Neuropharmacol., 17(8), 507-22.
Stratone, A., Stratone, C. & Topoliceanu, F. (2003). The neurotransmitters and Alcohol dependence. Rev. The neurotransmitters and Alcohol dependence. Rev. Med. Chir. Soc. Med. Nat. Lasi., 107, 231-136.
Strickland, T. L., Miller, B. L., Kowell, A. & Stein, R. (1998). Neurobiology of Cocaine-induced organic brain impairment: contributions from functional neuroimaging. Neuropsychol. Rev., 8, 1-9.
Sugihara, G., Ouchi, Y., Nakamura, K., Sekine, Y. & Mori, N. (2007). Advances in neuroimaging research of Asperger syndrome. Nippon Rinsho, 65, 449-452.
Szekeres, G., Pavics, L. & Janka, Z. (2002). Investigation of the dopamine dysregulation hypothesis of schizopherenia with neuroimaging techniques. Ideggyogy Sz., 55, 226-232.
Tian, Y., Liu, H. & Shi, P. (2006). Simultaneous reconstruction of tissue attenuation and radioactivity maps in SPECT. Med. Imag. Comput. Comput. Assist Interv Int Conf. Med. Image, 9, 397-404.
Van Dyck, C. H., Avery, R. A., Macavoy, M. G., Marek, K. L., Quinlan, D. M., Baldwin, R. M., Seibyl, J. P., Innis, R. B., Arnsten, A. F. (2008). Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol. Aging., 29(8), 1237-1246.
Van Heeringen, C., Audenaert, K., Van Laere, K., Dumont, F., Slegers, G., Mertens, J. & Dierckx, R. A. (2003). Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J. Affect Disord., 74, 149-158.
Vastenhouw, B. & Beckman, F. (2007). Sub-millimerter total-body murine imaging with U-SPECT-1. J. Nucl. Med., 48, 487-493.
Villemagne, V. L., Rowe, C. C., Macfarlane, S., Novakovic, K. E. & Masters, C. L. (2005). Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer’s disease. J. Clin. Neurosci., 12, 221-230.
Wang, Y. & Tsui, B. M. (2007). Pinhole SPECT with different data acquisition geometries: usefulness of unified projection operators in homogeneous coordinates, IEEE Trans Med. Imaging, 26, 298-308.
Yu, T. W., Liu, H. M. & Lee, W. T. (2007). The correlation between motor impairment and cerebral blood flow in Sturge-Weber syndrome. Eur. J. Paediatr. Neurol., 11, 96-103.

Chapter 21

Cunha, L., Horvath, I., Ferreira, S., Lemos, J., Costa, P., Vieira, D., Veres, D. S., Szigeti, K., Summavielle, T., Máthé, D. & Metello, L. F., (2014). Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Ther., 18(2), 153-173.
Czernin, J., Ta, L. & Herrmann, K., (2014). Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med., 8, 55(Supplement 2), 59S-62S.
Eckelman, W. C., Reba, R. C. & Kelloff, G. J. (2008). Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discovery Today, 13, 748–759.
Glasser, M. F., Goyal, M. S., Preuss, T. M., Raichle, M. E. & Van Essen, D. C. (2014). Trends and properties of human cerebral cortex: correlations with cortical myelin content. Neuroimage., 93 Pt 2, 165-175.
Gonfiotti, A., Jaus, M. O., Barale, D. & Macchiarini, P. (2014). Carinal Resection. Thorac Surg Clin., 24(4), 477-484.
Gould, R. W., Duke, A. N. & Nader, M. A. (2014). PET studies in nonhuman primate models of Cocaine abuse: translational research related to vulnerability and neuroadaptations. Neuropharmacology., 84, 138-151.
Hampel, H., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C., Bakardjian, H., Drzezga, A., Colliot, O., Epelbaum, S., Broich, K., Lehéricy, S., Brice, A., Khachaturian, Z. S., Aisen, P. S. & Dubois, B. (2014). Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020. Biochem Pharmacol., 88(4), 426-449.
Hargreaves, R. J. & Rabiner, E. A. (2014). Translational PET imaging research. Neurobiol Dis., 61, 32-38.
Hoffmann, M.. Kletter, K., Becherer, A., Jäger, U., Chott, A. & Raderer, M. (2003). 18F-FdG Positron Emission Tomography (18F-FDG-PET) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma. Oncology., 64, 336–340.
Jupp, B. & Dalley, J. W. (2014). Behavioral endophenotypes of drug addiction: Etiological insights from neuroimaging studies. Neuropharmacology., 76 Pt B, 487-497.
Keunen, O., Taxt, T., Grüner, R., Lund-Johansen, M., Tonn, J. C., Pavlin, T., Bjerkvig, R., Niclou, S. P. & Thorsen, F. (2014). Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev., 76, 98-115.
Le Foll, B., Wilson, A. A., Graff, A., Boileau, I. & Di Ciano, P. (2014). Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol., 5, 161.
Li, Y., Zhang, W., Wu, H. & Liu, G. (2014). Advanced Tracers in PET Imaging of Cardiovascular Disease. Biomed Res Int., 2014, 504-532.
Malaney, P., Nicosia, S. V. & Davé, V. (2014). One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett., 344(1), 1-12.
Massoud, T. F. & Gambhir, S. S. (2007). Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends in Molcular Medicine., 13, 183–191.
Nader, M. A. & Banks, M. L. (2014). Environmental modulation of drug taking: Nonhuman primate models of Cocaine abuse and PET neuroimaging. Neuropharmacology., 76, 510-517.
Neuner, I., Arrubla, J., Felder, J. & Shah, N. J. (2014). Simultaneous EEG-fMRI acquisition at low, high and ultra-high magnetic fields up to 9.4T: Perspectives and challenges. Neuroimage., 102, P1, 71-79.
Renaud, J. M., Mylonas, I., McArdle, B., Dowsley, T., Yip, K., Turcotte, E., Guimond, J., Trottier, M., Pibarot, P., Maguire, C., Lalonde, L., Gulenchyn, K., Wisenberg, G., Wells, R. G,, Ruddy, T., Chow, B., Beanlands, R. S. & deKemp, R. A. (2014). Clinical interpretation standards and quality assurance for the multicenter PET/CT trial rubidium-ARMI. J Nucl Med., 55(1), 58-64.
Rossmeisl, J. H. Jr., Garcia, P. A., Daniel, G. B., Bourland, J. D., Debinski, W., Dervisis, N. & Klahn, S. (2014). Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound., 55(2), 115-132.
Sharma, S. (2014). Nanotheranostics in Evidence-Based Personalized Medicine. Curr Drug Targets., 15(10), 915-930.
van de Watering, F. C., Rijpkema, M., Perk, L., Brinkmann, U., Oyen, W. J. & Boerman, O. C. (2014). Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int., 2014, 203601.
Wang, C., Schroeder, F. A. & Hooker, J. M. (2014). Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques. Neuroscience., 264, 186-197.
Wieder, H. A., Pomykala, K. L., Benz, M. R., Buck, A. K. & Herrmann, K. (2014). PET tracers in musculoskeletal disease beyond FDG. Semin Musculoskelet Radiol., 18(2), 123-132.
Wielpütz, M. O., Heußel, C. P., Herth, F. J. & Kauczor, H. U. (2014). Radiological diagnosis in lung disease: factoring treatment options into the choice of diagnostic modality. Dtsch Arztebl Int., 111(11), 181-187.
Xie, J, Chen, K., Huang, J., Lee, S., Wang, J., Gao, J., Li, X. & Chen, X. (2010). PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials, 31, 3016–3022.

Chapter 22

Adamson, P. D., Vesey, A. T., Joshi, N. V., Newby, D. E. & Dweck, M. R., (2015). Salt in the wound: 18F-fluoride positron emission tomography for identification of vulnerable coronary plaques. Cardiovasc Diagn Ther., 5(2), 150-155.
Ariza, M., Kolb, H. C., Moechars, D., Rombouts, F. & Andrés, J. I. (2015). Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. J Med Chem., 58(11), 4365-4382.
Benešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K. & Eder, M. (2015). Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med., 56(6), 914-920.
Borbély, K. (2015). [New trends and novel possibilities in the management of oncologic patients: clinical uses of PET/MRI]. Magy Onkol., 59(1), 10-16.
Deng, H., Wang, H. & Li, Z. (2015). Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery. Curr Drug Targets., 16(6), 610-624.
Deng, H., Wang, H. & Li, Z. (2015). Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery. Curr Drug Targets., 16(6), 610-624.
Dimitriu-Leen, A. C., Scholte, A. J. & Jacobson, A. F. (2015). 123I-MIBG SPECT for Evaluation of Patients with Heart Failure. J Nucl Med., 56 Suppl 4, 25S-30S.
Galldiks, N. & Langen, K. J. (2015). Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging., 59(1), 70-82.
Gavra, M., Syed, R., Fraioli, F., Afaq, A. & Bomanji, J. (2015). PET/MRI in the Upper Abdomen. Semin Nucl Med., 45(4), 282-292.
Giovannini, E., Lazzeri, P., Milano, A., Gaeta, M. C. & Ciarmiello, A. (2015). Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des., 21(1), 121-127.
Halime, Z., Frindel, M., Camus, N., Orain, P. Y., Lacombe, M., Chérel, M., Gestin, J. F., Faivre-Chauvet, A. & Tripier, R. (2015). New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and 64Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. Org Biomol Chem., 13(46), 11302-11314.
Hildebrandt, M. G., Kodahl, A. R., Teilmann-Jørgensen, D., Mogensen, O., Jensen, P. T., (2015). [18F]FdG PET/computed tomography in breast cancer and gynecologic cancers: a literature review. PET Clin., 10(1), 89-104.
Humbert, O., Cochet, A., Coudert, B., Berriolo-Riedinger, A., Kanoun, S., Brunotte, F. & Fumoleau, P. (2015). Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist., 20(2), 94-104.
Jacobson, O., Yan, X., Niu, G., Weiss, I. D., Ma, Y., Szajek, L. P., Shen, B., Kiesewetter, D. O. & Chen, X. (2015). PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. J Nucl Med., 2015 Apr, 56(4), 616-621.
Lemaire, C., Libert, L., Franci, X., Genon, J. L., Kuci, S., Giacomelli, F. & Luxen, A. (2015). Automated production at the curie level of no-carrier-added 6-[(18)F]Fluoro-L-dopa and 2-[(18)F]Fluoro-L-Tyrosine on a FAST lab synthesizer. J Labelled Comp Radiopharm. 58(7), 281-290.
Lewis, D. Y., Soloviev, D. & Brindle, K. M. (2015). Imaging tumor metabolism using positron emission tomography. Cancer J., 21(2), 129-136.
Lopci, E., Torzilli, G., Poretti, D., de Neto, L. J., Donadon, M., Rimassa, L., Lanza, E., Sabongi, J. G., Ceriani, R., Personeni, N., Palmisano, A., Pedicini, V., Comito, T., Scorsetti, M. & Chiti, A. (2015). Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging., 42(9), 1399-1407.
Lu, W., Wan, J. & Zhang, H. H. (2015). Computerized PET/CT image analysis in the evaluation of tumor response to therapy. Br J Radiol., 88(1048), 20140625.
Mattsson, S., Andersson, M. & Söderberg, M. (2015). Technological advances in hybrid imaging and impact on dose. Radiat Prot Dosimetry., 165(1-4), 410-415.
Notni, J., Steiger, K., Hoffmann, F., Reich, D., Kapp, T. L., Rechenmacher, F., Neubauer, S., Kessler, H. & Wester, H. J. (2015). Complementary, Selective PET-Imaging of Integrin Subtypes α5β1 and αvβ3 Using Ga-68-Aquibeprin and Ga-68-Avebetrin. J Nucl Med. 2015.
Oukoloff, K., Cieslikiewicz-Bouet, M., Chao, S., Da Costa Branquinho, E., Bouteiller, C. & Jean L, Renard, P. Y. (2015). PET and SPECT Radiotracers for Alzheimer’s Disease. Curr Med Chem., 22(28), 3278-304.
Palestro, C. J. (2015). Radionuclide imaging of osteomyelitis. Semin Nucl Med., 45(1), 32-46.
Petretta, M, Storto, G., Pellegrino, T., Bonaduce, D. & Cuocolo, A. (2015). Quantitative Assessment of Myocardial Blood Flow with SPECT. Prog Cardiovasc Dis., 57(6), 607-614.
Sager, S., Vatankulu, B., Erdogan, E., Mut, S., Teksoz, S., Ozturk, T., Sonmezoglu, K. & Kanmaz, B. (2015). Comparison of F-18 FDG-PET/CT and Tc-99m MIBI in the preoperative evaluation of cold thyroid nodules in the same patient group. Endocrine., 50(1), 138-145.
Salvatori, M., Biondi, B. & Rufini, V. (2015). Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol., 173(3), R115-130.
Sampath, S. C., Sampath, S. C., Mosci, C., Lutz, A. M., Willmann, J. K., Mittra, E. S., Gambhir, S. S. & Iagaru, A. (2015). Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. Clin Nucl Med., 40(3), e173-177.
Unschuld, P. G. (2015). Possibilities of modern imaging technologies in early diagnosis of Alzheimer disease]. Ther Umsch., 2015 Apr, 72(4), 261-269.
Uslu, L., Donig, J., Link, M., Rosenberg, J., Quon, A. & Daldrup-Link, H. E. (2015). Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med., 56(2), 274-286.
van Rossum, P. S., van Lier, A. L., Lips, I. M., Meijer, G. J., Reerink, O., van Vulpen, M., Lam, M. G., van Hillegersberg, R. & Ruurda, J. P. (2015). Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clin Radiol., 70(1), 81-95.
Withofs, N., Charlier, E., Simoni, P., Alvarez-Miezentseva, V., Mievis, F., Giacomelli, F., Mella, C., Gambhir, S. S., Malaise, O. & de Seny, D, Malaise, M, Hustinx, R. (2015). 18F-FPRGD2 PET/CT imaging of musculoskeletal disorders. Ann Nucl Med., 29(10), 839-847.
Zimmerman, B. E., Bergeron, D. E. & Cessna, J. T. (2015). Impact of Recent Change in the National Institute of Standards and Technology Standard for 18F on the Relative Response of 68Ge-Based Mock Syringe Dose Calibrator Standards. J Nucl Med., 2015 Sep, 56(9), 1453-1457.

This unique, informative, and timely released book will be a helpful guide, and applied text book for basic biomedical students, scientists, researchers, teachers, doctors, administrators, and affiliated staff, involved in current and future development of novel PET-RPs to accomplish the ultimate goal of EBPT

You have not viewed any product yet.